<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration - Evans, JR - 2023 | Cochrane Library</title> <meta content="Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration - Evans, JR - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000254.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration - Evans, JR - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000254.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000254.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration" name="citation_title"/> <meta content="Jennifer R Evans" name="citation_author"/> <meta content="International Centre for Eye Health, London School of Hygiene &amp; Tropical Medicine" name="citation_author_institution"/> <meta content="jennifer.evans@lshtm.ac.uk" name="citation_author_email"/> <meta content="John G Lawrenson" name="citation_author"/> <meta content="City University of London" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD000254.pub5" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/09/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000254.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000254.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000254.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antioxidants [therapeutic use]; beta Carotene; Dietary Supplements; *Geographic Atrophy [prevention &amp; control]; Lutein [therapeutic use]; *Macular Degeneration [epidemiology, prevention &amp; control]; *Malnutrition; Minerals; Vitamin A; Vitamin K; Vitamins [therapeutic use]; Zeaxanthins [therapeutic use]; Zinc" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000254.pub5&amp;doi=10.1002/14651858.CD000254.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="7a2tKMcJ";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000254\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000254\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000254\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000254\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","th","ms","ja","hr","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000254.pub5",title:"Antioxidant vitamin and mineral supplements for slowing the progression of age\\u2010related macular degeneration",firstPublishedDate:"Sep 13, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000254.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000254.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000254.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000254.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000254.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000254.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000254.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000254.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000254.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000254.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5490 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000254.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-sec-0064"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-sec-0038"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-sec-0058"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/appendices#CD000254-sec-0069"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/supinfo/CD000254-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/supinfo/CD000254-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/information#CD000254-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Jennifer R Evans</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000254.pub5/information#CD000254-cr-0005">John G Lawrenson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/information/en#CD000254-sec-0081">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 September 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000254.pub5">https://doi.org/10.1002/14651858.CD000254.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000254-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000254-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000254-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000254-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000254-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD000254-abs-0005">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000254-abs-0001" lang="en"> <section id="CD000254-sec-0001"> <h3 class="title" id="CD000254-sec-0001">Background</h3> <p>Age‐related macular degeneration (AMD) is a degenerative condition of the back of the eye that occurs in people over the age of 50 years. Antioxidants may prevent cellular damage in the retina by reacting with free radicals that are produced in the process of light absorption. Higher dietary levels of antioxidant vitamins and minerals may reduce the risk of progression of AMD. This is the third update of the review. </p> </section> <section id="CD000254-sec-0002"> <h3 class="title" id="CD000254-sec-0002">Objectives</h3> <p>To assess the effects of antioxidant vitamin and mineral supplements on the progression of AMD in people with AMD. </p> </section> <section id="CD000254-sec-0003"> <h3 class="title" id="CD000254-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, one other database, and three trials registers, most recently on 29 November 2022. </p> </section> <section id="CD000254-sec-0004"> <h3 class="title" id="CD000254-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that compared antioxidant vitamin or mineral supplementation to placebo or no intervention, in people with AMD. </p> </section> <section id="CD000254-sec-0005"> <h3 class="title" id="CD000254-sec-0005">Data collection and analysis</h3> <p>We used standard methods expected by Cochrane.</p> </section> <section id="CD000254-sec-0006"> <h3 class="title" id="CD000254-sec-0006">Main results</h3> <p>We included 26 studies conducted in the USA, Europe, China, and Australia. These studies enroled 11,952 people aged 65 to 75 years and included slightly more women (on average 56% women). We judged the studies that contributed data to the review to be at low or unclear risk of bias. </p> <p>Thirteen studies compared multivitamins with control in people with early and intermediate AMD. Most evidence came from the Age‐Related Eye Disease Study (AREDS) in the USA. People taking antioxidant vitamins were less likely to progress to late AMD (odds ratio (OR) 0.72, 95% confidence interval (CI) 0.58 to 0.90; 3 studies, 2445 participants; moderate‐certainty evidence). In people with early AMD, who are at low risk of progression, this means there would be approximately four fewer cases of progression to late AMD for every 1000 people taking vitamins (one fewer to six fewer cases). In people with intermediate AMD at higher risk of progression, this corresponds to approximately 78 fewer cases of progression for every 1000 people taking vitamins (26 fewer to 126 fewer). AREDS also provided evidence of a lower risk of progression for both neovascular AMD (OR 0.62, 95% CI 0.47 to 0.82; moderate‐certainty evidence) and geographic atrophy (OR 0.75, 95% CI 0.51 to 1.10; moderate‐certainty evidence), and a lower risk of losing 3 or more lines of visual acuity (OR 0.77, 95% CI 0.62 to 0.96; moderate‐certainty evidence). Low‐certainty evidence from one study of 110 people suggested higher quality of life scores (measured with the Visual Function Questionnaire) in treated compared with non‐treated people after 24 months (mean difference (MD) 12.30, 95% CI 4.24 to 20.36). In exploratory subgroup analyses in the follow‐on study to AREDS (AREDS2), replacing beta‐carotene with lutein/zeaxanthin gave hazard ratios (HR) of 0.82 (95% CI 0.69 to 0.96), 0.78 (95% CI 0.64 to 0.94), 0.94 (95% CI 0.70 to 1.26), and 0.88 (95% CI 0.75 to 1.03) for progression to late AMD, neovascular AMD, geographic atrophy, and vision loss, respectively. </p> <p>Six studies compared lutein (with or without zeaxanthin) with placebo and one study compared a multivitamin including lutein/zeaxanthin with multivitamin alone. The duration of supplementation and follow‐up ranged from six months to five years. Most evidence came from the AREDS2 study in the USA; almost all participants in AREDS2 also took the original AREDS supplementation formula. People taking lutein/zeaxanthin may have similar or slightly reduced risk of progression to late AMD (RR 0.94, 95% CI 0.87 to 1.01), neovascular AMD (RR 0.92, 95% CI 0.84 to 1.02), and geographic atrophy (RR 0.92, 95% CI 0.80 to 1.05) compared with control (1 study, 4176 participants, 6891 eyes; low‐certainty evidence). A similar risk of progression to visual loss of 15 or more letters was seen in the lutein/zeaxanthin and control groups (RR 0.98, 95% CI 0.91 to 1.05; 6656 eyes; low‐certainty evidence). Quality of life (Visual Function Questionnaire) was similar between groups (MD 1.21, 95% CI ‐2.59 to 5.01; 2 studies, 308 participants; moderate‐certainty evidence).<br/>One study in Australia randomised 1204 people to vitamin E or placebo with four years of follow‐up; 19% of participants had AMD. The number of late AMD events was low (N = 7) and the estimate of effect was uncertain (RR 1.36, 95% CI 0.31 to 6.05; very low‐certainty evidence). There was no evidence of any effect of treatment on visual loss (RR 1.04, 95% CI 0.74 to 1.47; low‐certainty evidence). There were no data on neovascular AMD, geographic atrophy, or quality of life.<br/>Five studies compared zinc with placebo. Evidence largely drawn from the largest study (AREDS) found a lower progression to late AMD over six years (OR 0.83, 95% CI 0.70 to 0.98; 3 studies, 3790 participants; moderate‐certainty evidence), neovascular AMD (OR 0.76, 95% CI 0.62 to 0.93; moderate‐certainty evidence), geographic atrophy (OR 0.84, 95% CI 0.64 to 1.10; moderate‐certainty evidence), or visual loss (OR 0.87, 95% CI 0.75 to 1.00; 2 studies, 3791 participants; moderate‐certainty evidence). There were no data on quality of life. Gastrointestinal symptoms were the main reported adverse effect. In AREDS, zinc was associated with a higher risk of genitourinary problems in men, but no difference was seen between high‐ and low‐dose zinc groups in AREDS2. </p> <p>Most studies were too small to detect rare adverse effects. Data from larger studies (AREDS/AREDS2) suggested there may be little or no effect on mortality with multivitamin (HR 0.87, 95% CI 0.60 to 1.25; low‐certainty evidence) or lutein/zeaxanthin supplementation (HR 1.06, 95% CI 0.87 to 1.31; very low‐certainty evidence), but confirmed the increased risk of lung cancer with beta‐carotene, mostly in former smokers. </p> </section> <section id="CD000254-sec-0007"> <h3 class="title" id="CD000254-sec-0007">Authors' conclusions</h3> <p>Moderate‐certainty evidence suggests that antioxidant vitamin and mineral supplementation (AREDS: vitamin C, E, beta‐carotene, and zinc) probably slows down progression to late AMD. People with intermediate AMD have a higher chance of benefiting from antioxidant supplements because their risk of progression is higher than people with early AMD. Although low‐certainty evidence suggested little effect with lutein/zeaxanthin alone compared with placebo, exploratory subgroup analyses from one large American study support the view that lutein/zeaxanthin may be a suitable replacement for the beta‐carotene used in the original AREDS formula. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000254-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000254-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD000254-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD000254-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000254-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000254-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD000254-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD000254-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD000254-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD000254-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD000254-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD000254-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000254-abs-0002" lang="en"> <h3>Do antioxidant vitamin and mineral supplements slow down the progression of age‐related macular degeneration (AMD)? </h3> <p><b>Key messages</b><br/>‐ Taking an antioxidant multivitamin supplement may slow down the progression of age‐related macular degeneration (AMD), an eye disease that blurs your central vision. </p> <p>‐ People with intermediate AMD have a higher chance of benefiting from antioxidant supplements because their risk of progression is higher than for people with early AMD. </p> <p>‐ Although vitamin supplements are generally regarded as safe, the studies included in this review did not provide good evidence as to safety as they were generally too small. </p> <p><b>What is age‐related macular degeneration?</b> </p> <p>Age‐related macular degeneration (AMD) is an eye disease that blurs your central vision. It is usually only diagnosed in people aged 50 years and above. AMD affects the central area (macula) of the back of the eye (retina), as the macula degenerates with age. </p> <p>In early AMD, yellow spots (called drusen) can be seen under the retina by an eye health professional. The affected person will probably be unaware that they have a problem. As the disease progresses, the drusen become larger (intermediate AMD). In the later stages of the disease, there may be loss of the cells – needed for vision – in the back of the eye. This is known as geographic atrophy. Sometimes, new (harmful) blood vessels grow in the macula. These new blood vessels may bleed and cause scarring. This is known as neovascular AMD. Neovascular AMD and geographic atrophy are known as late AMD. </p> <p><b>Why might antioxidant vitamins and minerals be helpful?</b> </p> <p>Antioxidant vitamins and minerals may help to protect the macula against this deterioration and loss of vision. Antioxidants are natural molecules that may prevent or delay some types of cell damage. Vitamins C and E, beta‐carotene, lutein, zeaxanthin, and zinc are examples of antioxidants commonly found in dietary supplements. </p> <p><b>What did we want to find out?</b><br/>We wanted to find out whether antioxidant vitamin and mineral supplements slow down the progression of age‐related macular degeneration (AMD) and prevent visual loss. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that compared antioxidant vitamin and mineral supplements with placebo (a ‘dummy’ treatment not containing any supplements) or no treatment. We only looked at the effects of these supplements in people with AMD. There is another Cochrane Review on the effects of these supplements in people who do not already have AMD. We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found 26 studies from the USA, Europe, China, and Australia that enroled 11,952 people with AMD. These studies compared multivitamin supplements, zinc, vitamin E, lutein (with or without zeaxanthin) with placebo. Participants were aged 65 to 75 years and there were slightly more women than men in the studies. </p> <p><b>Main findings</b> </p> <p>• Taking an antioxidant multivitamin supplement (AREDS formula containing vitamins E and C, beta‐carotene plus zinc) probably slows down the progression of AMD to late AMD and vision loss. This may result in a small improvement in quality of life. </p> <p>• People with intermediate AMD have a higher risk of progression to late AMD and so may be more likely to benefit from supplements (78 fewer cases of progression for every 1000 people taking supplements). People with early AMD have a low risk of progression and so may be less likely to benefit (4 fewer cases of progression to late AMD for every 1000 people taking supplements). </p> <p>• Lutein with or without zeaxanthin may have little or no effect on progression to late AMD but may be a suitable replacement for beta‐carotene in the AREDS formula. Beta‐carotene may increase the chance of lung cancer in people who have smoked. </p> <p>• The effects of vitamin E alone on the progression to late AMD and vision loss are uncertain. </p> <p>Although vitamin supplements are generally regarded as safe, the studies included in this review did not provide good evidence about safety because most of the studies were small and reported on harmful effects inconsistently. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the evidence ranged from moderate to very low. This is because most of the included studies were small, and they did not cover all the comparisons and outcomes we were interested in. </p> <p><b>How up to date is this review?</b><br/>This review updates our previous version. The evidence is up to date to 29 November 2022. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000254-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000254-sec-0064"></div> <h3 class="title" id="CD000254-sec-0065">Implications for practice</h3> <section id="CD000254-sec-0065"> <p>People with age‐related macular degeneration (AMD) probably experience moderate delay in progression of the disease with antioxidant vitamin and mineral supplementation. This finding was drawn from one large study conducted in a relatively well‐nourished American population. Until it is replicated by other large‐scale studies in other populations, we will not know whether these findings can be applied more generally. People with intermediate AMD have a higher chance of benefiting from antioxidant supplements because their risk of progression is higher than people with early AMD. Although low‐certainty evidence suggested little effect with lutein/zeaxanthin alone compared with placebo, exploratory subgroup analyses from one large study in the USA suggest lutein/zeaxanthin may be a suitable replacement for beta‐carotene as used in the original Age‐Related Eye Disease Study (AREDS) formula. Beta‐carotene is known to be associated with an increased risk of lung cancer in people who have smoked or have been exposed to asbestos. </p> <p>Antioxidant vitamin and mineral supplements are readily available for purchase without prescription in many countries. The decision to take these supplements is at the discretion of the person with AMD. The following benefits and harms need to be considered. People with AMD may delay the progression of their condition if they take antioxidant vitamins and zinc at the levels described in this review. Given that there are few other interventions that offer much in the way of disease prevention or cure, this is an important consideration. Participants in the study providing most of the evidence took supplements for an average of six years. Harmful effects associated with long‐term vitamin supplementation, particularly in smokers and people with vascular disease, cannot be ruled out. A healthy diet with a variety of fresh fruit and vegetables will have many benefits and is unlikely to be harmful. However, it may be difficult to consume, as part of a normal diet, the levels of antioxidants and zinc described in the studies included in this review. </p> </section> <h3 class="title" id="CD000254-sec-0066">Implications for research</h3> <section id="CD000254-sec-0066"> <p>Studies in other populations, preferably with a variety of nutritional statuses, are required. These studies should have large enough sample sizes, and long enough durations, to demonstrate effects that are meaningful for people. They should also include outcomes relevant to people affected by AMD, including quality of life assessment. Core outcome sets should be used as much as possible. It is likely that AMD develops over many years. Three categories of people may be identified: healthy people at risk because of age or genetic factors; people with early stages of the disease; and people with intermediate or late‐stage disease. If antioxidant supplementation is protective, there may be differences in the effect, depending on the stage of the disease. </p> <p>Study reporting should include enough information to assess the risk of selective outcome reporting bias (ideally, by providing online access to the protocol for the study), and clearer information about follow‐up of participants in the study; in particular, reasons for participant exclusion. </p> <p>As antioxidant vitamin and mineral supplements have systemic effects, the literature on this topic would be much improved by a systematic review of the potential harms of such products, including sources of evidence broader than randomised controlled studies alone. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000254-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000254-sec-0008"></div> <div class="table" id="CD000254-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antioxidant multivitamin and mineral supplement versus placebo or no treatment for slowing the progression of age‐related macular degeneration</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Antioxidant multivitamin and mineral supplement versus placebo or no treatment for slowing the progression of age‐related macular degeneration </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with AMD<br/><b>Setting:</b> community<br/><b>Intervention:</b> AREDS formula: vitamin C 500 mg, vitamin E 400 IU, beta‐carotene 15 mg daily, plus zinc 80 mg as zinc oxide, copper 2 mg as cupric oxide (daily)<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with antioxidant multivitamin and mineral supplement</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to late AMD (neovascular AMD, geographic atrophy, or both)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.72<br/>(0.58 to 0.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2445<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Most evidence from AREDS study with average follow‐up of 6 years.</p> <p>AREDS formula (minus beta‐carotene) with lutein/zeaxanthin versus AREDS formula with beta‐carotene: hazard ratio (HR) 0.82 (95% CI 0.69 to 0.96) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/>(9 to 14) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>352 per 1000<br/>(304 to 404) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to neovascular AMD</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.62<br/>(0.47 to 0.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1206<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 6 years. Estimate of effect from study population including AMD categories 3 &amp; 4 only. </p> <p>AREDS formula (minus beta‐carotene) with lutein/zeaxanthin versus AREDS formula with beta‐carotene: HR 0.78 (95% CI 0.64 to 0.94). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/>(5 to 8) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000<br/>(168 to 260) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to geographic atrophy</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.75<br/>(0.51 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1206<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 6 years. Estimate of effect from study population including AMD categories 3 &amp; 4 only. </p> <p>AREDS formula (minus beta‐carotene) with lutein/zeaxanthin versus AREDS formula with beta‐carotene: HR </p> <p>0.94 (95% CI 0.70 to 1.26).</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/>(5 to 11) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>243 per 1000<br/>(179 to 320) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to visual loss (loss of 3 or more lines on logMAR chart)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.77<br/>(0.62 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1791<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Average follow‐up of 6 years</p> <p>AREDS formula (minus beta‐carotene) with lutein/zeaxanthin versus AREDS formula with beta‐carotene: HR 0.88 (95% CI 0.75 to 1.03) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/>(9 to 14) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>367 per 1000<br/>(319 to 420) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life assessed with: change in National Eye Institute Visual Function Questionnaire (NEI‐VFQ) score (higher scores better) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in NEI‐VFQ score in the control group was ‐8.7</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean NEI‐VFQ quality of life score in the intervention group was 12.3 higher (4.24 higher to 20.36 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follow‐up of 24 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Most studies were too small to detect rare adverse effects. Data from AREDS suggested little or no effect on mortality (HR 0.87, 95% CI 0.60 to 1.25). Participants in the antioxidant arms of AREDS more frequently reported yellow skin (8.3% versus 6.0%, P = 0.008). Additional data from AREDS2 found increased risk of lung cancer in the beta‐carotene versus no beta‐carotene group (23 (2.0%) versus 11 (0.9%)), mostly in former smokers. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resource use and costs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is estimated using data from AREDS: low risk = AREDS category 2; high risk = AREDS category 4. </p> <p><b>AMD:</b> age‐related macular degeneration; <b>AREDS:</b> Age‐Related Eye Disease Study; <b>CI:</b> confidence interval; <b>logMAR:</b> logarithm of the minimum angle of resolution; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision because upper confidence interval within range 0.8 to 1.25. <br/><sup>b</sup>Downgraded one level for risk of bias because study was not placebo‐controlled and at high risk of performance and detection bias, and one level for imprecision because confidence intervals included clinically insignificant effect.<br/><sup>c</sup>Downgraded one level for imprecision because included studies were underpowered to look at adverse events, and one level for risk of bias as adverse events were reported inconsistently. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000254-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Lutein with or without zeaxanthin versus placebo for slowing the progression of age‐related macular degeneration</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Lutein with or without zeaxanthin versus placebo for slowing the progression of age‐related macular degeneration </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with AMD<br/><b>Setting:</b> community<br/><b>Intervention:</b> lutein 10 mg, zeaxanthin 2 mg<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lutein/zeaxanthin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to late AMD (neovascular AMD, geographic atrophy, or both)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.94 (0.87 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6891 eyes</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 5 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000 (13 to 15)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>404 per 1000 (374 to 434)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to neovascular AMD</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.92 (0.84 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6891 eyes</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 5 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> <p>(8 to 10)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>276 per 1000</p> <p>(252 to 306)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to geographic atrophy</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.92 (0.80 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6891 eyes</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 5 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> <p>(8 to 11)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>276 per 1000</p> <p>(240 to 315)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to visual loss (loss of 3 or more lines on logMAR chart)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.98 (0.91 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6656 eyes</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝ Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 5 years</p> <p>On average, visual acuity was the same: 0.00 logMAR (95% CI ‐0.05 to 0.05; 3 studies, 231 participants; follow‐up of 12 months) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> <p>(14 to 16)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>421 per 1000</p> <p>(391 to 452)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life assessed with Visual Function Questionnaire (VFQ) (higher scores better)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VFQ quality of life score in the control group ranged from 73.1 to 77.3</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VFQ quality of life score in the intervention group was 1.21 higher (better) (2.59 lower to 5.01 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>308<br/>(2 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝ Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follow‐up of 12 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Most studies were too small to detect rare adverse effects. Data from AREDS2 suggested little or no effect on mortality (HR 1.06, 95% CI 0.87 to 1.31). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resource use and costs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is estimated using data from AREDS: low risk = AREDS category 2; high risk = AREDS category 4. </p> <p><b>AMD:</b> age‐related macular degeneration; <b>AREDS:</b> Age‐Related Eye Disease Study; <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>logMAR:</b> logarithm of the minimum angle of resolution; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision, as confidence interval includes 1 null effect, and one level for indirectness, as study was not placebo‐controlled.<br/><sup>b</sup>Downgraded one level for imprecision, as confidence interval includes 0 null effect, and one level for risk of bias, as studies were poorly reported. <br/><sup>c</sup>Downgraded one level for imprecision as studies were small to detect adverse effects and (for mortality in AREDS2) confidence interval includes 1 null effect; downgraded one level for indirectness as study was not placebo‐controlled; downgraded one level as adverse effects were inconsistently reported. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000254-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Vitamin E versus placebo for slowing the progression of age‐related macular degeneration</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Vitamin E versus placebo for slowing the progression of age‐related macular degeneration</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with AMD<br/><b>Setting:</b> community<br/><b>Intervention:</b> vitamin E (500 IU per day: natural vitamin E in soybean oil medium)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>**</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with vitamin E supplement</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to late AMD (neovascular AMD, geographic atrophy or both)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.36 (0.31 to 6.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>998<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 4 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(5 to 91) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>585 per 1000<br/>(133 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression to neovascular AMD</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression to geographic atrophy</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to visual loss (loss of 3 or more lines on logMAR chart)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.04<br/>(0.74 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1179<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 4 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>16 per 1000<br/>(11 to 22) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>447 per 1000<br/>(318 to 632) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No serious adverse effects were seen. Similar numbers of people in the vitamin E and placebo groups withdrew due to adverse effects (4 versus 7), reported any adverse effect (91 versus 83), or ocular adverse effect (105 versus 90). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resource use and costs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is estimated using data from AREDS: low risk = AREDS category 2; high risk = AREDS category 4. </p> <p><b>AMD:</b> age‐related macular degeneration; <b>AREDS:</b> Age‐Related Eye Disease Study; <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>logMAR:</b> logarithm of the minimum angle of resolution; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for imprecision as only 7 events.<br/><sup>b</sup>Downgraded one level for indirectness as over 80% of the participants in this study had no signs of AMD at baseline.<br/><sup>c</sup>Downgraded three levels for imprecision as the study was underpowered to look at rare adverse effects. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000254-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Zinc versus placebo for slowing the progression of age‐related macular degeneration</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Zinc versus placebo for slowing the progression of age‐related macular degeneration</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with AMD<br/><b>Setting:</b> community<br/><b>Intervention:</b> zinc*<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>**</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with zinc</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to late AMD (neovascular AMD, geographic atrophy or both)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.83<br/>(0.70 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3790<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Most evidence from AREDS study with average follow‐up of 6 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/>(11 to 15) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>385 per 1000<br/>(346 to 425) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to neovascular AMD</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.76<br/>(0.62 to 0.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2442<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 6 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/>(6 to 9) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>246 per 1000<br/>(210 to 285) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to geographic atrophy</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.84<br/>(0.64 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2442<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 6 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/>(6 to 11) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265 per 1000<br/>(215 to 320) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to visual loss (loss of 3 or more lines on logMAR chart)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.87<br/>(0.75 to 1.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3791<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up in study contributing most of the events was 6 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000<br/>(11 to 15) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>396 per 1000<br/>(361 to 430) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>In some studies, gastrointestinal symptoms were reported as a reason for withdrawal. Of 286 people randomised into studies of zinc sulfate supplementation compared with placebo (not including AREDS), 5/146 zinc‐treated people withdrew due to gastrointestinal symptoms compared with 2/140 controls. No one developed copper‐deficiency anaemia (high zinc intakes can inhibit copper absorption). In AREDS, participants in the zinc arms reported more anaemia (13.2% versus 10.2%, P = 0.004); however, serum haematocrit levels were the same. In AREDS, zinc was associated with higher risk of genitourinary problems in men, but no difference seen between high‐ and low‐dose zinc groups in AREDS2. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resource use and costs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* Most of the evidence in this table is drawn from the AREDS study, which studied a daily dose of zinc 80 mg as zinc oxide, copper 2 mg as cupric oxide. </p> <p>**<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is estimated using data from AREDS: low risk = AREDS category 2; high risk = AREDS category 4. </p> <p><b>AMD:</b> age‐related macular degeneration; <b>AREDS:</b> Age‐Related Eye Disease Study; <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>logMAR:</b> logarithm of the minimum angle of resolution; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision because upper confidence interval within range 0.8 to 1.25. <br/><sup>b</sup>Downgraded for one level for imprecision (as included studies were underpowered to look at adverse effects), one level for risk of bias (adverse effects were inconsistently reported), and one level for inconsistency (inconsistent results reported). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000254-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000254-sec-0009"></div> <section id="CD000254-sec-0010"> <h3 class="title" id="CD000254-sec-0010">Description of the condition</h3> <p>Age‐related macular degeneration (AMD) is a disease affecting the central area of the retina (macula). In the early stages of the disease, lipid material accumulates in deposits underneath the retinal pigment epithelium. These deposits are known as drusen and can be seen as pale yellow spots on the retina. The pigment of the retinal pigment epithelium may become disturbed, with areas of hyperpigmentation and hypopigmentation. In the later stages of the disease, the retinal pigment epithelium may atrophy completely. This loss can occur in small focal areas or can be widespread (geographic atrophy). In some cases, new blood vessels grow under the retinal pigment epithelium and, occasionally, into the subretinal space (exudative or neovascular AMD). Haemorrhage can occur, which often results in increased scarring of the retina. </p> <p>There have been a number of different clinical classifications of the condition, based on observations of drusen, pigmentary abnormalities, neovascular AMD, and geographic atrophy. In this review, we use the Beckman Initiative classification (<a href="#CD000254-tbl-0005">Table 1</a>; <a href="./references#CD000254-bbs2-0115" title="Ferris FL 3rd, WilkinsonCP , BirdA , ChakravarthyU , ChewE , CsakyK , et al, Beckman Initiative for Macular Research Classification Committee. Clinical classification of age-related macular degeneration. Ophthalmology2013;120(4):844-51.">Ferris 2013</a>). In this classification, people with no drusen, or small drusen only and no pigmentary abnormalities, are considered to have no AMD or normal ageing changes. The term 'early AMD' is restricted to people with medium‐sized drusen (≥ 63 μm and &lt; 125 μm) and no pigmentary abnormalities. 'Intermediate AMD' refers to people with large drusen (≥ 125 μm) and pigmentary abnormalities. 'Late AMD' defines people with neovascular AMD, geographic atrophy, or both. <a href="#CD000254-tbl-0005">Table 1</a> also shows how this classification maps on to the categories used in the Age‐Related Eye Disease Study (AREDS)(<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>). </p> <div class="table" id="CD000254-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">AMD clinical classification (Beckman Initiative for Macular Research Classification Committee)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Classification of AMD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition<br/>(lesions assessed within 2 disc<br/>diameters of fovea in either eye)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison with AREDS categories</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terminology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small drusen &lt; 63 μm</p> <p>Medium drusen ≥ 63 μm and &lt; 125 μm</p> <p>Large drusen ≥ 125 μm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small drusen &lt; 63 μm</p> <p>Intermediate drusen ≥ 63 μm and &lt; 125 μm</p> <p>Large drusen ≥ 125 μm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No apparent aging changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No drusen and</p> <p>no AMD pigmentary abnormalities*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMD Category 1</p> <p>No or small drusen</p> <p>No pigment abnormalities</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal aging changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only small drusen and</p> <p>no AMD pigmentary abnormalities*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMD Category 1</p> <p>No or small drusen</p> <p>No pigment abnormalities</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium drusen</p> <p>No AMD pigmentary abnormalities*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMD category 2</p> <p>Intermediate drusen</p> <p>Pigment abnormalities may be absent or present</p> <p>Also includes small drusen if cover more than 1/150 disc areas</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Large drusen and/or</p> <p>any AMD pigmentary abnormalities*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMD category 3</p> <p>Broader category including intermediate, large drusen, and noncentral geographic atrophy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Late AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neovascular AMD and/or<br/>any geographic atrophy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMD category 4</p> <p>Neovascular AMD or geographic atrophy</p> <p>Also includes visual acuity worse than 6/9 due to AMD</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>From: <a href="./references#CD000254-bbs2-0115" title="Ferris FL 3rd, WilkinsonCP , BirdA , ChakravarthyU , ChewE , CsakyK , et al, Beckman Initiative for Macular Research Classification Committee. Clinical classification of age-related macular degeneration. Ophthalmology2013;120(4):844-51.">Ferris 2013</a> </p> <p>AMD: age‐related macular degeneration; AREDS: Age‐related Eye Disease Study</p> <p>*AMD pigmentary abnormalities: any definite hyper‐ or hypopigmentary abnormalities associated with medium or large drusen but not associated with known disease entities </p> </div> </div> <p>In general, the early stages of the disease are asymptomatic. In the later stages, there may be a considerable distortion of vision and complete loss of visual function, particularly in the central area of vision. </p> <p>Large genome‐wide association studies have identified several AMD‐associated genetic variants (<a href="./references#CD000254-bbs2-0149" title="WarwickA , LoteryA . Genetics and genetic testing for age-related macular degeneration. Eye2018;32:849–57.">Warwick 2018</a>). Variations in two genes, in particular, appear to be most strongly associated with both the development of AMD and its progression to the advanced stages of the disease. These are the complement factor H (CFH) gene on chromosome 1 and the age‐related maculopathy susceptibility 2 (ARMS2) gene on chromosome 10. </p> <p>Population‐based studies suggest that, in older people (80 years and above), approximately one in three people have early signs of the disease (<a href="./references#CD000254-bbs2-0128" title="KleinR , KleinBE , LintonKL . Prevalence of age-related maculopathy. The beaver dam eye study. Ophthalmology1992;99(6):933-43.">Klein 1992</a>). The estimated prevalence of late AMD is 1.4% (95% credible interval (CrI) 1.0% to 2.0%) at 70 years of age, 5.6% (95% CrI 3.9% to 7.7%) at age 80, and 20% (95% CrI 14% to 27%) at age 90 (<a href="./references#CD000254-bbs2-0143" title="RudnickaAR , JarrarZ , WormaldR , CookDG , FletcherA , OwenCG . Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology2012;119(3):571-80.">Rudnicka 2012</a>). It is the most common cause of blindness and visual impairment in industrialised countries (<a href="./references#CD000254-bbs2-0100" title="BunceC , XingW , WormaldR . Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008. Eye2010;24(11):1692-9.">Bunce 2010</a>). </p> </section> <section id="CD000254-sec-0011"> <h3 class="title" id="CD000254-sec-0011">Description of the intervention</h3> <p>Antioxidants micronutrients are any vitamin or mineral that is known to have antioxidant properties in vivo, or that has been shown to be an important component of an antioxidant enzyme present in the retina. The following vitamins and minerals are usually considered to be 'antioxidant': vitamin C, vitamin E, carotenoids, selenium, and zinc. These supplements are taken orally and may be taken alone or in combination. </p> <p>Supplementation has two aims: either to prevent nutritional deficiency, by ensuring recommended daily intakes are achieved; or to provide a high pharmaceutical dose with potentially therapeutic effects. <a href="#CD000254-tbl-0006">Table 2</a> shows the recommended daily intakes for these micronutrients, along with examples of 'high dose' amounts seen in eye health supplements. Currently, there are no recommended daily intakes for carotenoids. Some carotenoids (α‐carotene, β‐carotene, and β‐cryptoxanthin) can be converted into retinol (vitamin A), and others not (lycopene, lutein, and zeaxanthin). </p> <div class="table" id="CD000254-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Dietary reference values for adults for antioxidant vitamins and minerals from the Food and Nutrition Board of the National Academies of Sciences, Engineering, and Medicine in the USA and the European Food Safety Authority</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Antioxidant vitamin / mineral</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Recommended daily intake</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Tolerable daily upper intake levels***</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Example of 'high dose' in eye supplement</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>USA: RDA*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>European: PRI**</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>USA</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>European</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin C</p> <p>mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 (men)</p> <p>75 (women)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (men)</p> <p>95 (women)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 (AREDS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E</p> <p>mg (international units, IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg (28 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AI****</p> <p>13 (men)</p> <p>11 (women)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 (1465 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 IU (AREDS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carotenoids</p> <p>(none set)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selenium μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (Ocupower)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc</p> <p>mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (men)</p> <p>8 (women)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>*****</p> <p>11 (men)</p> <p>8.9 (women)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (AREDS)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Data sources: <a href="./references#CD000254-bbs2-0126" title="Institute of Medicine. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Available at nap.nationalacademies.org/9810. Washington, DC: The National Academies Press, 2000.">Institute of Medicine 2000</a>; <a href="./references#CD000254-bbs2-0127" title="Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum,Nickel, Silicon, Vanadium, and Zinc. Available at nap.nationalacademies.org/10026. Washington, DC: The National Academies Press, 2001.">Institute of Medicine 2001</a>; <a href="./references#CD000254-bbs2-0114" title="European Food Safety Authority. Dietary reference values. www.efsa.europa.eu/en/topics/topic/dietary-reference-values (accessed 31 January 2023).">European Food Safety Authority 2023</a>. </p> <p>* US standards: the recommended daily allowance (RDA) is the average daily level of intake sufficient to meet the nutrient requirements of nearly all (97–98%) healthy individuals; often used to plan nutritionally adequate diets for individuals.<br/>** European standards: the population reference intake (PRI) is the intake of a nutrient that is likely to meet the needs of almost all healthy people in a population.<br/>*** The tolerable upper intake level is the maximum chronic daily intake of a nutrient (from all sources) judged to be unlikely to pose a risk of adverse health effects to humans.<br/>****Adequate intake: an adequate intake (AI) is used when there isn't enough data to calculate an average requirement. An AI is the average nutrient level, based on observations or experiments, that is assumed to be adequate for the population's needs.<br/>***** Different recommendations according to phytate in diet. This is for 900 mg/day phytate in the diet. </p> </div> </div> <p>There have been many observational studies reporting the association between dietary antioxidants and AMD, with inconsistent findings (see examples of reviews: <a href="./references#CD000254-bbs2-0107" title="ChongEW , WongTY , KreisAJ , SimpsonJA , GuymerRH . Dietary antioxidants and primary prevention of age-related macular degeneration: systematic review and meta-analysis. BMJ2007;335(7623):755.">Chong 2007</a>; <a href="./references#CD000254-bbs2-0117" title="FletcherAE . Free radicals, antioxidants and eye diseases: evidence from epidemiological studies on cataract and age-related macular degeneration. Ophthalmic Research2010;44(3):191-8.">Fletcher 2010</a>). Data on vitamin intake in observational studies should be considered with caution, as people who have a diet rich in antioxidant vitamins and minerals, or who choose to take supplements regularly, are different in many ways from those who do not. People who take supplements may adopt a more healthy lifestyle (e.g. not smoking, taking regular exercise), which may reduce their risk of AMD. These differences may not be adequately controlled by statistical analysis. A randomised controlled trial (RCT) design, whereby people are randomly allocated to supplements or placebo, is the best study design to answer questions about associations between antioxidants and the progression of AMD. </p> </section> <section id="CD000254-sec-0012"> <h3 class="title" id="CD000254-sec-0012">How the intervention might work</h3> <p>A dietary antioxidant is defined as "a substance in foods which significantly decreases the adverse effects of reactive oxygen species, reactive nitrogen species, or both on normal physiologic function in humans" (<a href="./references#CD000254-bbs2-0151" title="YoungVR , ErdmanJW , KingJC . Dietary reference intakes. Proposed definition and plan for review of dietary antioxidant and related compounds. Washington, DC: National Academy Press, 1998.">Young 1998</a>). Antioxidants may also help to maintain membrane stability (<a href="./references#CD000254-bbs2-0118" title="Food and Agriculture Organization of the United Nations (FAO)/World Health Organization (WHO) expert consultation. Human Vitamin and Mineral Requirements: Report of a Joint FAO/WHO Expert Consultation; Bangkok, Thailand; 2001. Available at: www.fao.org/3/y2809e/y2809e00.pdf (accessed 30 January 2023).">Food and Agriculture Organization 2001</a>). </p> <p>Photoreceptors in the retina are subject to oxidative stress throughout life, due to combined exposures to light and oxygen. As part of normal physiological processes involving oxygen, reactive oxygen species (including radicals superoxide and hydroxyl ions, hydrogen peroxide, and singlet oxygen) are produced (<a href="./references#CD000254-bbs2-0102" title="CaiJ , NelsonKC , WuM , Sternberg P Jr, JonesDP . Oxidative damage and protection of the RPE. Progress in Retinal and Eye Research2000;19(2):205-21.">Cai 2000</a>). These active and potentially damaging molecules have to be cleared by antioxidant defence systems, including enzymes (e.g. superoxide dismutase, glutathione peroxidase, catalase). Antioxidant vitamins, such as vitamin C, vitamin E, and carotenoids, may also play a role. There are many carotenoids but lutein and zeaxanthin are the main constituents of the macular pigment and are thought both to mop up reactive singlet oxygen and play a role in filtering blue light to avoid damage to the sensory neurons (<a href="./references#CD000254-bbs2-0102" title="CaiJ , NelsonKC , WuM , Sternberg P Jr, JonesDP . Oxidative damage and protection of the RPE. Progress in Retinal and Eye Research2000;19(2):205-21.">Cai 2000</a>). One theory for the pathology of age‐related macular degeneration is that the balance between the development and elimination of the reactive oxygen species is affected, leading to damage to the retinal tissues. It has been proposed that antioxidants may prevent cellular damage in the retina by limiting the damaging effects of free radicals produced in the process of light absorption (<a href="./references#CD000254-bbs2-0108" title="ChristenWG , GlynnRJ , HennekensCH . Antioxidants and age-related eye disease. Current and future perspectives. Annals of Epidemiology1996;6(1):60-6.">Christen 1996</a>). </p> <p>The vitamins and minerals considered in this review may also have anti‐inflammatory, neuroprotective, immune‐modulating effects, effects on gene expression, or both (<a href="./references#CD000254-bbs2-0097" title="AzziA . Many tocopherols, one vitamin E. Molecular Aspects of Medicine2018 ;61:92-103.">Azzi 2018</a>; <a href="./references#CD000254-bbs2-0118" title="Food and Agriculture Organization of the United Nations (FAO)/World Health Organization (WHO) expert consultation. Human Vitamin and Mineral Requirements: Report of a Joint FAO/WHO Expert Consultation; Bangkok, Thailand; 2001. Available at: www.fao.org/3/y2809e/y2809e00.pdf (accessed 30 January 2023).">Food and Agriculture Organization 2001</a>; <a href="./references#CD000254-bbs2-0151" title="YoungVR , ErdmanJW , KingJC . Dietary reference intakes. Proposed definition and plan for review of dietary antioxidant and related compounds. Washington, DC: National Academy Press, 1998.">Young 1998</a>). These other physiological effects may also be important in the progression of AMD, in addition to the antioxidant effects proposed. </p> </section> <section id="CD000254-sec-0013"> <h3 class="title" id="CD000254-sec-0013">Why it is important to do this review</h3> <p>Antioxidant vitamin and mineral supplements are increasingly being marketed for use in age‐related eye diseases, including AMD. A critical appraisal and summary of the evidence will be of use to the following groups: (1) people with AMD, who need reliable information in order to decide whether to take vitamin supplements; (2) people who are treating or supporting individuals with AMD, who need reliable information to share with patients; (3) eye care clinicians, who need appraised evidence to inform their practice; and (4) healthcare professionals preparing clinical guidelines, who need high‐quality evidence syntheses. This is the third update of this review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000254-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000254-sec-0014"></div> <p>To assess the effects of antioxidant vitamin and mineral supplements on the progression of AMD in people with AMD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000254-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000254-sec-0015"></div> <section id="CD000254-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000254-sec-0017"> <h4 class="title">Types of studies</h4> <p>This review included randomised controlled trials (RCTs).</p> </section> <section id="CD000254-sec-0018"> <h4 class="title">Types of participants</h4> <p>Participants in the studies were people with AMD in one or both eyes. We did not place any restrictions on participants but note that AMD is usually diagnosed in people aged 50 years and above and increases with increasing age; therefore, most participants in included studies were older adults. </p> </section> <section id="CD000254-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies which compared antioxidant vitamin or mineral supplementation, alone or in combination, with placebo or no intervention. We defined antioxidants as any vitamin or mineral known to have antioxidant properties in vivo, or known to be an important component of an antioxidant enzyme present in the retina. The following were considered: vitamin C, vitamin E, carotenoids (including the macular pigment carotenoids lutein and zeaxanthin), selenium, and zinc. We excluded studies where antioxidant vitamins were combined with other potentially active ingredients. </p> <p>The overall objective of the review was to assess the impact of antioxidant vitamin and mineral supplements on the progression of AMD. Studies in this area fall into two broad categories: those evaluating a single vitamin or mineral (for example, vitamin E or zinc), and those investigating a multivitamin formulation (for example, Ocuguard). We considered the following comparisons in this review. </p> <p> <ul id="CD000254-list-0001"> <li> <p>Multivitamin formulation versus placebo. All the formulations which include two or more antioxidant vitamins or minerals fall into this category. </p> </li> <li> <p>Single‐component formulations versus placebo. Currently, only vitamin E, zinc, and lutein have been studied as single formulations. However, in principle, any of the antioxidant vitamins or minerals could be assessed as individual components. </p> </li> </ul> </p> </section> <section id="CD000254-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We modified our protocol for the update in 2017 to include outcomes specified by the UK National Institute for Health and Care Excellence (NICE) macular degeneration guideline panel (<a href="./references#CD000254-bbs2-0137" title="National Institute for Health and Care Excellence (NICE). Age-related macular degeneration. NICE guideline NG82; January 2018. www.nice.org.uk/guidance/ng82 (accessed 23 March 2021).">NICE 2018</a>); see <a href="#CD000254-sec-0085">Differences between protocol and review</a>. </p> <p>We considered the following outcomes:</p> <p> <ul id="CD000254-list-0002"> <li> <p>progression to late AMD (neovascular AMD, geographic atrophy, or both);</p> </li> <li> <p>progression to neovascular AMD;</p> </li> <li> <p>progression to geographic atrophy;</p> </li> <li> <p>progression to visual loss (loss of 3 or more lines on logarithm of the minimum angle of resolution (logMAR) chart)*; </p> </li> <li> <p>quality of life;</p> </li> <li> <p>resource use and costs.</p> </li> </ul> </p> <p>*As visual acuity is also commonly reported as a 'mean score', we also include mean visual acuity as a continuous outcome. </p> <p>We considered the maximum follow‐up identified in the studies at any point in time.</p> <section id="CD000254-sec-0021"> <h5 class="title">Adverse effects</h5> <p>We considered any adverse effects reported by the included studies.</p> </section> </section> </section> <section id="CD000254-sec-0022"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD000254-sec-0023"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision Information Specialist conducted systematic searches in the databases listed below for randomised controlled trials and controlled clinical trials. There were no restrictions on language or year of publication. The date of the search was 29 November 2022. </p> <p> <ul id="CD000254-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2022, Issue 11) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (searched 29 November 2022) (<a href="./appendices#CD000254-sec-0070">Appendix 1</a>). </p> </li> <li> <p>MEDLINE Ovid (1946 to 29 November 2022) (<a href="./appendices#CD000254-sec-0071">Appendix 2</a>). </p> </li> <li> <p>Embase Ovid (1980 to 29 November 2022) (<a href="./appendices#CD000254-sec-0072">Appendix 3</a>). </p> </li> <li> <p>AMED (Allied and Complementary Medicine Database) (1985 to 29 November 2022) (<a href="./appendices#CD000254-sec-0073">Appendix 4</a>). </p> </li> <li> <p>ISRCTN registry (<a href="http://www.isrctn.com/editAdvancedSearch" target="_blank">www.isrctn.com/editAdvancedSearch</a>; searched 29 November 2022) (<a href="./appendices#CD000254-sec-0074">Appendix 5</a>). </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 29 November 2022) (<a href="./appendices#CD000254-sec-0075">Appendix 6</a>). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>; searched 29 November 2022) (<a href="./appendices#CD000254-sec-0076">Appendix 7</a>). </p> </li> </ul> </p> <p>For the 2012 and 2017 updates, we specifically looked for adverse effects, using a simple search aimed to identify systematic reviews of adverse effects of vitamin supplements; see <a href="./appendices#CD000254-sec-0077">Appendix 8</a> for search strategy. </p> <p>For the 2022 update, we did not search OpenGrey as this resource has now been archived.</p> </section> <section id="CD000254-sec-0024"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of identified study reports to find additional studies. We used the Science Citation Index to find studies that cited the identified studies. We contacted investigators of included studies to identify additional published and unpublished studies. </p> </section> </section> <section id="CD000254-sec-0025"> <h3 class="title" id="CD000254-sec-0025">Data collection and analysis</h3> <section id="CD000254-sec-0026"> <h4 class="title">Selection of studies</h4> <p>Both review authors independently assessed the titles and abstracts of all reports of studies identified by the electronic searches. We obtained the full texts of possibly relevant studies. We selected relevant studies according to the definitions in the <a href="#CD000254-sec-0016">Criteria for considering studies for this review</a>. </p> </section> <section id="CD000254-sec-0027"> <h4 class="title">Data extraction and management</h4> <p>We extracted data using a standardised form, developed by Cochrane Eyes and Vision. For the initial review, we sent these data for verification to the investigators of all studies included in the review. In the 2012 and current updates, both review authors independently extracted data. We compared our datasets and resolved any disagreements through discussion. One author cut and pasted the data into Review Manager Web (<a href="./references#CD000254-bbs2-0141" title="Review Manager Web (RevMan Web). Version 4.24.0. The Cochrane Collaboration, 2023. Available at revman.cochrane.org.">Review Manager Web 2023</a>), and the other author checked for accuracy and fidelity. In the current update, we screened citations and extracted duplicate data using web‐based review management software (<a href="./references#CD000254-bbs2-0109" title="Covidence. Version accessed 30 November 2022. Melbourne, Australia: Veritas Health Innovation. Available at www.covidence.org.">Covidence</a>). </p> </section> <section id="CD000254-sec-0028"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risk of bias using Cochrane's tool for assessing the risk of bias, as described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000254-bbs2-0124" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). </p> </section> <section id="CD000254-sec-0029"> <h4 class="title">Measures of treatment effect</h4> <p>We used the risk ratio (RR) for dichotomous outcomes where possible. As one of the main large studies reported odds ratios (OR) and their confidence intervals only (derived from repeated‐measures logistic regression), we used the OR as the measure of effect for analyses that included this study (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>). </p> <p>For continuous outcomes, we used the mean difference (MD). Where possible, we checked for skewness using methods outlined in Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000254-bbs2-0111" title="DeeksJJ , HigginsJP , Altman DG (editors), on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>). </p> </section> <section id="CD000254-sec-0030"> <h4 class="title">Unit of analysis issues</h4> <p>The main study design method in this area is the parallel‐group randomised controlled trial. Cluster‐randomised studies were unlikely, but we would have considered them. Cross‐over studies would not generally be appropriate in this area because of the uncertain and complex natural history of AMD. If we identify eligible cross‐over studies in the future, we will only use data from the first phase. </p> <p>As the intervention is applied to the individual, the unit of randomisation is the individual person. As people have two eyes, it is possible for there to be a unit of analysis issue if eyes are reported, rather than results for the person. For each included study, we documented whether the unit of analysis was the same as the unit of randomisation and noted any implications for the analysis. For studies reporting right and left eyes separately, we extracted data for the right eye. </p> </section> <section id="CD000254-sec-0031"> <h4 class="title">Dealing with missing data</h4> <p>The data included in the review represent an 'available‐case analysis'. The majority of the data in the current review came from two large studies with high (over 95%) follow‐up. </p> <p>Two studies specifically excluded people who experienced a neovascular event (one component of late‐stage AMD) from the analyses (<a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a>; <a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a>). The published reports did not give enough information to include these people in the analyses. </p> </section> <section id="CD000254-sec-0032"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity by looking at the forest plots to see whether the effect measures for the different studies were in the same direction and of a similar order of effect. We interpreted an I² statistic value of 50% or more to indicate considerable inconsistency of results, such that a pooled result may be inaccurate and should not be reported. The I² statistic aims to assess the consistency of the study results in meta‐analyses: it describes the percentage of variation across studies that is due to heterogeneity rather than chance (<a href="./references#CD000254-bbs2-0123" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [DOI: 10.1136/bmj.327.7414.557]">Higgins 2003</a>). </p> <p>The main clinical heterogeneity was the type of supplement. We incorporated this into the analysis strategy by considering the formulations by type. </p> </section> <section id="CD000254-sec-0033"> <h4 class="title">Assessment of reporting biases</h4> <p>In future versions of this review, when sufficient studies are included in the meta‐analyses (10 or more), we plan to examine the funnel plot to assess whether there is any evidence that smaller studies are reporting larger effects, which may indicate publication bias. </p> </section> <section id="CD000254-sec-0034"> <h4 class="title">Data synthesis</h4> <p>We planned to pool data using a random‐effects model (because it was likely that the effects of antioxidant vitamin and mineral supplementation may vary in different population groups), but with the proviso that, if there were three or fewer studies, we would use the fixed‐effect model. Most of our analyses fell into the latter category, and so we largely used a fixed‐effect model. </p> </section> <section id="CD000254-sec-0035"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Currently, there are insufficient included studies to perform useful subgroup analyses; thus, subgroup analyses are not proposed for this version of the review. Characteristics that may be important are the type and severity of AMD, and we may consider these in future review updates. </p> </section> <section id="CD000254-sec-0036"> <h4 class="title">Sensitivity analysis</h4> <p>We did not plan any sensitivity analyses.</p> </section> <section id="CD000254-sec-0037"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared separate summary of findings tables for the different types of vitamin supplement. </p> <p>We assessed the certainty of the evidence (GRADE) for each outcome using customised software (<a href="./references#CD000254-bbs2-0120" title="GRADEpro. Version accessed 31 January 2023. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro</a>). JE carried out the initial assessment of evidence certainty; JL checked the assessments. We considered risk of bias, inconsistency, indirectness, imprecision, and publication bias when judging the certainty of the evidence (<a href="./references#CD000254-bbs2-0146" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from handbook.cochrane.org.">Schünemann 2019</a>). </p> <p>The summary of findings tables include an estimate of the risk of each outcome in the general population. We used data from AREDS to estimate the risk in the control group in low‐risk (AREDS category 2) and high‐risk (AREDS category 4) populations. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000254-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000254-sec-0038"></div> <section id="CD000254-sec-0039"> <h3 class="title">Description of studies</h3> <section id="CD000254-sec-0040"> <h4 class="title">Results of the search</h4> <p>Please see <a href="#CD000254-tbl-0007">Table 3</a> for a summary of searches for previous versions of this review. </p> <div class="table" id="CD000254-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results of searches for previous versions of this review</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Date review published</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Date searches up to date</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Newly included studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of studies included in the review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of excluded studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Studies awaiting assessment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ongoing studies</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>November 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>August 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0001" title="RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 1: design, subjects and procedures. Journal of the American Optometric Association1996;67(1):12-29. RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 2: antioxidant intervention and conclusions. Journal of the American Optometry Association1996;67(1):30-49. ">AMDSG 1996</a>; <a href="./references#CD000254-bbs2-0020" title="NewsomeDA , SwartzM , LeoneNC , ElstonRC , MillerE . Oral zinc in macular degeneration. Archives of Ophthalmology1988;106(2):192-8. ">Newsome 1988</a>; <a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a> (included February 2002) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>; <a href="./references#CD000254-bbs2-0025" title="GarrettSK , McNeilJJ , SilagyC , SinclairM , ThomasAP , RobmanLD , et al. Methodology of the VECAT study: vitamin E intervention in cataract and age-related maculopathy. Ophthalmic Epidemiology1999;6(3):195-208. GarrettSK , ThomasAP , CicuttiniF , SilagyC , TaylorHR , McNeilJJ . Community-based recruitment strategies for a longitudinal interventional study: the VECAT experience. Journal of Clinical Epidemiology2000;53(5):541-8. RobmanLD , TikellisG , GarrettSK , HarperCA , McNeilJJ , TaylorHR , et al. Baseline ophthalmic findings in the vitamin E, cataract and age-related maculopathy (VECAT) study. Australian and New Zealand Journal of Ophthalmology1999;27(6):410-6. TaylorHR , TikellisG , RobmanLD , McCartyCA , McNeilJJ . Vitamin E supplementation and age-related maculopathy. Investigative Ophthalmology and Visual Science2001;42:S311. TikellisG , RobmanLD , HarperCA , GarrettSK , McNeilJJ , TaylorHR , et al. The VECAT study: methodology and statistical power for measurement of age-related macular features. Vitamin E, cataract, and age-related maculopathy study. Ophthalmic Epidemiology1999;6(3):181-94. ">VECAT 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>November 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>October 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0013" title="KaiserHJ , FlammerJ , StumpfigD , HendricksonP . Visaline in the treatment of age-related macular degeneration: a pilot study. Ophthalmologica1995;209(6):302-5. ">Kaiser 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0010" title="There is no publication for this study. ">France 1998</a> (unpublished but included in 2017 update) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>February 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>November 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>; <a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a>; <a href="./references#CD000254-bbs2-0025" title="GarrettSK , McNeilJJ , SilagyC , SinclairM , ThomasAP , RobmanLD , et al. Methodology of the VECAT study: vitamin E intervention in cataract and age-related maculopathy. Ophthalmic Epidemiology1999;6(3):195-208. GarrettSK , ThomasAP , CicuttiniF , SilagyC , TaylorHR , McNeilJJ . Community-based recruitment strategies for a longitudinal interventional study: the VECAT experience. Journal of Clinical Epidemiology2000;53(5):541-8. RobmanLD , TikellisG , GarrettSK , HarperCA , McNeilJJ , TaylorHR , et al. Baseline ophthalmic findings in the vitamin E, cataract and age-related maculopathy (VECAT) study. Australian and New Zealand Journal of Ophthalmology1999;27(6):410-6. TaylorHR , TikellisG , RobmanLD , McCartyCA , McNeilJJ . Vitamin E supplementation and age-related maculopathy. Investigative Ophthalmology and Visual Science2001;42:S311. TikellisG , RobmanLD , HarperCA , GarrettSK , McNeilJJ , TaylorHR , et al. The VECAT study: methodology and statistical power for measurement of age-related macular features. Vitamin E, cataract, and age-related maculopathy study. Ophthalmic Epidemiology1999;6(3):181-94. ">VECAT 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>February 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>January 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0026" title="WangH , LiRX , WangMF . Effects of zinc and antioxidant on visual function of patients with age-related macular degeneration. Zhongguo Linchuant Kangfu2004;8:1290-1. ">Wang 2004</a> (included November 2007) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>November 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>August 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0026" title="WangH , LiRX , WangMF . Effects of zinc and antioxidant on visual function of patients with age-related macular degeneration. Zhongguo Linchuant Kangfu2004;8:1290-1. ">Wang 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>October 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>August 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0005" title="BartlettH , EperjesiF . A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology. Nutrition Journal2003;2:12. BartlettHE , EperjesiF . Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. European Journal of Clinical Nutrition2007;61(9):1121-7. ">Bartlett 2007</a>; <a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a>; <a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a>; <a href="./references#CD000254-bbs2-0021" title="NewsomeDA . A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Current Eye Research2008;33(7):591-8. ">Newsome 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a> (included 2017 update) </p> <p><a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a> and <a href="./references#CD000254-bbs2-0041" title="FalsiniB , PiccardiM , MinnellaA , SavastanoC , CapoluongaE , FaddaA , et al. Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration. Investigative Ophthalmology and Visual Science2010;51(12):6118-24. ">Falsini 2010</a> (both excluded 2017 update) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> and NCT91948476 (<a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a>) (both included 2017 update): NCT00879671 (this is the same trial as <a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a> included in October 2012) </p> <p><a href="./references#CD000254-bbs2-0060" title="NCT00893724. Supplemental adjuvants for intracellular nutrition and treatment (SAINTS) [The effect of supplemental adjuvants for intracellular nutrition and treatment on diabetic macular edema and neovascular age-related macular degeneration]. clinicaltrials.gov/ct2/show/NCT00893724 (first received 4 May 2009). ">NCT00893724</a> (excluded 2017 update) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>June 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>March 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>; <a href="./references#CD000254-bbs2-0006" title="BerrowEJ , BartlettHE , EperjesiF , GibsonJM . The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy - a randomised controlled trial. British Journal of Nutrition2013;109(11):2008-14. ">Berrow 2013</a>; <a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a>; <a href="./references#CD000254-bbs2-0009" title="MurrayIJ , MakridakiM , Van der VeenRL , CardenD , ParryNR , BerendschotTT . Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Investigative Ophthalmology and Visual Science2013;54(3):1781-8. TianY , KijlstraA , Van der VeenRL , MakridakiM , MurrayIJ , BerendschotTT . The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d. PLoS One2013;8:e73387. ">CLEAR 2013</a>; <a href="./references#CD000254-bbs2-0010" title="There is no publication for this study. ">France 1998</a>*; <a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0087" title="NCT01694680. Intervention trial in early age-related macular degeneration (I-TEAM) [Intervention study to assess the effect of daily consumption of a lutein-enriched-egg beverage on maintenance of visual function in subjects with early signs of age-related macular degeneration]. clinicaltrials.gov/ct2/show/NCT01694680 (first received 25 September 2012). ">NCT01694680</a>; <a href="./references#CD000254-bbs2-0088" title="NCT02625376. Resveratrol for exudative age-related macular degeneration (AGED) [Influence of resveratrol and resvega versus placebo on incidence of bilateralisation of exudative AMD: a double masked prospective study]. clinicaltrials.gov/ct2/show/NCT02625376 (first received 6 August 2015). ">NCT02625376</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Current Update (2023)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>November 2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0004" title="AzarG , Quaranta-El MaftouhiM , MasellaJJ , Mauget-FaÿsseM . Macular pigment density variation after supplementation of lutein and zeaxanthin using the Visucam® 200 pigment module: impact of age-related macular degeneration and lens status. Journal Français d'Ophtalmologie2017;40(4):303-13. ">Azar 2017</a>; <a href="./references#CD000254-bbs2-0011" title="AbraldesMJ , NascimentoJ , Hernández-GalileaE , Olmedilla-AlonsoB , Escobar-BarrancoJJ , ZapataMA , et al. A randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration. Nutrients2021;13(4):1253. ">Garcia‐Layana 2021</a>; <a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a>; <a href="./references#CD000254-bbs2-0016" title="LiS , LiuN , LinL , SunED , LiJD , LiPK . Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration. International Journal of Ophthalmology2018;11(6):970-5. ">Li 2018</a>; <a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a>***; <a href="./references#CD000254-bbs2-0022" title="ParravanoM , TedeschiM , MancaD , CostanzoE , Di RenzoA , GiornoP , et al. Effects of Macuprev® supplementation in age-related macular degeneration: a double-blind randomized morpho-functional study along 6 months of follow-up. Advances in Therapy2019;36(9):2493-505. ">Parravano 2019</a>; <a href="./references#CD000254-bbs2-0023" title="PiattiA , CroceA , MazzacaneD , TrainaG , AmbrosinoL , BoniL , et al. Effect of 2-year nutritional supplementation on progression of age-related macular degeneration. European Journal of Ophthalmology2020;30(2):376-81. ">Piatti 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0086" title="ChiosiF , MinutilloE , RinaldiM , GalloO , ManziG . The anti-oxidant effect of vitamin D and homotaurine on progression of early-intermediate age-related macular degeneration. Investigative Ophthalmology and Visual Science2020;61(7):ARVO E-abstract 1789. ">Chiosi 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0087" title="NCT01694680. Intervention trial in early age-related macular degeneration (I-TEAM) [Intervention study to assess the effect of daily consumption of a lutein-enriched-egg beverage on maintenance of visual function in subjects with early signs of age-related macular degeneration]. clinicaltrials.gov/ct2/show/NCT01694680 (first received 25 September 2012). ">NCT01694680</a>; <a href="./references#CD000254-bbs2-0088" title="NCT02625376. Resveratrol for exudative age-related macular degeneration (AGED) [Influence of resveratrol and resvega versus placebo on incidence of bilateralisation of exudative AMD: a double masked prospective study]. clinicaltrials.gov/ct2/show/NCT02625376 (first received 6 August 2015). ">NCT02625376</a>; <a href="./references#CD000254-bbs2-0089" title="NCT03845582. Phase 3 study of ALK-001 in geographic atrophy (SAGA). clinicaltrials.gov/ct2/show/NCT03845582 (first received 19 February 2019). ">NCT03845582</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* This is an unpublished trial for which we are unlikely to be able to obtain the data. We originally excluded this, but following more recent guidelines (see MECIR standard C12; <a href="http://methods.cochrane.org/mecir" target="_blank">methods.cochrane.org/mecir</a>), we included this study in the June 2017 update. </p> <p>** In the 2017 review, the following studies were listed separately as excluded studies, but we note they are the same study and have combined them in one record for the current update. </p> <p> <ul id="CD000254-list-0004"> <li> <p><a href="./references#CD000254-bbs2-0035" title="CangemiFE . TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD. BMC Ophthalmology2007;7:3. ">Cangemi 2007</a> and ISRCTN57556290 </p> </li> <li> <p><a href="./references#CD000254-bbs2-0070" title="KhachikF , deMouraFF , ChewEY , DouglassLW , Ferris FL 3rd, KimJ , et al. The effect of lutein and zeaxanthin supplementation on metabolites of these carotenoids in the serum of persons aged 60 or older. Investigative Ophthalmology and Visual Science2006;47(12):5234-42. RosenthalJM , KimJ , deMonasterioF , deMonastarioF , ThompsonDJ , BoneRA , et al. Dose-ranging study of lutein supplementation in persons aged 60 years or older. Investigative Ophthalmology and Visual Science2006;47(12):5227-33. ">Rosenthal 2006</a>, Khachik 2006 and NCT00006202 </p> </li> <li> <p>Scalinci 2002 and <a href="./references#CD000254-bbs2-0074" title="ScorolliL , ScalinciSZ , LimoliPG , MoraraM , VismaraS , ScorolliL , et al. Photodynamic therapy for age related macular degeneration with and without antioxidants. Canadian Journal of Ophthalmology2002;37(7):399-404. ">Scorolli 2002</a> </p> </li> <li> <p><a href="./references#CD000254-bbs2-0082" title="Wolf-SchnurrbuschUE , ZinkernagelMS , MunkMR , EbneterA , WolfS . Oral lutein supplementation enhances macular pigment density and contrast sensitivity but not in combination with polyunsaturated fatty acids. Investigative Ophthalmology and Visual Science2015;56(13):8069-74. ">Wolf‐Schnurrbusch 2015</a> and NCT00563979 </p> </li> </ul> </p> <p>*** <a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a> excluded in 2017 version of this review. </p> </div> </div> <p>Update searches run on 29 November 2022 yielded a further 1175 records (<a href="#CD000254-fig-0001">Figure 1</a>). After 237 duplicates were removed, the Cochrane Information Specialist screened the remaining 938 records and removed 723 references that were not relevant to the scope of the review. We screened the remaining 215 references. For 191 of these 215 references, it was clear from the title and abstract that the study was not relevant to the review. We obtained 24 full‐text reports for further assessment. These reports comprised: </p> <div class="figure" id="CD000254-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram" data-id="CD000254-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram</p> </div> </div> </div> <p> <ul id="CD000254-list-0005"> <li> <p>six new studies (published in seven reports): <a href="./references#CD000254-bbs2-0004" title="AzarG , Quaranta-El MaftouhiM , MasellaJJ , Mauget-FaÿsseM . Macular pigment density variation after supplementation of lutein and zeaxanthin using the Visucam® 200 pigment module: impact of age-related macular degeneration and lens status. Journal Français d'Ophtalmologie2017;40(4):303-13. ">Azar 2017</a>, <a href="./references#CD000254-bbs2-0011" title="AbraldesMJ , NascimentoJ , Hernández-GalileaE , Olmedilla-AlonsoB , Escobar-BarrancoJJ , ZapataMA , et al. A randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration. Nutrients2021;13(4):1253. ">Garcia‐Layana 2021</a>, <a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a>, <a href="./references#CD000254-bbs2-0016" title="LiS , LiuN , LinL , SunED , LiJD , LiPK . Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration. International Journal of Ophthalmology2018;11(6):970-5. ">Li 2018</a>, <a href="./references#CD000254-bbs2-0022" title="ParravanoM , TedeschiM , MancaD , CostanzoE , Di RenzoA , GiornoP , et al. Effects of Macuprev® supplementation in age-related macular degeneration: a double-blind randomized morpho-functional study along 6 months of follow-up. Advances in Therapy2019;36(9):2493-505. ">Parravano 2019</a>, and <a href="./references#CD000254-bbs2-0023" title="PiattiA , CroceA , MazzacaneD , TrainaG , AmbrosinoL , BoniL , et al. Effect of 2-year nutritional supplementation on progression of age-related macular degeneration. European Journal of Ophthalmology2020;30(2):376-81. ">Piatti 2020</a>; </p> </li> <li> <p>ancillary publications (seven reports) for two already included studies, <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> and <a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>; </p> </li> <li> <p>one study (one report) awaiting classification, as it is currently published only as an abstract (<a href="./references#CD000254-bbs2-0086" title="ChiosiF , MinutilloE , RinaldiM , GalloO , ManziG . The anti-oxidant effect of vitamin D and homotaurine on progression of early-intermediate age-related macular degeneration. Investigative Ophthalmology and Visual Science2020;61(7):ARVO E-abstract 1789. ">Chiosi 2020</a>); </p> </li> <li> <p>one new ongoing study (one report): <a href="./references#CD000254-bbs2-0089" title="NCT03845582. Phase 3 study of ALK-001 in geographic atrophy (SAGA). clinicaltrials.gov/ct2/show/NCT03845582 (first received 19 February 2019). ">NCT03845582</a>; and </p> </li> <li> <p>eight excluded studies (eight reports).</p> </li> </ul> </p> </section> <section id="CD000254-sec-0041"> <h4 class="title">Included studies</h4> <p>A total of 26 studies are now included in the review (20 studies already identified in previous versions of the review and six new studies). A total of 11,952 people were enroled in these studies. Below is a summary of the 26 studies. See <a href="./references#CD000254-sec-0087" title="">Characteristics of included studies</a> for detailed information on individual studies and <a href="#CD000254-tbl-0008">Table 4</a> for a summary. </p> <div class="table" id="CD000254-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Characteristics of included studies</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Type of AMD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Treatment (dose/day)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Treatment duration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Data on eyes or people</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Visual acuity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Progression AMD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0001" title="RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 1: design, subjects and procedures. Journal of the American Optometric Association1996;67(1):12-29. RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 2: antioxidant intervention and conclusions. Journal of the American Optometry Association1996;67(1):30-49. ">AMDSG 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ocuguard:</p> <p>Beta‐carotene 20,000 IU</p> <p>Vitamin E 200 IU</p> <p>Vitamin C 750 mg</p> <p>Citrus bioflavonoid complex 125 mg</p> <p>Quercitin (bioflavonoid) 50 mg</p> <p>Bilberry extract (bioflavonoid) 5 mg</p> <p>Rutin (bioflavonoid) 50 mg</p> <p>Zinc picolinate 12.5 mg</p> <p>Selenium 50 µg</p> <p>Taurine 100 mg</p> <p>N‐acetyl cysteine 100 mg</p> <p>L‐glutathione 5 mg</p> <p>Vitamin B2 25 mg</p> <p>Chromium 100 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Right and left eyes reported separately</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measured using Snellen chart but reported in logMAR units</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Based on Chesapeake Bay grading but using indirect ophthalmoscopy: expressed as an average grade </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMD and VA 20/32 or better in 1 eye</p> <p>956/3640 had AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antioxidants:</p> <p>Vitamin C 500 mg</p> <p>Vitamin E 400 IU</p> <p>Beta‐carotene 15 mg</p> <p>Zinc (zinc oxide) 80 mg</p> <p>Cupric oxide 2 mg</p> <p>Factorial design</p> <p>Antioxidants x zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average duration 6.3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average follow‐up 6.3 years; 2.4% lost to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Person; outcome 'in at least one eye'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss of 3 or more lines VA (equivalent to doubling visual angle) measured using ETDRS chart </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression to advanced AMD: photocoagulation or other treatment for CNV; GA involving centre of the macula, RPE detachment, haemorrhage under the retina, subretinal fibrosis. </p> <p>Colour fundus photography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bilateral large drusen or non‐foveal geographic atrophy (no advanced AMD) or large drusen or non‐foveal geographic atrophy in one eye and advanced AMD in the fellow eye (AREDS Simple Scale Score of 2, 3 or 4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein 10 mg and zeaxanthin 2 mg (1 tablet/day)</p> <p>Almost all participants in both intervention and comparator groups took AREDS supplement and multivitamin with the study medication. </p> <p>Other study arm: there was another study arm looking at docosahexaenoic acid (DHA) 350 mg and eicosapentaenoic acid (EPA) 650 mg (2 soft‐gel capsules/day); it was not included in this review </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 years (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 years (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eyes adjusted for within‐person correlation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression to moderate vision loss using ETDRS charts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression to advanced AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control group had AREDS formula</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0004" title="AzarG , Quaranta-El MaftouhiM , MasellaJJ , Mauget-FaÿsseM . Macular pigment density variation after supplementation of lutein and zeaxanthin using the Visucam® 200 pigment module: impact of age-related macular degeneration and lens status. Journal Français d'Ophtalmologie2017;40(4):303-13. ">Azar 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with stage 4 exudative AMD in only one eye (AREDS criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein (5 mg), zeaxanthin (1 mg), omega‐3 fatty acids (DHA 560 mg and GLA 420 mg), vitamin C (80 mg), vitamin E (10 mg), vitamin B6 (2 mg), vitamin B9 (200 micrograms), vitamin B12 (1 microgram), zinc (10 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial eye ‐ eye with non‐exudative AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear how measured, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported, probably not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0005" title="BartlettH , EperjesiF . A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology. Nutrition Journal2003;2:12. BartlettHE , EperjesiF . Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. European Journal of Clinical Nutrition2007;61(9):1121-7. ">Bartlett 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Soft or<br/>hard drusen, and areas of increased or decreased pigment associated with these drusen </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein esters 6 mg<br/>Retinol 750 mg<br/>Vitamin C 250 mg<br/>Vitamin E 34 mg<br/>Zinc 10 mg<br/>Copper 0.5 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial eye selected (initial visit only); if both eyes were eligible for inclusion, the right eye was used </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in logMAR acuity measured using ETDRS chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundus photographs graded using AREDS classification system (4 categories). Mean (standard deviation) grade was reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0006" title="BerrowEJ , BartlettHE , EperjesiF , GibsonJM . The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy - a randomised controlled trial. British Journal of Nutrition2013;109(11):2008-14. ">Berrow 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ocuvite Duo (Bausch and Lomb) vitamin C 150 mg, cupric oxide 400 µg, vitamin E 15 mg, zinc oxide 20 mg, lutein 12 mg, zeaxanthin 0.6 mg, EPA 240 mg, DHA 840 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 weeks and 60 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye per participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3m ETDRS (logMAR)<br/>750 lux retro‐illuminated chart (Sussex Vision) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severity of early AMD in one eye and late AMD (neovascular AMD or central geographic atrophy) in the fellow eye. The study eye was the eye free of late‐stage AMD. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ocuvite (Bausch and Lomb, Berlin, Germany) lutein 12 mg, zeaxanthin 0.6 mg, vitamin E 15 mg, vitamin C 150 mg, zinc oxide 20 mg, copper 0.4 mg (daily dose). One tablet twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Every 6 months for 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixture of one and two eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ETDRS charts (logMAR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grading of colour fundus photographs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMD in at least 1 eye having extensive (as measured by drusen area) intermediate (≥ 63 mm, &lt; 125 mm) drusen; and at least one large (≥ 125 mm) drusen or geographic atrophy not involving the centre of the macula </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin C 180 mg</p> <p>Vitamin E 30 mg</p> <p>Zinc 22.5 mg</p> <p>Copper 1 mg</p> <p>Lutein 10 mg</p> <p>Zeaxanthin 1 mg</p> <p>Astaxanthin 4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The eye with the best VA was selected; when both eyes had the same VA, the right eye was chosen for final analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Letters and lines reported as continuous variable (ETDRS chart)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0009" title="MurrayIJ , MakridakiM , Van der VeenRL , CardenD , ParryNR , BerendschotTT . Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Investigative Ophthalmology and Visual Science2013;54(3):1781-8. TianY , KijlstraA , Van der VeenRL , MakridakiM , MurrayIJ , BerendschotTT . The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d. PLoS One2013;8:e73387. ">CLEAR 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMD grade 0 to 4 in one eye (Rotterdam grading) and visual acuity 0.5 or better</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye per participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early Treatment<br/>Diabetic Retinopathy Study (ETDRS) logMAR chart at 4 m </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0010" title="There is no publication for this study. ">France 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neovascular AMD in one eye and drusen in the other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc 30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye per person</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0011" title="AbraldesMJ , NascimentoJ , Hernández-GalileaE , Olmedilla-AlonsoB , Escobar-BarrancoJJ , ZapataMA , et al. A randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration. Nutrients2021;13(4):1253. ">Garcia‐Layana 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neovascular AMD in one eye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retilut® (Laboratorios Thea, Barcelona, Spain) vitamin C 160 mg; vitamin E 24 mg; zinc 20 mg, copper 2 mg, lutein 10 mg, zeaxanthin 2.6 mg, DHA 400 mg, resveratrol 30 mg, hydroxytryosol 3 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye per person</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EDTRS letters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Development of CNV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator group: Theavit® (Laboratorios Mayoli Spindler, Barcelona, Spain) vitamin C 120 mg, vitamin E 20 mg, zinc 15 mg, beta‐carotene 800 mg, vitamin A 800 mg, manganese 2 mg, selenium 50 microgram </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with drusen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc sulfate 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated but assume same as follow‐up duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear but assumed to be people</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'Incidence of new exudative or dry macula lesions'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0013" title="KaiserHJ , FlammerJ , StumpfigD , HendricksonP . Visaline in the treatment of age-related macular degeneration: a pilot study. Ophthalmologica1995;209(6):302-5. ">Kaiser 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nonserous AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visaline:</p> <p>Buphenine HCL 1.5 mg<br/>Beta‐carotene 10 mg<br/>Tocopherol acetate 10 mg<br/>Vitamin C 50 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study eye identified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decimal acuity measured using a Snellen chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atrophic AMD and reduced vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein 10 mg</p> <p>Ocupower:</p> <p>Natural beta‐carotene (Betatenem) 15,000 IU</p> <p>Vitamin C 1500 mg (as calcium ascorbate‐Ester</p> <p>CB)</p> <p>Vitamin D3 400 IU</p> <p>Vitamin E 500 IU (d‐alpha tocopherol succinate)</p> <p>Vitamin B1 50 mg</p> <p>Vitamin B2 10 mg</p> <p>Vitamin B3 70 mg</p> <p>Vitamin B5 50 mg</p> <p>Vitamin B6 50 mg</p> <p>Vitamin B12 500 µg</p> <p>Folic acid 800 µg</p> <p>Biotin 300 µg</p> <p>Calcium 500 mg</p> <p>Magnesium 300 mg</p> <p>Iodine 75 µg</p> <p>Zinc 25 mg (as zinc L‐methionine‐L‐OptiZincB)</p> <p>Copper 1 mg</p> <p>Manganese 2 mg</p> <p>Selenium 200 µg</p> <p>Chromium 200 µg</p> <p>Molybdenum 75 µg</p> <p>Lycopene 600 µg</p> <p>Bilberry extract 160 mg (standardised to 25% anthocyanosides)</p> <p>Alpha lipoic acid 150 mg</p> <p>N‐acetyl cysteine 200 mg</p> <p>Quercetin 100 mg</p> <p>Rutin 100 mg</p> <p>Citrus bioflavonoids 250 mg</p> <p>Plant enzymes 50 mg</p> <p>Black pepper extract 5 mg (BioperineB)</p> <p>Malic acid 325 mg</p> <p>Taurine 900 mg</p> <p>L‐glycine 100 mg</p> <p>L‐glutathione 10 mg</p> <p>Boron 2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Right and left eyes reported separately</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in logMAR score. Measured using Snellen chart but reported in logMAR units</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early‐stage AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein 20mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear how eyes reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear how measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported, probably not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0016" title="LiS , LiuN , LinL , SunED , LiJD , LiPK . Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration. International Journal of Ophthalmology2018;11(6):970-5. ">Li 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis of early AMD, which was defined as the presence of soft distinct drusen and/or soft indistinct drusen and/or reticular drusen and/or pigmentary abnormalities. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Goji berries (wolfberry)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear how eyes reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measured on a logMAR scale, not reported which chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported, probably not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AREDS categories 2, 3, or 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein 20 mg a day for 3 months and then lutein 10 mg a day for 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study eye identified; if both eyes were eligible, one eye was selected randomly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in graph form, not possible to extract data. Measured using ETDRS chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐exudative AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein 10 mg, zeaxanthin 1 mg, concentrated fish oil 255 mg, DHA 100 mg, EPA 30 mg, vitamin C 60 mg, vitamin E 20 mg, zinc 10 mg, copper 0.25 mg. </p> <p>1 group 1 capsule per day; 1 group 2 capsules per day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study eye: unclear how selected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measured using an ETDRS chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early AMD (drusen, pigmentary abnormalities)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein 10 mg</p> <p>Lutein 20 mg</p> <p>Lutein 10 mg and zeaxanthin 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear how many eyes included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear how measured but reported in logMAR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0020" title="NewsomeDA , SwartzM , LeoneNC , ElstonRC , MillerE . Oral zinc in macular degeneration. Archives of Ophthalmology1988;106(2):192-8. ">Newsome 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drusen or pigmentary change (or both), VA 20/80 or better</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc sulfate 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported by eye; also data from 2 eyes averaged</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of letters lost on EDTRS chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Difficult to extract data on this. Reported number with increased pigment, drusen and atrophy for 2 observers. In general, found results favouring the zinc‐treated group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0021" title="NewsomeDA . A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Current Eye Research2008;33(7):591-8. ">Newsome 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence of macular drusen with or without pigment<br/>changes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc‐monocysteine 25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Right and left eyes reported separately</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of letters read on EDTRS chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0022" title="ParravanoM , TedeschiM , MancaD , CostanzoE , Di RenzoA , GiornoP , et al. Effects of Macuprev® supplementation in age-related macular degeneration: a double-blind randomized morpho-functional study along 6 months of follow-up. Advances in Therapy2019;36(9):2493-505. ">Parravano 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AREDS category 3 features (intermediate AMD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MacuPrev (Farmaplus Italia s.r.l., Italy) lutein 20 mg, zeaxanthin 4 mg, N‐acetylcysteine 140 mg, bromelain 2500GDU 80 mg, vitamin D3 800 IU, vitamin B12 18 mg, alpha‐lipoic acid 140 mg, rutin 157 mg, vitamin C 160 mg, zinc oxide 16 mg, <i>Vaccinium myrtillus</i> 36% Anthocyanosides 90 mg, <i>Ganoderma lucidum</i> 600 mg, zinc‐monocysteine 50 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye per person: Quote: "When both eyes fulfilled the inclusion criteria, the eye with the best VA was selected; when both eyes had the same VA, the right eye was chosen for analysis" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear how measured, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported, probably not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0023" title="PiattiA , CroceA , MazzacaneD , TrainaG , AmbrosinoL , BoniL , et al. Effect of 2-year nutritional supplementation on progression of age-related macular degeneration. European Journal of Ophthalmology2020;30(2):376-81. ">Piatti 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate AMD (AREDS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein 10 mg, astaxanthin 4 mg, zeaxanthin 2 mg, vitamin C 90 mg, vitamin E 30 mg, zinc 22.5 mg plus copper 1 mg, omega‐3 fatty acids (fish oil 500 mg, containing EPA 185 mg and DHA 140 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study eye: eye with the best visual acuity was selected for the study; if both eyes had the same VA, the right eye was chosen. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measured using ETDRS chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "retinography"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neovascular AMD in 1 eye, VA better than 20/40 in other eye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc sulfate 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study eye, which was fellow eye; other eye had neovascular AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean logMAR score measured using Bailey‐Lovie chart</p> <p>Note: participants with neovascular event excluded from this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incidence of neovascular lesion in study eye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Original trial of N = 500 terminated by sponsor (Astra) because statistical evaluation of first 40 participants at 24 months follow‐up "did not show any treatment benefit" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0025" title="GarrettSK , McNeilJJ , SilagyC , SinclairM , ThomasAP , RobmanLD , et al. Methodology of the VECAT study: vitamin E intervention in cataract and age-related maculopathy. Ophthalmic Epidemiology1999;6(3):195-208. GarrettSK , ThomasAP , CicuttiniF , SilagyC , TaylorHR , McNeilJJ . Community-based recruitment strategies for a longitudinal interventional study: the VECAT experience. Journal of Clinical Epidemiology2000;53(5):541-8. RobmanLD , TikellisG , GarrettSK , HarperCA , McNeilJJ , TaylorHR , et al. Baseline ophthalmic findings in the vitamin E, cataract and age-related maculopathy (VECAT) study. Australian and New Zealand Journal of Ophthalmology1999;27(6):410-6. TaylorHR , TikellisG , RobmanLD , McCartyCA , McNeilJJ . Vitamin E supplementation and age-related maculopathy. Investigative Ophthalmology and Visual Science2001;42:S311. TikellisG , RobmanLD , HarperCA , GarrettSK , McNeilJJ , TaylorHR , et al. The VECAT study: methodology and statistical power for measurement of age-related macular features. Vitamin E, cataract, and age-related maculopathy study. Ophthalmic Epidemiology1999;6(3):181-94. ">VECAT 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early AMD (18%)</p> <p>Late AMD (0.5%)</p> <p>Rest presumably had no signs of AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E 500 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse eye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss of more than 9 letters (2 or more lines) on Bailey‐Lovie chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigators defined 6 stages of AMD progression and defined progression as movement from a lower stage to a higher stage in their worst eye </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0026" title="WangH , LiRX , WangMF . Effects of zinc and antioxidant on visual function of patients with age-related macular degeneration. Zhongguo Linchuant Kangfu2004;8:1290-1. ">Wang 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early (38%) or late (62%) AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc oxide 80 mg, vitamin C, vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 to 32 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Every 6 months from 24 to 32 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse eye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear how measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear how measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AMD: age‐related macular degeneration<br/>CNV: choroidal neovascularisation<br/>DHA: docosahexaenoic acid<br/>EPA: eicosapentaenoic acid<br/>ETDRS: Early Treatment Diabetic Retinopathy Study<br/>GA: geographic atrophy<br/>GLA: gamma‐Linolenic acid<br/>logMAR: logarithm of the minimum angle of resolution<br/>RPE: retinal pigment epithelium<br/>VA: visual acuity </p> </div> </div> <p>Three studies had more than one treatment arm:</p> <p> <ul id="CD000254-list-0006"> <li> <p><a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> had a multivitamin arm and a zinc arm; we considered these separately in this review; </p> </li> <li> <p><a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a> had both multivitamin and lutein/zeaxanthin arms; we considered these separately; </p> </li> <li> <p>the two intervention groups in <a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a> were similar, differing only in dose; we combined these groups for this review. </p> </li> </ul> </p> <p>In the following discussion, we use the Beckman Initiative terminology for the clinical classification of AMD (<a href="./references#CD000254-bbs2-0115" title="Ferris FL 3rd, WilkinsonCP , BirdA , ChakravarthyU , ChewE , CsakyK , et al, Beckman Initiative for Macular Research Classification Committee. Clinical classification of age-related macular degeneration. Ophthalmology2013;120(4):844-51.">Ferris 2013</a>, <a href="#CD000254-tbl-0005">Table 1</a>). </p> <section id="CD000254-sec-0042"> <h5 class="title">Multivitamin supplements (13 studies)</h5> <p>Eleven studies compared multivitamin supplements with placebo (<a href="./references#CD000254-bbs2-0001" title="RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 1: design, subjects and procedures. Journal of the American Optometric Association1996;67(1):12-29. RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 2: antioxidant intervention and conclusions. Journal of the American Optometry Association1996;67(1):30-49. ">AMDSG 1996</a>; <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>; <a href="./references#CD000254-bbs2-0005" title="BartlettH , EperjesiF . A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology. Nutrition Journal2003;2:12. BartlettHE , EperjesiF . Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. European Journal of Clinical Nutrition2007;61(9):1121-7. ">Bartlett 2007</a>; <a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a>; <a href="./references#CD000254-bbs2-0011" title="AbraldesMJ , NascimentoJ , Hernández-GalileaE , Olmedilla-AlonsoB , Escobar-BarrancoJJ , ZapataMA , et al. A randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration. Nutrients2021;13(4):1253. ">Garcia‐Layana 2021</a>; <a href="./references#CD000254-bbs2-0013" title="KaiserHJ , FlammerJ , StumpfigD , HendricksonP . Visaline in the treatment of age-related macular degeneration: a pilot study. Ophthalmologica1995;209(6):302-5. ">Kaiser 1995</a>; <a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a>; <a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a>; <a href="./references#CD000254-bbs2-0022" title="ParravanoM , TedeschiM , MancaD , CostanzoE , Di RenzoA , GiornoP , et al. Effects of Macuprev® supplementation in age-related macular degeneration: a double-blind randomized morpho-functional study along 6 months of follow-up. Advances in Therapy2019;36(9):2493-505. ">Parravano 2019</a>; <a href="./references#CD000254-bbs2-0023" title="PiattiA , CroceA , MazzacaneD , TrainaG , AmbrosinoL , BoniL , et al. Effect of 2-year nutritional supplementation on progression of age-related macular degeneration. European Journal of Ophthalmology2020;30(2):376-81. ">Piatti 2020</a>; <a href="./references#CD000254-bbs2-0026" title="WangH , LiRX , WangMF . Effects of zinc and antioxidant on visual function of patients with age-related macular degeneration. Zhongguo Linchuant Kangfu2004;8:1290-1. ">Wang 2004</a>), and two studies compared multivitamin supplements with no treatment (<a href="./references#CD000254-bbs2-0006" title="BerrowEJ , BartlettHE , EperjesiF , GibsonJM . The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy - a randomised controlled trial. British Journal of Nutrition2013;109(11):2008-14. ">Berrow 2013</a>; <a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a>). <a href="#CD000254-tbl-0009">Table 5</a> summarises the daily dose of key antioxidant vitamin and mineral supplements considered. These studies were conducted in the USA (<a href="./references#CD000254-bbs2-0001" title="RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 1: design, subjects and procedures. Journal of the American Optometric Association1996;67(1):12-29. RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 2: antioxidant intervention and conclusions. Journal of the American Optometry Association1996;67(1):30-49. ">AMDSG 1996</a>; <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>; <a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a>), Europe (<a href="./references#CD000254-bbs2-0005" title="BartlettH , EperjesiF . A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology. Nutrition Journal2003;2:12. BartlettHE , EperjesiF . Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. European Journal of Clinical Nutrition2007;61(9):1121-7. ">Bartlett 2007</a>; <a href="./references#CD000254-bbs2-0006" title="BerrowEJ , BartlettHE , EperjesiF , GibsonJM . The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy - a randomised controlled trial. British Journal of Nutrition2013;109(11):2008-14. ">Berrow 2013</a>; <a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a>; <a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a>; <a href="./references#CD000254-bbs2-0011" title="AbraldesMJ , NascimentoJ , Hernández-GalileaE , Olmedilla-AlonsoB , Escobar-BarrancoJJ , ZapataMA , et al. A randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration. Nutrients2021;13(4):1253. ">Garcia‐Layana 2021</a>; <a href="./references#CD000254-bbs2-0013" title="KaiserHJ , FlammerJ , StumpfigD , HendricksonP . Visaline in the treatment of age-related macular degeneration: a pilot study. Ophthalmologica1995;209(6):302-5. ">Kaiser 1995</a>; <a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a>; <a href="./references#CD000254-bbs2-0022" title="ParravanoM , TedeschiM , MancaD , CostanzoE , Di RenzoA , GiornoP , et al. Effects of Macuprev® supplementation in age-related macular degeneration: a double-blind randomized morpho-functional study along 6 months of follow-up. Advances in Therapy2019;36(9):2493-505. ">Parravano 2019</a>; <a href="./references#CD000254-bbs2-0023" title="PiattiA , CroceA , MazzacaneD , TrainaG , AmbrosinoL , BoniL , et al. Effect of 2-year nutritional supplementation on progression of age-related macular degeneration. European Journal of Ophthalmology2020;30(2):376-81. ">Piatti 2020</a>), and China (<a href="./references#CD000254-bbs2-0026" title="WangH , LiRX , WangMF . Effects of zinc and antioxidant on visual function of patients with age-related macular degeneration. Zhongguo Linchuant Kangfu2004;8:1290-1. ">Wang 2004</a>). </p> <div class="table" id="CD000254-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Multivitamin supplements</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study (brand name)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vitamin A</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vitamin C</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vitamin E</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Beta‐carotene</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Lutein</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Zeaxanthin</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Zinc</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Selenium</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMDSG 1996 (OcuGuard, Twin Lab Inc, Ronkonkoma, NY)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>750 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,000 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5 mg as zinc picolinate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrus bioflavonoid complex 125 mg quercitin (bioflavonoid) 50 mg bilberry extract (bioflavonoid) 5 mg rutin (bioflavonoid) 50 mg taurine 100 mg N‐acetyl cysteine 100 mg L‐glutathione 5 mg vitamin B2 25 mg chromium 100 µg </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AREDS 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>80 mg as zinc oxide with cupric oxide 2 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Berrow 2013, (Ocuvite Duo, Bausch and Lomb, Berlin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>25 mg as zinc oxide with cupric oxide 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>omega‐3 fatty acids: EPA 240 mg and DHA 840 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bartlett 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retinol 750 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>10 mg with copper 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CARMA 2013 (Ocuvite, Bausch and Lomb, Berlin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>20 mg as zinc oxide with copper gluconate 0.4 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CARMIS 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg plus astaxanthin 4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>zinc 22.5 mg copper 1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Garcia‐Layana 2021 (Retilut)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>20 mg, copper 2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHA 400 mg, resveratrol 30 mg, hydroxytryosol 3 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kaiser 1995 (Visaline, Novopharma Cham, Switzerland)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 mg buphenine HCl</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LAST 2004 (OcuPower, Nutraceutical Sciences Institute (NSI), Boynton Beach, Florida, FloraGlo (Kemin Foods International, Des Moines, Iowa) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2500 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1500 mg vitamin C (as calcium ascorbate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 IU natural vitamin E (d‐alpha tocopherol succinate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,000 IU natural beta carotene (Betatenem)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg as zinc L‐methionine‐L‐OptiZincB 1 mg copper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 IU vitamin D3 50 mg vitamin B1 10 mg vitamin B2 70 mg vitamin B3 50 mg vitamin B 550 mg vitamin B6 500 µg vitamin B12 800 µg folic acid 300 µg biotin 500 mg calcium 75 µg iodine 300 mg magnesium 2 mg manganese 200 µg chromium 75 µg molybdenum 600 µg lycopene 160 mg bilberry extract (standardised to 25% anthocyanosides) 150 mg alpha lipoic acid 200 mg N‐acetyl cysteine 100 mg quercetin 100 mg rutin 250 mg citrus bioflavonoids 50 mg plant enzymes 5 mg black pepper extract (BioperineB) 325 mg malic acid 900 mg taurine 100 mg L‐glycine 10 mg L‐glutathione 2 mg boron </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LUTEGA 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>zinc 10 mg, copper 0.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>concentrated fish oil 255 mg (DHA 100 mg, EPA 30 mg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parravano 2019 (Macuprev, Farmaplus Italia s.r.l., Italy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>16 mg as zinc oxide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N‐acetylcysteine 140 mg, bromelain 2500GDU 80 mg, vitamin D3 800 IU, vitamin B12 18 mg, alpha‐lipoic acid 140 mg, rutin 157 mg, Vaccinium myrtillus 36% anthocyanosides 90 mg, Ganoderma lucidum 600 mg </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Piatti 2020 (Azyr Mega, SIFI S.p.A, Italy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>astaxanthin 4 mg zeaxanthin 2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.5 mg plus copper 1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>fish oil 500 mg, containing EPA 185 mg and DHA 140 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wang 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> </div> <p><a href="./references#CD000254-bbs2-0001" title="RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 1: design, subjects and procedures. Journal of the American Optometric Association1996;67(1):12-29. RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 2: antioxidant intervention and conclusions. Journal of the American Optometry Association1996;67(1):30-49. ">AMDSG 1996</a>, <a href="./references#CD000254-bbs2-0005" title="BartlettH , EperjesiF . A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology. Nutrition Journal2003;2:12. BartlettHE , EperjesiF . Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. European Journal of Clinical Nutrition2007;61(9):1121-7. ">Bartlett 2007</a>, <a href="./references#CD000254-bbs2-0006" title="BerrowEJ , BartlettHE , EperjesiF , GibsonJM . The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy - a randomised controlled trial. British Journal of Nutrition2013;109(11):2008-14. ">Berrow 2013</a>, <a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a>, and <a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a> only enroled people with early AMD. <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> and <a href="./references#CD000254-bbs2-0026" title="WangH , LiRX , WangMF . Effects of zinc and antioxidant on visual function of patients with age-related macular degeneration. Zhongguo Linchuant Kangfu2004;8:1290-1. ">Wang 2004</a> recruited people with both early and late AMD. <a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a> enroled people with either late AMD in one eye and any AMD in the other, or people with AMD features of "sufficient severity" in both eyes (i.e. either more than 20 drusen, or a combination of drusen and pigmentary abnormalities). <a href="./references#CD000254-bbs2-0013" title="KaiserHJ , FlammerJ , StumpfigD , HendricksonP . Visaline in the treatment of age-related macular degeneration: a pilot study. Ophthalmologica1995;209(6):302-5. ">Kaiser 1995</a> recruited people with "non‐serous" AMD and <a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a> with non‐exudative AMD. <a href="./references#CD000254-bbs2-0022" title="ParravanoM , TedeschiM , MancaD , CostanzoE , Di RenzoA , GiornoP , et al. Effects of Macuprev® supplementation in age-related macular degeneration: a double-blind randomized morpho-functional study along 6 months of follow-up. Advances in Therapy2019;36(9):2493-505. ">Parravano 2019</a> and <a href="./references#CD000254-bbs2-0023" title="PiattiA , CroceA , MazzacaneD , TrainaG , AmbrosinoL , BoniL , et al. Effect of 2-year nutritional supplementation on progression of age-related macular degeneration. European Journal of Ophthalmology2020;30(2):376-81. ">Piatti 2020</a> recruited people with intermediate AMD. <a href="./references#CD000254-bbs2-0011" title="AbraldesMJ , NascimentoJ , Hernández-GalileaE , Olmedilla-AlonsoB , Escobar-BarrancoJJ , ZapataMA , et al. A randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration. Nutrients2021;13(4):1253. ">Garcia‐Layana 2021</a> enroled people with unilateral neovascular AMD. </p> <p>People taking part in the studies were identified by referral from local ophthalmologists (<a href="./references#CD000254-bbs2-0013" title="KaiserHJ , FlammerJ , StumpfigD , HendricksonP . Visaline in the treatment of age-related macular degeneration: a pilot study. Ophthalmologica1995;209(6):302-5. ">Kaiser 1995</a>), from people attending Department of Veterans Medical Centers (<a href="./references#CD000254-bbs2-0001" title="RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 1: design, subjects and procedures. Journal of the American Optometric Association1996;67(1):12-29. RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 2: antioxidant intervention and conclusions. Journal of the American Optometry Association1996;67(1):30-49. ">AMDSG 1996</a>; <a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a>), from retinal speciality clinics and general population volunteers (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>), from eye outpatient clinics (<a href="./references#CD000254-bbs2-0006" title="BerrowEJ , BartlettHE , EperjesiF , GibsonJM . The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy - a randomised controlled trial. British Journal of Nutrition2013;109(11):2008-14. ">Berrow 2013</a>; <a href="./references#CD000254-bbs2-0023" title="PiattiA , CroceA , MazzacaneD , TrainaG , AmbrosinoL , BoniL , et al. Effect of 2-year nutritional supplementation on progression of age-related macular degeneration. European Journal of Ophthalmology2020;30(2):376-81. ">Piatti 2020</a>; <a href="./references#CD000254-bbs2-0026" title="WangH , LiRX , WangMF . Effects of zinc and antioxidant on visual function of patients with age-related macular degeneration. Zhongguo Linchuant Kangfu2004;8:1290-1. ">Wang 2004</a>), and from regional tertiary referral centres (<a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a>). <a href="./references#CD000254-bbs2-0005" title="BartlettH , EperjesiF . A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology. Nutrition Journal2003;2:12. BartlettHE , EperjesiF . Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. European Journal of Clinical Nutrition2007;61(9):1121-7. ">Bartlett 2007</a> recruited participants by sending letters to "local optometrists, ophthalmologists, and a specialist centre for rehabilitation of people with sight loss"; participants were then seen at the university research centre. In <a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a> and <a href="./references#CD000254-bbs2-0022" title="ParravanoM , TedeschiM , MancaD , CostanzoE , Di RenzoA , GiornoP , et al. Effects of Macuprev® supplementation in age-related macular degeneration: a double-blind randomized morpho-functional study along 6 months of follow-up. Advances in Therapy2019;36(9):2493-505. ">Parravano 2019</a>, it was not clear how they identified participants. In <a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a>, participants were from the "local population" but it was not clear how they were identified. </p> <p>The number of participants enroled in multivitamin supplement studies ranged from 14 (<a href="./references#CD000254-bbs2-0006" title="BerrowEJ , BartlettHE , EperjesiF , GibsonJM . The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy - a randomised controlled trial. British Journal of Nutrition2013;109(11):2008-14. ">Berrow 2013</a>) to 3640 (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>). Apart from <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>, all these studies recruited fewer than 500 people; the median number randomised was 85. The average age of participants ranged from 65 to 75 years; the median percentage of women was 56%, and two studies recruited mainly men (<a href="./references#CD000254-bbs2-0001" title="RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 1: design, subjects and procedures. Journal of the American Optometric Association1996;67(1):12-29. RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 2: antioxidant intervention and conclusions. Journal of the American Optometry Association1996;67(1):30-49. ">AMDSG 1996</a>; <a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a>). </p> <p>The duration of supplementation and follow‐up ranged from nine months (<a href="./references#CD000254-bbs2-0005" title="BartlettH , EperjesiF . A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology. Nutrition Journal2003;2:12. BartlettHE , EperjesiF . Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. European Journal of Clinical Nutrition2007;61(9):1121-7. ">Bartlett 2007</a>) to six years (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>). Only one study followed up beyond two years (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>). </p> </section> <section id="CD000254-sec-0043"> <h5 class="title">Lutein (with or without zeaxanthin) supplements (eight studies)</h5> <p>Six studies compared lutein supplements with placebo (<a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>; <a href="./references#CD000254-bbs2-0009" title="MurrayIJ , MakridakiM , Van der VeenRL , CardenD , ParryNR , BerendschotTT . Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Investigative Ophthalmology and Visual Science2013;54(3):1781-8. TianY , KijlstraA , Van der VeenRL , MakridakiM , MurrayIJ , BerendschotTT . The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d. PLoS One2013;8:e73387. ">CLEAR 2013</a>; <a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a>; <a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a>; <a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a>; <a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a>). In <a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>, all participants also took the AREDS formula (<a href="#CD000254-tbl-0009">Table 5</a>). The daily dose of lutein used in these studies was 10 mg (<a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>; <a href="./references#CD000254-bbs2-0009" title="MurrayIJ , MakridakiM , Van der VeenRL , CardenD , ParryNR , BerendschotTT . Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Investigative Ophthalmology and Visual Science2013;54(3):1781-8. TianY , KijlstraA , Van der VeenRL , MakridakiM , MurrayIJ , BerendschotTT . The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d. PLoS One2013;8:e73387. ">CLEAR 2013</a>; <a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a>; <a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a>) and 20 mg (<a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a>; <a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a>; <a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a>). Two of these studies combined lutein with zeaxanthin, either a dose of 2 mg (<a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>), or 10 mg (<a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a>). These studies were conducted in the USA (<a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>; <a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a>), Europe (<a href="./references#CD000254-bbs2-0009" title="MurrayIJ , MakridakiM , Van der VeenRL , CardenD , ParryNR , BerendschotTT . Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Investigative Ophthalmology and Visual Science2013;54(3):1781-8. TianY , KijlstraA , Van der VeenRL , MakridakiM , MurrayIJ , BerendschotTT . The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d. PLoS One2013;8:e73387. ">CLEAR 2013</a>; <a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a>), and China (<a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a>; <a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a>). </p> <p><a href="./references#CD000254-bbs2-0009" title="MurrayIJ , MakridakiM , Van der VeenRL , CardenD , ParryNR , BerendschotTT . Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Investigative Ophthalmology and Visual Science2013;54(3):1781-8. TianY , KijlstraA , Van der VeenRL , MakridakiM , MurrayIJ , BerendschotTT . The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d. PLoS One2013;8:e73387. ">CLEAR 2013</a>, <a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a>, <a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a>, and <a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a> only considered people with early AMD. <a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> enroled people "at risk for progression to advanced AMD, with bilateral large drusen, or large drusen in one eye and advanced AMD in the fellow eye". <a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a> recruited individuals in categories 2, 3, and 4 according to AREDS criteria (similar to the participants in <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>). </p> <p>One study compared lutein (5 mg) and zeaxanthin (1 mg) combined with omega‐3 fatty acids, vitamins and zinc with a control of omega‐3 fatty acids, vitamins and zinc (<a href="./references#CD000254-bbs2-0004" title="AzarG , Quaranta-El MaftouhiM , MasellaJJ , Mauget-FaÿsseM . Macular pigment density variation after supplementation of lutein and zeaxanthin using the Visucam® 200 pigment module: impact of age-related macular degeneration and lens status. Journal Français d'Ophtalmologie2017;40(4):303-13. ">Azar 2017</a>). One study compared a multivitamin supplement, including lutein 10 mg and zeaxanthin 2.6 mg, with a supplement without lutein or zeaxanthin but including beta‐carotene 800 mg (<a href="./references#CD000254-bbs2-0011" title="AbraldesMJ , NascimentoJ , Hernández-GalileaE , Olmedilla-AlonsoB , Escobar-BarrancoJJ , ZapataMA , et al. A randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration. Nutrients2021;13(4):1253. ">Garcia‐Layana 2021</a>). Both studies were from Europe and recruited people with stage 4 exudative AMD in one eye (AREDS criteria) and followed up the fellow eye. </p> <p>People taking part in the studies were identified from people attending Department of Veterans Medical Centers (<a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a>), from "clinical centers" (<a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>) or sites (<a href="./references#CD000254-bbs2-0011" title="AbraldesMJ , NascimentoJ , Hernández-GalileaE , Olmedilla-AlonsoB , Escobar-BarrancoJJ , ZapataMA , et al. A randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration. Nutrients2021;13(4):1253. ">Garcia‐Layana 2021</a>), hospital (<a href="./references#CD000254-bbs2-0004" title="AzarG , Quaranta-El MaftouhiM , MasellaJJ , Mauget-FaÿsseM . Macular pigment density variation after supplementation of lutein and zeaxanthin using the Visucam® 200 pigment module: impact of age-related macular degeneration and lens status. Journal Français d'Ophtalmologie2017;40(4):303-13. ">Azar 2017</a>; <a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a>), and "local communities" (<a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a>). In <a href="./references#CD000254-bbs2-0009" title="MurrayIJ , MakridakiM , Van der VeenRL , CardenD , ParryNR , BerendschotTT . Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Investigative Ophthalmology and Visual Science2013;54(3):1781-8. TianY , KijlstraA , Van der VeenRL , MakridakiM , MurrayIJ , BerendschotTT . The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d. PLoS One2013;8:e73387. ">CLEAR 2013</a>, an "advertising campaign was conducted within the universities and in local newspapers". In <a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a>, it was not clear how they identified participants. </p> <p>The number of participants enroled in lutein and zeaxanthin supplement studies ranged from 79 (<a href="./references#CD000254-bbs2-0004" title="AzarG , Quaranta-El MaftouhiM , MasellaJJ , Mauget-FaÿsseM . Macular pigment density variation after supplementation of lutein and zeaxanthin using the Visucam® 200 pigment module: impact of age-related macular degeneration and lens status. Journal Français d'Ophtalmologie2017;40(4):303-13. ">Azar 2017</a>) to 4203 (<a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>). Apart from <a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>, all of these studies recruited fewer than 250 people. The average age of participants ranged from 69 to 75 years; the median percentage of women was 57%, and one study recruited mainly men (<a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a>). </p> <p>The duration of supplementation and follow‐up ranged from six months (<a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a>) to five years (<a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>). The majority of studies followed up to 12 months; only one study followed up to two years (<a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a>). </p> </section> <section id="CD000254-sec-0044"> <h5 class="title">Vitamin E (one study)</h5> <p>One study, conducted in Australia, compared vitamin E with placebo (<a href="./references#CD000254-bbs2-0025" title="GarrettSK , McNeilJJ , SilagyC , SinclairM , ThomasAP , RobmanLD , et al. Methodology of the VECAT study: vitamin E intervention in cataract and age-related maculopathy. Ophthalmic Epidemiology1999;6(3):195-208. GarrettSK , ThomasAP , CicuttiniF , SilagyC , TaylorHR , McNeilJJ . Community-based recruitment strategies for a longitudinal interventional study: the VECAT experience. Journal of Clinical Epidemiology2000;53(5):541-8. RobmanLD , TikellisG , GarrettSK , HarperCA , McNeilJJ , TaylorHR , et al. Baseline ophthalmic findings in the vitamin E, cataract and age-related maculopathy (VECAT) study. Australian and New Zealand Journal of Ophthalmology1999;27(6):410-6. TaylorHR , TikellisG , RobmanLD , McCartyCA , McNeilJJ . Vitamin E supplementation and age-related maculopathy. Investigative Ophthalmology and Visual Science2001;42:S311. TikellisG , RobmanLD , HarperCA , GarrettSK , McNeilJJ , TaylorHR , et al. The VECAT study: methodology and statistical power for measurement of age-related macular features. Vitamin E, cataract, and age-related maculopathy study. Ophthalmic Epidemiology1999;6(3):181-94. ">VECAT 2002</a>). This study randomised 1204 people to vitamin E 400 IU (international units) daily or placebo, and followed up for four years. Participants were enroled from the general population and only 19% had AMD, mainly early AMD. Participants' average age was 66 years, and 56% were women. </p> </section> <section id="CD000254-sec-0045"> <h5 class="title">Zinc (six studies)</h5> <p>Six studies compared zinc with placebo (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>; <a href="./references#CD000254-bbs2-0010" title="There is no publication for this study. ">France 1998</a>; <a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a>; <a href="./references#CD000254-bbs2-0020" title="NewsomeDA , SwartzM , LeoneNC , ElstonRC , MillerE . Oral zinc in macular degeneration. Archives of Ophthalmology1988;106(2):192-8. ">Newsome 1988</a>; <a href="./references#CD000254-bbs2-0021" title="NewsomeDA . A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Current Eye Research2008;33(7):591-8. ">Newsome 2008</a>; <a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a>). </p> <p>In <a href="./references#CD000254-bbs2-0010" title="There is no publication for this study. ">France 1998</a>, 170 people with neovascular AMD in one eye and drusen in the other were randomised to receive zinc 30 mg or placebo. This study was unpublished, and we have no further information. </p> <p>Three studies considered zinc sulphate 200 mg daily (<a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a>; <a href="./references#CD000254-bbs2-0021" title="NewsomeDA . A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Current Eye Research2008;33(7):591-8. ">Newsome 2008</a>; <a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a>), one study investigated zinc oxide 80 mg daily (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>), and one study used zinc‐monocysteine 50 mg daily (<a href="./references#CD000254-bbs2-0021" title="NewsomeDA . A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Current Eye Research2008;33(7):591-8. ">Newsome 2008</a>). </p> <p><a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a> and <a href="./references#CD000254-bbs2-0021" title="NewsomeDA . A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Current Eye Research2008;33(7):591-8. ">Newsome 2008</a> only enroled people with early AMD; <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> and <a href="./references#CD000254-bbs2-0020" title="NewsomeDA , SwartzM , LeoneNC , ElstonRC , MillerE . Oral zinc in macular degeneration. Archives of Ophthalmology1988;106(2):192-8. ">Newsome 1988</a> recruited people with both early and late AMD; <a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a> only enroled people with late AMD in one eye. </p> <p>The number of participants enroled in zinc supplement studies ranged from 58 (<a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a>) to 3640 (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>). Apart from <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>, all of these studies recruited fewer than 500 people; the median number randomised was 141. The average age of people participating in the studies ranged from 65 to 74 years; the median percentage of women was 57%. </p> <p>People taking part in the studies were identified by referral from local ophthalmologists (<a href="./references#CD000254-bbs2-0020" title="NewsomeDA , SwartzM , LeoneNC , ElstonRC , MillerE . Oral zinc in macular degeneration. Archives of Ophthalmology1988;106(2):192-8. ">Newsome 1988</a>), eye outpatient clinics (<a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a>), retinal speciality clinics and general population volunteers (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>). In <a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a> and <a href="./references#CD000254-bbs2-0021" title="NewsomeDA . A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Current Eye Research2008;33(7):591-8. ">Newsome 2008</a>, it was not clear how they identified participants. </p> <p>The duration of supplementation and follow‐up in these studies ranged from six months to seven years. </p> </section> <section id="CD000254-sec-0046"> <h5 class="title">Other (one study)</h5> <p>One study in China compared goji berry supplement to usual diet and followed up for 90 days (<a href="./references#CD000254-bbs2-0016" title="LiS , LiuN , LinL , SunED , LiJD , LiPK . Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration. International Journal of Ophthalmology2018;11(6):970-5. ">Li 2018</a>). Goji berries are a source of carotenoids and zinc. </p> </section> </section> <section id="CD000254-sec-0047"> <h4 class="title">Excluded studies</h4> <p>We have listed 59 excluded studies, including the eight studies identified in this review update, in the <a href="./references#CD000254-sec-0088" title="">Characteristics of excluded studies</a> section. </p> <p>The reasons for exclusion were as follows:</p> <p> <ul id="CD000254-list-0007"> <li> <p>ineligible population: participants did not have AMD in one or both eyes (n = 21);</p> </li> <li> <p>ineligible design: not an RCT (n = 18);</p> </li> <li> <p>ineligible intervention: not an antioxidant vitamin or mineral supplement (n = 8);</p> </li> <li> <p>ineligible comparator: no placebo or untreated group in the study (n = 8);</p> </li> <li> <p>ineligible intervention: supplement combined with other active intervention (n = 3);</p> </li> <li> <p>ineligible outcome: review outcomes were not measured (n = 1).</p> </li> </ul> </p> </section> </section> <section id="CD000254-sec-0048"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD000254-fig-0002">Figure 2</a> and <a href="#CD000254-fig-0003">Figure 3</a> summarise the risk of bias assessment. Overall, we considered the studies to be at low risk of bias for the main types of bias; in particular, selection bias (allocation sequence generation and concealment) and performance and detection bias. This is because all studies, except <a href="./references#CD000254-bbs2-0006" title="BerrowEJ , BartlettHE , EperjesiF , GibsonJM . The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy - a randomised controlled trial. British Journal of Nutrition2013;109(11):2008-14. ">Berrow 2013</a>, <a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a>, and <a href="./references#CD000254-bbs2-0016" title="LiS , LiuN , LinL , SunED , LiJD , LiPK . Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration. International Journal of Ophthalmology2018;11(6):970-5. ">Li 2018</a> had a placebo control. Five studies were not well reported (<a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a>; <a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a>; <a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a>; <a href="./references#CD000254-bbs2-0016" title="LiS , LiuN , LinL , SunED , LiJD , LiPK . Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration. International Journal of Ophthalmology2018;11(6):970-5. ">Li 2018</a>; <a href="./references#CD000254-bbs2-0026" title="WangH , LiRX , WangMF . Effects of zinc and antioxidant on visual function of patients with age-related macular degeneration. Zhongguo Linchuant Kangfu2004;8:1290-1. ">Wang 2004</a>), and one study was unpublished (<a href="./references#CD000254-bbs2-0010" title="There is no publication for this study. ">France 1998</a>). </p> <div class="figure" id="CD000254-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD000254-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD000254-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD000254-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD000254-sec-0049"> <h4 class="title">Allocation</h4> <p>In 12 studies, randomisation appeared to have been executed properly; that is, an unpredictable sequence of treatment allocation was adequately concealed from people recruiting participants into the study. In the remaining studies, the judgements were unclear for one or both of these aspects of study conduct because of poor reporting. </p> </section> <section id="CD000254-sec-0050"> <h4 class="title">Blinding</h4> <p>Three studies had a 'no treatment' control group; we considered these to be at high risk for performance and detection bias (<a href="./references#CD000254-bbs2-0006" title="BerrowEJ , BartlettHE , EperjesiF , GibsonJM . The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy - a randomised controlled trial. British Journal of Nutrition2013;109(11):2008-14. ">Berrow 2013</a>; <a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a>; <a href="./references#CD000254-bbs2-0016" title="LiS , LiuN , LinL , SunED , LiJD , LiPK . Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration. International Journal of Ophthalmology2018;11(6):970-5. ">Li 2018</a>). </p> <p>In general, there was not a lot of information to judge the success of the masking. In <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>, four people were documented as being unmasked to study group. More people in the antioxidant group (8.3%) reported changes in skin colour (yellowing) than in the placebo group (6.0%, P &lt; 0.01), and more people in the zinc groups reported difficulty swallowing the study tablets (17.8% versus 15.3%, P = 0.04). However, there was little evidence of unmasking when participants were asked to guess their treatment assignment at the end of the study. The percentages of participants who guessed correctly, by treatment assignment, were: placebo 17%, antioxidants alone 16%, zinc alone 18%, and antioxidants plus zinc 16%. In <a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a>, the tablets were apparently identical in appearance, but it was not clear whether taste or systemic effects differed between the different groups. </p> </section> <section id="CD000254-sec-0051"> <h4 class="title">Incomplete outcome data</h4> <p>Included studies did not always clearly report information that would allow us to assess the likelihood of attrition bias. We judged three studies to be at high risk of attrition bias. </p> <p>In <a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a>, 19% of the treated group and 38% of the untreated group were excluded from the final analysis. </p> <p>In <a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a>, members of the placebo group were removed from analysis, due to the fact that they had taken lutein. </p> <p>In <a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a>, analysis of the main outcome measures (visual function and progression of disease) was not done on a strictly intention‐to‐treat basis, as anyone experiencing the study endpoint of late‐stage AMD (neovascularisation) was withdrawn from the study. Contact with the study investigator revealed that all of these participants ended up with visual acuity of 20/200 (6/60) or less, and that these participants were excluded because the investigators wished to detect functional changes caused by degeneration of the retinal pigment epithelium and the sensory retina, and not vision losses caused by choroidal neovascularisation (CNV). Similarly, <a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a> excluded people with CNV from analyses of visual acuity. </p> </section> <section id="CD000254-sec-0052"> <h4 class="title">Selective reporting</h4> <p>There was some evidence of selective reporting in eight studies (<a href="./references#CD000254-bbs2-0004" title="AzarG , Quaranta-El MaftouhiM , MasellaJJ , Mauget-FaÿsseM . Macular pigment density variation after supplementation of lutein and zeaxanthin using the Visucam® 200 pigment module: impact of age-related macular degeneration and lens status. Journal Français d'Ophtalmologie2017;40(4):303-13. ">Azar 2017</a>; <a href="./references#CD000254-bbs2-0005" title="BartlettH , EperjesiF . A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology. Nutrition Journal2003;2:12. BartlettHE , EperjesiF . Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. European Journal of Clinical Nutrition2007;61(9):1121-7. ">Bartlett 2007</a>; <a href="./references#CD000254-bbs2-0006" title="BerrowEJ , BartlettHE , EperjesiF , GibsonJM . The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy - a randomised controlled trial. British Journal of Nutrition2013;109(11):2008-14. ">Berrow 2013</a>; <a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a>; <a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a>; <a href="./references#CD000254-bbs2-0020" title="NewsomeDA , SwartzM , LeoneNC , ElstonRC , MillerE . Oral zinc in macular degeneration. Archives of Ophthalmology1988;106(2):192-8. ">Newsome 1988</a>; <a href="./references#CD000254-bbs2-0022" title="ParravanoM , TedeschiM , MancaD , CostanzoE , Di RenzoA , GiornoP , et al. Effects of Macuprev® supplementation in age-related macular degeneration: a double-blind randomized morpho-functional study along 6 months of follow-up. Advances in Therapy2019;36(9):2493-505. ">Parravano 2019</a>; <a href="./references#CD000254-bbs2-0025" title="GarrettSK , McNeilJJ , SilagyC , SinclairM , ThomasAP , RobmanLD , et al. Methodology of the VECAT study: vitamin E intervention in cataract and age-related maculopathy. Ophthalmic Epidemiology1999;6(3):195-208. GarrettSK , ThomasAP , CicuttiniF , SilagyC , TaylorHR , McNeilJJ . Community-based recruitment strategies for a longitudinal interventional study: the VECAT experience. Journal of Clinical Epidemiology2000;53(5):541-8. RobmanLD , TikellisG , GarrettSK , HarperCA , McNeilJJ , TaylorHR , et al. Baseline ophthalmic findings in the vitamin E, cataract and age-related maculopathy (VECAT) study. Australian and New Zealand Journal of Ophthalmology1999;27(6):410-6. TaylorHR , TikellisG , RobmanLD , McCartyCA , McNeilJJ . Vitamin E supplementation and age-related maculopathy. Investigative Ophthalmology and Visual Science2001;42:S311. TikellisG , RobmanLD , HarperCA , GarrettSK , McNeilJJ , TaylorHR , et al. The VECAT study: methodology and statistical power for measurement of age-related macular features. Vitamin E, cataract, and age-related maculopathy study. Ophthalmic Epidemiology1999;6(3):181-94. ">VECAT 2002</a>), but this was generally difficult to assess, and we could not be confident that selective reporting did not occur in other included studies. </p> </section> </section> <section id="CD000254-sec-0053"> <h3 class="title" id="CD000254-sec-0053">Effects of interventions</h3> <p>See: <a href="./full#CD000254-tbl-0001"><b>Summary of findings 1</b> Antioxidant multivitamin and mineral supplement versus placebo or no treatment for slowing the progression of age‐related macular degeneration</a>; <a href="./full#CD000254-tbl-0002"><b>Summary of findings 2</b> Lutein with or without zeaxanthin versus placebo for slowing the progression of age‐related macular degeneration</a>; <a href="./full#CD000254-tbl-0003"><b>Summary of findings 3</b> Vitamin E versus placebo for slowing the progression of age‐related macular degeneration</a>; <a href="./full#CD000254-tbl-0004"><b>Summary of findings 4</b> Zinc versus placebo for slowing the progression of age‐related macular degeneration</a> </p> <p>We provide more information on the outcomes and follow‐up times relating to the data included in these analyses in <a href="#CD000254-tbl-0008">Table 4</a>. </p> <section id="CD000254-sec-0054"> <h4 class="title">Antioxidant multivitamin and mineral supplement versus placebo or no treatment</h4> <p>See <a href="./full#CD000254-tbl-0001">summary of findings Table 1</a>. </p> <p><a href="#CD000254-tbl-0009">Table 5</a> summarises the multivitamin supplements in the 13 studies included here. There was considerable heterogeneity in constituents of these supplements, but as most of the evidence comes from the AREDS study, we have focused on the AREDS formula here (i.e. vitamin C, vitamin E, carotenoids, and zinc). </p> <p>Only three studies reported data on our primary outcome of progression to late AMD (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>; <a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a>; <a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a>), and only one of these studies reported data separately on neovascular AMD and geographic atrophy (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>). Mean visual acuity was more commonly reported, but there was considerable variability in the measurement and reporting of this outcome. <a href="./references#CD000254-bbs2-0001" title="RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 1: design, subjects and procedures. Journal of the American Optometric Association1996;67(1):12-29. RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 2: antioxidant intervention and conclusions. Journal of the American Optometry Association1996;67(1):30-49. ">AMDSG 1996</a> and <a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a> measured visual acuity using a Snellen chart and converted the score into logMAR units. <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>, <a href="./references#CD000254-bbs2-0005" title="BartlettH , EperjesiF . A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology. Nutrition Journal2003;2:12. BartlettHE , EperjesiF . Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. European Journal of Clinical Nutrition2007;61(9):1121-7. ">Bartlett 2007</a>, <a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a>, and <a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a> used the logMAR visual acuity chart developed as part of the Early Treatment of Diabetic Retinopathy Study (<a href="./references#CD000254-bbs2-0113" title="Early Treatment Diabetic Retinopathy Study Research Group. Early Treatment Diabetic Retinopathy Study Manual of Operations. Baltimore (MD): ETDRS Co-ordinating Center, 1980.">ETDRS 1980</a>). No useable data could be extracted for <a href="./references#CD000254-bbs2-0006" title="BerrowEJ , BartlettHE , EperjesiF , GibsonJM . The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy - a randomised controlled trial. British Journal of Nutrition2013;109(11):2008-14. ">Berrow 2013</a>, <a href="./references#CD000254-bbs2-0013" title="KaiserHJ , FlammerJ , StumpfigD , HendricksonP . Visaline in the treatment of age-related macular degeneration: a pilot study. Ophthalmologica1995;209(6):302-5. ">Kaiser 1995</a>, <a href="./references#CD000254-bbs2-0022" title="ParravanoM , TedeschiM , MancaD , CostanzoE , Di RenzoA , GiornoP , et al. Effects of Macuprev® supplementation in age-related macular degeneration: a double-blind randomized morpho-functional study along 6 months of follow-up. Advances in Therapy2019;36(9):2493-505. ">Parravano 2019</a>, and <a href="./references#CD000254-bbs2-0026" title="WangH , LiRX , WangMF . Effects of zinc and antioxidant on visual function of patients with age-related macular degeneration. Zhongguo Linchuant Kangfu2004;8:1290-1. ">Wang 2004</a>. Only one study reported on quality of life, using the Italian version of the National Eye Institute Visual function questionnaire (NEI‐VFQ) (<a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a>). </p> <p>There were several different strategies for dealing with eyes. Some studies reported AMD for the person, which means that the unit of analysis was the person. They were counted as having AMD if it was present in one or both eyes (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>). Some studies reported findings on right eyes and left eyes separately (<a href="./references#CD000254-bbs2-0001" title="RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 1: design, subjects and procedures. Journal of the American Optometric Association1996;67(1):12-29. RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 2: antioxidant intervention and conclusions. Journal of the American Optometry Association1996;67(1):30-49. ">AMDSG 1996</a>; <a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a>), selected a study eye (<a href="./references#CD000254-bbs2-0005" title="BartlettH , EperjesiF . A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology. Nutrition Journal2003;2:12. BartlettHE , EperjesiF . Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. European Journal of Clinical Nutrition2007;61(9):1121-7. ">Bartlett 2007</a>; <a href="./references#CD000254-bbs2-0013" title="KaiserHJ , FlammerJ , StumpfigD , HendricksonP . Visaline in the treatment of age-related macular degeneration: a pilot study. Ophthalmologica1995;209(6):302-5. ">Kaiser 1995</a>; <a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a>; <a href="./references#CD000254-bbs2-0026" title="WangH , LiRX , WangMF . Effects of zinc and antioxidant on visual function of patients with age-related macular degeneration. Zhongguo Linchuant Kangfu2004;8:1290-1. ">Wang 2004</a>), or averaged the data for the two eyes in participants where both eyes were included (<a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a>). </p> <p>Data from <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> were reported as adjusted odds ratios only. The odds ratios were calculated using repeated‐measures logistic regression and were adjusted for baseline co‐variates age, sex, race, AMD category, and smoking status. </p> <p>People taking antioxidant vitamins were less likely to progress to late AMD (odds ratio (OR) 0.72, 95% confidence interval (CI) 0.58 to 0.90; 3 studies, 2445 participants; moderate‐certainty evidence; <a href="./references#CD000254-fig-0004" title="">Analysis 1.1</a>). Most evidence came from <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>, with follow‐up of six years. In people with early AMD, who are at low risk of progression, this would equate to approximately four fewer cases of progression to late AMD for every 1000 people taking vitamins (one fewer to six fewer cases). In people with intermediate AMD at higher risk of progression, this would correspond to approximately 78 fewer cases of progression for every 1000 people taking vitamins (26 fewer to 126 fewer). The other two studies were smaller and provided different estimates (OR after 12 months of follow‐up: 0.84, 95% CI 0.51 to 1.39; 509 participants in <a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a>; and OR after 24 months of follow‐up: 1.37, 95% CI 0.42 to 4.48; 145 participants in <a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a>). We did not downgrade for inconsistency because the confidence intervals were completely overlapping for the three studies. </p> <p>Over six years, evidence from <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> suggests people taking antioxidant vitamins and zinc were probably less likely to progress to neovascular AMD (OR 0.62, 95% CI 0.47 to 0.82; 1 study, 1206 participants; moderate‐certainty evidence; <a href="./references#CD000254-fig-0005" title="">Analysis 1.2</a>) and geographic atrophy (OR 0.75, 95% CI 0.51 to 1.10; 1 study, 1206 participants; moderate‐certainty evidence; <a href="./references#CD000254-fig-0006" title="">Analysis 1.3</a>), and probably less likely to lose 3 or more lines of visual acuity (OR 0.77, 95% CI 0.62 to 0.96; 1 study, 1791 participants; moderate‐certainty evidence; <a href="./references#CD000254-fig-0007" title="">Analysis 1.4</a>). </p> <p>Studies reporting mean visual acuity in continuous format were smaller and had shorter treatment and follow‐up durations (<a href="./references#CD000254-bbs2-0001" title="RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 1: design, subjects and procedures. Journal of the American Optometric Association1996;67(1):12-29. RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 2: antioxidant intervention and conclusions. Journal of the American Optometry Association1996;67(1):30-49. ">AMDSG 1996</a>; <a href="./references#CD000254-bbs2-0005" title="BartlettH , EperjesiF . A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology. Nutrition Journal2003;2:12. BartlettHE , EperjesiF . Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. European Journal of Clinical Nutrition2007;61(9):1121-7. ">Bartlett 2007</a>; <a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a>; <a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a>; <a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a>; <a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a>). No effect of treatment on visual acuity was seen from these analyses. The pooled mean difference (MD) was 0.0 logMAR (95% CI ‐0.04 to 0.03; I<sup>2</sup> = 46%; 6 studies, 740 participants; <a href="./references#CD000254-fig-0008" title="">Analysis 1.5</a>). </p> <p>Low‐certainty evidence from one study of 110 people suggested higher quality of life scores (National Eye Institute Visual Function Questionnaire) in treated compared with the non‐treated people after 24 months (<a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a>) (mean difference (MD) 12.30, 95% CI 4.24 to 20.36; <a href="./references#CD000254-fig-0009" title="">Analysis 1.6</a>). </p> <p>In exploratory subgroup analyses in the follow‐on study to AREDS (<a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>), replacing beta‐carotene with lutein/zeaxanthin gave hazard ratios (HR) of 0.82 (95% CI 0.69 to 0.96), 0.78 (95% CI 0.64 to 0.94), 0.94 (95% CI 0.70 to 1.26) and 0.88 (95% CI 0.75 to 1.03) for progression to late AMD, neovascular AMD, geographic atrophy, and vision loss, respectively. One study comparing Retulit (AREDS with lutein/zeaxanthin) versus Theavit (AREDS with beta‐carotene) found little evidence of a difference in visual acuity (difference in ETDRS letters –1.63, 95% CI –0.83 to 4.09; P = 0.192) in 93 people after 12 months of follow‐up (<a href="./references#CD000254-bbs2-0011" title="AbraldesMJ , NascimentoJ , Hernández-GalileaE , Olmedilla-AlonsoB , Escobar-BarrancoJJ , ZapataMA , et al. A randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration. Nutrients2021;13(4):1253. ">Garcia‐Layana 2021</a>) (<a href="#CD000254-tbl-0009">Table 5</a>). </p> <p><a href="#CD000254-tbl-0010">Table 6</a> summarises information available on adverse effects. Low‐certainty evidence was available on adverse effects from these included studies. They were underpowered to look at adverse effects and reported them inconsistently. Data from <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> suggested no important effect on mortality associated with multivitamin use (hazard ratio for mortality 0.87, 95% CI 0.60 to 1.25). In <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>, participants in the antioxidant arms more frequently reported yellow skin (8.3% versus 6.0%, P = 0.008). Additional data from <a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> found an increased chance of lung cancer in the beta‐carotene versus no beta‐carotene group (23 (2.0%) versus 11 (0.9%)), mostly in former smokers. </p> <div class="table" id="CD000254-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Adverse effects in the included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study number</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effects</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0001" title="RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 1: design, subjects and procedures. Journal of the American Optometric Association1996;67(1):12-29. RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 2: antioxidant intervention and conclusions. Journal of the American Optometry Association1996;67(1):30-49. ">AMDSG 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin (Ocuguard)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One person developed an "allergic reaction", although it was not clear whether this was related to the treatment. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin and zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Over 100 comparisons of zinc versus no zinc and antioxidants versus no antioxidants. Participants in the antioxidant arms more frequently reported yellow skin (8.3% versus 6.0%, P = 0.008). No important effect on mortality associated with multivitamin use (hazard ratio for mortality 0.87, 95% CI 0.60 to 1.25). </p> <p>Participants in the zinc arms reported more anaemia (13.2% versus 10.2%, P = 0.004); however, serum haematocrit levels were the same. They found that participants taking zinc had a lower mortality. Later follow‐up of the cohort of people taking part in the AREDS study found that there was a significant increase in hospital admissions due to genitourinary diseases in people taking zinc supplements (11.1% versus 7.6%, P = 0.0003). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein and zeaxanthin (plus AREDs formula)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "No clinically or statistically significant differences in reported serious adverse events, including rates of development of neoplasms, were noted across the treatment groups in the primary randomization. However, secondary randomization excluding participants who were smokers showed more lung cancers in the beta carotene group than in the no beta carotene group (23 [2.0%] vs 11 [0.9%]) (nominal P = .04)". Quote: "Rates of reported gastrointestinal disorders and hospitalizations for genitourinary diseases were similar in the 2 randomly assigned groups (high‐dose zinc, low‐dose zinc) in AREDS2". Quote: "The HR for mortality comparing lutein zeaxanthin vs no lutein zeaxanthin was 1.06 (95% CI, 0.87‐1.31; P = .56) for lutein zeaxanthin vs no lutein zeaxanthin". Quote: "More lung cancers were noted in the beta carotene vs no beta carotene group (23 [2.0%] vs 11 [0.9%], nominal P=.04), mostly in former smokers." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0004" title="AzarG , Quaranta-El MaftouhiM , MasellaJJ , Mauget-FaÿsseM . Macular pigment density variation after supplementation of lutein and zeaxanthin using the Visucam® 200 pigment module: impact of age-related macular degeneration and lens status. Journal Français d'Ophtalmologie2017;40(4):303-13. ">Azar 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein and zeaxanthin with multivitamins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "No serious adverse events related to the supplements occurred across treatment"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0005" title="BartlettH , EperjesiF . A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology. Nutrition Journal2003;2:12. BartlettHE , EperjesiF . Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. European Journal of Clinical Nutrition2007;61(9):1121-7. ">Bartlett 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "There were no reported adverse effects from any of the study participants."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0006" title="BerrowEJ , BartlettHE , EperjesiF , GibsonJM . The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy - a randomised controlled trial. British Journal of Nutrition2013;109(11):2008-14. ">Berrow 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin (Ocuvite)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not report adverse effects</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin (Ocuvite)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not report adverse effects</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "There were no significant systemic or ocular adverse events related to the nutritional supplementation." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0009" title="MurrayIJ , MakridakiM , Van der VeenRL , CardenD , ParryNR , BerendschotTT . Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Investigative Ophthalmology and Visual Science2013;54(3):1781-8. TianY , KijlstraA , Van der VeenRL , MakridakiM , MurrayIJ , BerendschotTT . The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d. PLoS One2013;8:e73387. ">CLEAR 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/42 in the lutein group and 1/42 in the placebo group "discontinued due to medical reasons", but it was unclear if these were complications, per se. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0010" title="There is no publication for this study. ">France 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unpublished study, no data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0011" title="AbraldesMJ , NascimentoJ , Hernández-GalileaE , Olmedilla-AlonsoB , Escobar-BarrancoJJ , ZapataMA , et al. A randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration. Nutrients2021;13(4):1253. ">Garcia‐Layana 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin (Retilut and Theavit)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/109 adverse events in people receiving multivitamins, including 6 cases of cataract and 5 cases of exudative AMD. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "the zinc therapy was well‐tolerated".</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0013" title="KaiserHJ , FlammerJ , StumpfigD , HendricksonP . Visaline in the treatment of age-related macular degeneration: a pilot study. Ophthalmologica1995;209(6):302-5. ">Kaiser 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not report adverse effects</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin (OcuPower) and lutein (FloraGlo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The number of adverse effects were tabulated, but the study was underpowered to detect any differences. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not report adverse effects</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0016" title="LiS , LiuN , LinL , SunED , LiJD , LiPK . Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration. International Journal of Ophthalmology2018;11(6):970-5. ">Li 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Goji berries (wolfberry)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote in Discussion: "... without causing any detectable adverse effects"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein (Lutamax)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "In two subjects, the withdrawal was due to serious adverse events. One subject had a myocardial infarction, and the other subject developed CNV in the study eye." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "No adverse or other unintended effects were noted in any of the observed groups in the present study" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein and zeaxanthin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "No adverse events were observed or reported." Quote: "No significant adverse events or changes in biochemical or hematologic profiles were observed or reported in any subject throughout the study. No subject developed or reported occasional skin pigmentation (carotenodermia)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0020" title="NewsomeDA , SwartzM , LeoneNC , ElstonRC , MillerE . Oral zinc in macular degeneration. Archives of Ophthalmology1988;106(2):192-8. ">Newsome 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "In the zinc‐treated group, one subject stopped study participation due to the feeling that the study tablet aggravated preexisting peptic ulcer symptoms. Another subject taking zinc complained of gastrointestinal tract upset, which was relieved by taking the study tablet with food." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0021" title="NewsomeDA . A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Current Eye Research2008;33(7):591-8. ">Newsome 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc mono‐cysteine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "ZMC (zinc mono‐cysteine) appeared to be well tolerated"; 1/40 had gastrointestinal symptoms attributable to treatment. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0022" title="ParravanoM , TedeschiM , MancaD , CostanzoE , Di RenzoA , GiornoP , et al. Effects of Macuprev® supplementation in age-related macular degeneration: a double-blind randomized morpho-functional study along 6 months of follow-up. Advances in Therapy2019;36(9):2493-505. ">Parravano 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin (Macuprev)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not report adverse effects</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0023" title="PiattiA , CroceA , MazzacaneD , TrainaG , AmbrosinoL , BoniL , et al. Effect of 2-year nutritional supplementation on progression of age-related macular degeneration. European Journal of Ophthalmology2020;30(2):376-81. ">Piatti 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin (Azyr Mega)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "During the entire study, no significant adverse events were recorded."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/56 in the zinc‐treated group and 2/56 in the placebo group withdrew because of gastrointestinal symptoms. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0025" title="GarrettSK , McNeilJJ , SilagyC , SinclairM , ThomasAP , RobmanLD , et al. Methodology of the VECAT study: vitamin E intervention in cataract and age-related maculopathy. Ophthalmic Epidemiology1999;6(3):195-208. GarrettSK , ThomasAP , CicuttiniF , SilagyC , TaylorHR , McNeilJJ . Community-based recruitment strategies for a longitudinal interventional study: the VECAT experience. Journal of Clinical Epidemiology2000;53(5):541-8. RobmanLD , TikellisG , GarrettSK , HarperCA , McNeilJJ , TaylorHR , et al. Baseline ophthalmic findings in the vitamin E, cataract and age-related maculopathy (VECAT) study. Australian and New Zealand Journal of Ophthalmology1999;27(6):410-6. TaylorHR , TikellisG , RobmanLD , McCartyCA , McNeilJJ . Vitamin E supplementation and age-related maculopathy. Investigative Ophthalmology and Visual Science2001;42:S311. TikellisG , RobmanLD , HarperCA , GarrettSK , McNeilJJ , TaylorHR , et al. The VECAT study: methodology and statistical power for measurement of age-related macular features. Vitamin E, cataract, and age-related maculopathy study. Ophthalmic Epidemiology1999;6(3):181-94. ">VECAT 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 in the vitamin E and 7 in the control group died; 16 in the vitamin E group and 17 in the control group had an adverse reaction. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0026" title="WangH , LiRX , WangMF . Effects of zinc and antioxidant on visual function of patients with age-related macular degeneration. Zhongguo Linchuant Kangfu2004;8:1290-1. ">Wang 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin and zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not report adverse effects.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AMD: age‐related macular degeneration<br/>AREDS: Age‐Related Eye Disease Study<br/>CNV: choroidal neovascularisation<br/>HR: hazard ratio </p> </div> </div> <p>None of the studies reported resource use and costs.</p> <p>The study comparing goji berries to usual diet was small (57 in each group) and followed participants for only 90 days (<a href="./references#CD000254-bbs2-0016" title="LiS , LiuN , LinL , SunED , LiJD , LiPK . Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration. International Journal of Ophthalmology2018;11(6):970-5. ">Li 2018</a>). Best‐corrected visual acuity was similar in the two groups at the end of follow‐up (0.21 standard deviation (SD) 0.18 in the intervention group compared with 0.22 SD 0.19 in the control). The authors reported in the discussion only that there were "no detectable adverse effects". </p> </section> <section id="CD000254-sec-0055"> <h4 class="title">Lutein (with or without zeaxanthin) versus placebo</h4> <p>See <a href="./full#CD000254-tbl-0002">summary of findings Table 2</a>. </p> <p>Six studies compared lutein supplements (10 mg or 20 mg) with placebo and followed participants for six months to five years (<a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>; <a href="./references#CD000254-bbs2-0009" title="MurrayIJ , MakridakiM , Van der VeenRL , CardenD , ParryNR , BerendschotTT . Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Investigative Ophthalmology and Visual Science2013;54(3):1781-8. TianY , KijlstraA , Van der VeenRL , MakridakiM , MurrayIJ , BerendschotTT . The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d. PLoS One2013;8:e73387. ">CLEAR 2013</a>; <a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a>; <a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a>; <a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a>; <a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a>). In <a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>, all participants also took the AREDS formula. </p> <p>Only one study reported data on progression to late AMD, neovascular AMD, and geographic atrophy (<a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>). <a href="./references#CD000254-bbs2-0009" title="MurrayIJ , MakridakiM , Van der VeenRL , CardenD , ParryNR , BerendschotTT . Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Investigative Ophthalmology and Visual Science2013;54(3):1781-8. TianY , KijlstraA , Van der VeenRL , MakridakiM , MurrayIJ , BerendschotTT . The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d. PLoS One2013;8:e73387. ">CLEAR 2013</a>, <a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a>, and <a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a> reported mean logMAR visual acuity. <a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a> measured visual acuity using a Snellen chart and converted the score into logMAR units. <a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a> did not report any data in a form that could be used in this review. Data from <a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a> could not be used because it was not clear how visual acuity was measured and reported. Two studies reported on quality of life, using the Chinese version of the NEI‐VFQ (<a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a>; <a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a>). </p> <p>There were several different strategies for dealing with eyes. <a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> reported by eye. The study reports hazard ratios adjusted for one or two eyes per person. We have extracted data on eyes only. The confidence intervals for effect estimates from this study, as reported in this review, are therefore narrower than they should be, as they do not take into account within‐person correlation. Some studies reported findings on right eyes and left eyes separately (<a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a>), or selected a study eye (<a href="./references#CD000254-bbs2-0009" title="MurrayIJ , MakridakiM , Van der VeenRL , CardenD , ParryNR , BerendschotTT . Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Investigative Ophthalmology and Visual Science2013;54(3):1781-8. TianY , KijlstraA , Van der VeenRL , MakridakiM , MurrayIJ , BerendschotTT . The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d. PLoS One2013;8:e73387. ">CLEAR 2013</a>; <a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a>). In some studies, there was insufficient information to establish their approach (<a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a>; <a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a>). </p> <p>Compared to placebo, people taking lutein with or without zeaxanthin may have similar or slightly reduced risk of progression to late AMD over five years (risk ratio (RR) 0.94, 95% CI 0.87 to 1.01; 1 study, 6891 eyes; low‐certainty evidence), neovascular AMD (RR 0.92, 95% CI 0.84 to 1.02; 1 study, 6891 eyes; low‐certainty evidence), and geographic atrophy (RR 0.92, 95% CI 0.80 to 1.05; 1 study, 6891 eyes; low‐certainty evidence). A similar risk of progression to visual loss of 15 or more letters was seen in both the lutein/zeaxanthin and control groups (RR 0.98, 95% CI 0.91 to 1.05; 1 study, 6656 eyes; low‐certainty evidence). </p> <p>Three studies reported mean logMAR visual acuity. There was no evidence of any difference between treatment and control groups (MD 0.00 logMAR, 95% CI ‐0.05 to 0.05; I<sup>2</sup> = 0%; 231 participants; <a href="./references#CD000254-fig-0014" title="">Analysis 2.5</a>). </p> <p>There was moderate‐certainty evidence of little or no difference between lutein with or without zeaxanthin and control groups in quality of life from 308 participants in two studies (MD 1.21, 95% CI ‐2.59 to 5.01; <a href="./references#CD000254-fig-0015" title="">Analysis 2.6</a>). </p> <p><a href="#CD000254-tbl-0010">Table 6</a> summarises information available on adverse effects. Very low‐certainty evidence was available on adverse effects from these included studies. They were underpowered to look at adverse effects and reported them inconsistently. Data from <a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> suggested no serious adverse effects associated with lutein and zeaxanthin use. The hazard ratio for mortality comparing lutein/zeaxanthin to no lutein/zeaxanthin was 1.06 (95% CI 0.87 to 1.31). </p> <p>None of the studies reported resource use and costs.</p> <p><a href="./references#CD000254-bbs2-0004" title="AzarG , Quaranta-El MaftouhiM , MasellaJJ , Mauget-FaÿsseM . Macular pigment density variation after supplementation of lutein and zeaxanthin using the Visucam® 200 pigment module: impact of age-related macular degeneration and lens status. Journal Français d'Ophtalmologie2017;40(4):303-13. ">Azar 2017</a> compared lutein/zeaxanthin plus omega‐3 fatty acids and vitamins with omega‐3 fatty acids and vitamins but did not report any of our review outcomes, aside from a comment to the effect that there were no serious adverse effects observed. </p> </section> <section id="CD000254-sec-0056"> <h4 class="title">Vitamin E versus placebo</h4> <p>See <a href="./full#CD000254-tbl-0003">summary of findings Table 3</a>. </p> <p>Only one included study investigated vitamin E alone (<a href="./references#CD000254-bbs2-0025" title="GarrettSK , McNeilJJ , SilagyC , SinclairM , ThomasAP , RobmanLD , et al. Methodology of the VECAT study: vitamin E intervention in cataract and age-related maculopathy. Ophthalmic Epidemiology1999;6(3):195-208. GarrettSK , ThomasAP , CicuttiniF , SilagyC , TaylorHR , McNeilJJ . Community-based recruitment strategies for a longitudinal interventional study: the VECAT experience. Journal of Clinical Epidemiology2000;53(5):541-8. RobmanLD , TikellisG , GarrettSK , HarperCA , McNeilJJ , TaylorHR , et al. Baseline ophthalmic findings in the vitamin E, cataract and age-related maculopathy (VECAT) study. Australian and New Zealand Journal of Ophthalmology1999;27(6):410-6. TaylorHR , TikellisG , RobmanLD , McCartyCA , McNeilJJ . Vitamin E supplementation and age-related maculopathy. Investigative Ophthalmology and Visual Science2001;42:S311. TikellisG , RobmanLD , HarperCA , GarrettSK , McNeilJJ , TaylorHR , et al. The VECAT study: methodology and statistical power for measurement of age-related macular features. Vitamin E, cataract, and age-related maculopathy study. Ophthalmic Epidemiology1999;6(3):181-94. ">VECAT 2002</a>). This study randomised 587 participants to vitamin E supplementation and 592 to placebo, and followed them for an average of four years. Over 80% of the participants in this study had no signs of AMD. The study included one eye per person. </p> <p>The number of late AMD events was low (4/494 in the vitamin E and 3/504 in the placebo group). Therefore, the estimate of effect was very uncertain (RR 1.36, 95% CI 0.31 to 6.05). We judged this to be very low‐certainty evidence as there were only seven events (downgraded two levels for imprecision) and only 19% of the study population had AMD (downgraded one level for indirectness). There were no data on neovascular AMD or geographic atrophy. </p> <p>There was no evidence of any effect of treatment on visual acuity: 59 people in the vitamin E group and 57 people in the placebo group lost more than nine letters of acuity (equivalent to 2 or more lines) on the Bailey‐Lovie chart (RR 1.04, 95% CI 0.74 to 1.47). We downgraded for imprecision and indirectness, giving low‐certainty evidence for this outcome. </p> <p>No serious adverse effects were seen. Similar numbers of people in the vitamin E and placebo groups withdrew due to adverse effects (four versus seven), reported any adverse effect (91 versus 83), or ocular adverse effect (105 versus 90). </p> <p>There were no data on quality of life or resource use and costs.</p> </section> <section id="CD000254-sec-0057"> <h4 class="title">Zinc versus placebo</h4> <p>See <a href="./full#CD000254-tbl-0004">summary of findings Table 4</a>. </p> <p>Four studies investigated the effect of zinc supplementation (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>; <a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a> (published in abstract form only); <a href="./references#CD000254-bbs2-0020" title="NewsomeDA , SwartzM , LeoneNC , ElstonRC , MillerE . Oral zinc in macular degeneration. Archives of Ophthalmology1988;106(2):192-8. ">Newsome 1988</a>; <a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a>). In addition, we are aware of one unpublished study for which we have no data (<a href="./references#CD000254-bbs2-0010" title="There is no publication for this study. ">France 1998</a>). One further study investigated zinc‐monocysteine (<a href="./references#CD000254-bbs2-0021" title="NewsomeDA . A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Current Eye Research2008;33(7):591-8. ">Newsome 2008</a>). </p> <p>Three studies reported data on our primary outcome of progression to late AMD (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>; <a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a>; <a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a>); only one of these studies reported data separately for neovascular AMD and geographic atrophy (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>). Two studies reported mean visual acuity (<a href="./references#CD000254-bbs2-0020" title="NewsomeDA , SwartzM , LeoneNC , ElstonRC , MillerE . Oral zinc in macular degeneration. Archives of Ophthalmology1988;106(2):192-8. ">Newsome 1988</a>; <a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a>). </p> <p>There were several different strategies for dealing with eyes. Some studies reported AMD for the person; this means that the unit of analysis was the person, and they were counted as having AMD if it was present in one or both eyes (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>). Some studies reported findings on right eyes and left eyes separately (<a href="./references#CD000254-bbs2-0021" title="NewsomeDA . A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Current Eye Research2008;33(7):591-8. ">Newsome 2008</a>), selected a study eye (<a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a>), or averaged the data for the two eyes in participants where both eyes were included (<a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a>; <a href="./references#CD000254-bbs2-0020" title="NewsomeDA , SwartzM , LeoneNC , ElstonRC , MillerE . Oral zinc in macular degeneration. Archives of Ophthalmology1988;106(2):192-8. ">Newsome 1988</a>). In some studies, there was insufficient information to establish how eyes had been dealt with (<a href="./references#CD000254-bbs2-0010" title="There is no publication for this study. ">France 1998</a>; <a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a>). </p> <p>Data from <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> were reported as adjusted odds ratios only. The odds ratios were calculated using repeated‐measures logistic regression and were adjusted for baseline covariates age, sex, race, AMD category, and smoking status. </p> <p>People taking zinc supplements may be less likely to progress to late AMD (OR 0.83, 95% CI 0.70 to 0.98; 3 studies, 3790 participants; moderate‐certainty evidence; <a href="./references#CD000254-fig-0018" title="">Analysis 4.1</a>), neovascular AMD (OR 0.76, 95% CI 0.62 to 0.93; 1 study, 2442 participants; moderate‐certainty evidence; <a href="./references#CD000254-fig-0019" title="">Analysis 4.2</a>), geographic atrophy (OR 0.84, 95% CI 0.64 to 1.10; 1 study, 2442 participants; moderate‐certainty evidence; <a href="./references#CD000254-fig-0020" title="">Analysis 4.3</a>), and visual loss (OR 0.87, 95% CI 0.75 to 1.00; 2 studies, 3791 participants; moderate‐certainty evidence; <a href="./references#CD000254-fig-0021" title="">Analysis 4.4</a>). </p> <p>Most of the data came from <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>, with follow‐up over six years. The other two studies were smaller and provided different estimates for progression to late AMD. We did not downgrade for inconsistency because the confidence intervals were completely overlapping for the three studies. </p> <p>Only one study investigated zinc‐monocysteine (<a href="./references#CD000254-bbs2-0021" title="NewsomeDA . A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Current Eye Research2008;33(7):591-8. ">Newsome 2008</a>). At six months, people taking zinc‐monocysteine read more letters (distance visual acuity). In people treated with zinc‐monocysteine, the mean (SD) number of letters read correctly on an EDTRS chart with best correction was 39 (0.672) at baseline and 43 (0.784) at six months in their right eyes. In people taking placebo, the values were 40 (0.649) at baseline and 39 (0.921) in their right eyes. Differences between the groups were statistically significant. Similar findings were seen for the left eye. </p> <p>In <a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a>, the primary outcome was incidence of choroidal neovascularisation (CNV) in all participants. During the treatment period, a CNV developed in the study eye in 14 participants (nine in the treatment group, five in the placebo group). People who experienced a CNV were not included in the analyses of visual acuity. </p> <p><a href="#CD000254-tbl-0010">Table 6</a> summarises information available on adverse effects. Very low‐certainty evidence was available on adverse effects from these included studies. They were underpowered to look at adverse effects and reported them inconsistently. </p> <p>The main reported adverse effect leading to withdrawal from the studies was gastrointestinal symptoms. Of 286 people randomised into studies of zinc sulphate supplementation compared with placebo (excluding <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>), 5/146 zinc‐treated people withdrew due to gastrointestinal symptoms compared with 2/140 controls. No one developed copper‐deficiency anaemia (high zinc intake can inhibit copper absorption). In <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>, participants in the zinc arms reported more anaemia (13.2% versus 10.2%, P = 0.004); however, serum haematocrit levels were the same. Later follow‐up of the cohort of people taking part in the AREDS study found that there was a significant increase in hospital admissions due to genitourinary diseases in people taking zinc supplements (11.1% versus 7.6%, P = 0.0003). <a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> reported that gastrointestinal disorders and hospitalisations for genitourinary diseases were similar between high‐dose and low‐dose zinc groups. </p> <p>There were no data on quality of life or resource use and costs.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000254-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000254-sec-0058"></div> <section id="CD000254-sec-0059"> <h3 class="title" id="CD000254-sec-0059">Summary of main results</h3> <p>The current update (2023) identified six new included studies (<a href="./references#CD000254-bbs2-0004" title="AzarG , Quaranta-El MaftouhiM , MasellaJJ , Mauget-FaÿsseM . Macular pigment density variation after supplementation of lutein and zeaxanthin using the Visucam® 200 pigment module: impact of age-related macular degeneration and lens status. Journal Français d'Ophtalmologie2017;40(4):303-13. ">Azar 2017</a>; <a href="./references#CD000254-bbs2-0011" title="AbraldesMJ , NascimentoJ , Hernández-GalileaE , Olmedilla-AlonsoB , Escobar-BarrancoJJ , ZapataMA , et al. A randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration. Nutrients2021;13(4):1253. ">Garcia‐Layana 2021</a>; <a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a>; <a href="./references#CD000254-bbs2-0016" title="LiS , LiuN , LinL , SunED , LiJD , LiPK . Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration. International Journal of Ophthalmology2018;11(6):970-5. ">Li 2018</a>; <a href="./references#CD000254-bbs2-0022" title="ParravanoM , TedeschiM , MancaD , CostanzoE , Di RenzoA , GiornoP , et al. Effects of Macuprev® supplementation in age-related macular degeneration: a double-blind randomized morpho-functional study along 6 months of follow-up. Advances in Therapy2019;36(9):2493-505. ">Parravano 2019</a>; <a href="./references#CD000254-bbs2-0023" title="PiattiA , CroceA , MazzacaneD , TrainaG , AmbrosinoL , BoniL , et al. Effect of 2-year nutritional supplementation on progression of age-related macular degeneration. European Journal of Ophthalmology2020;30(2):376-81. ">Piatti 2020</a>). We also included a study that we had previously excluded because lutein was combined with omega‐3 fatty acids (<a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a>). We revised our decision for this update because some of the multivitamin supplements used in other included studies include omega‐3 fatty acids, plus there is little evidence that omega‐3 fatty acids are an active ingredient (<a href="./references#CD000254-bbs2-0131" title="Lawrenson JG , Evans JR . Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration. Cochrane Database of Systematic Reviews2015, Issue 4. Art. No: CD010015. [DOI: 10.1002/14651858.CD010015.pub3]">Lawrenson 2015</a>). </p> <p>These six new included studies were small and scant useable data could be extracted.</p> <p>The studies contributing to this review fall into two categories. There were three large studies with reasonably long treatment duration and follow‐up of four to six years (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>; <a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>; <a href="./references#CD000254-bbs2-0025" title="GarrettSK , McNeilJJ , SilagyC , SinclairM , ThomasAP , RobmanLD , et al. Methodology of the VECAT study: vitamin E intervention in cataract and age-related maculopathy. Ophthalmic Epidemiology1999;6(3):195-208. GarrettSK , ThomasAP , CicuttiniF , SilagyC , TaylorHR , McNeilJJ . Community-based recruitment strategies for a longitudinal interventional study: the VECAT experience. Journal of Clinical Epidemiology2000;53(5):541-8. RobmanLD , TikellisG , GarrettSK , HarperCA , McNeilJJ , TaylorHR , et al. Baseline ophthalmic findings in the vitamin E, cataract and age-related maculopathy (VECAT) study. Australian and New Zealand Journal of Ophthalmology1999;27(6):410-6. TaylorHR , TikellisG , RobmanLD , McCartyCA , McNeilJJ . Vitamin E supplementation and age-related maculopathy. Investigative Ophthalmology and Visual Science2001;42:S311. TikellisG , RobmanLD , HarperCA , GarrettSK , McNeilJJ , TaylorHR , et al. The VECAT study: methodology and statistical power for measurement of age-related macular features. Vitamin E, cataract, and age-related maculopathy study. Ophthalmic Epidemiology1999;6(3):181-94. ">VECAT 2002</a>). The other 23 studies were smaller (ranging from 20 to 500 participants) and had shorter durations of treatment and follow‐up (six to 24 months). </p> <p>The large studies provide answers to different questions. The <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> study provided evidence that long‐term supplementation with vitamins C, E, beta‐carotene, and zinc in people with AMD probably reduces the risk of progression to late AMD and loss of visual acuity. The overall benefit demonstrated in that study was modest, with a relative risk reduction in the order of 20% to 25% over five years. However, given that treatment options for AMD are limited, and vision loss is rarely recovered, this may be of interest to people with AMD, particularly intermediate AMD where the risk of progression is higher. </p> <p>People with early AMD have a low risk of progression to late AMD and visual loss. The evidence as to the effect of antioxidant supplements in this group is uncertain. In the AREDS study, there were too few events to assess the effects of supplementation in people with early AMD. The authors concluded that the "low event rate makes it impossible to assess treatment effects in this category (category 2) for the AMD outcome and less likely that any of the treatments would be recommended. Therefore, analyses are also presented for those participants most likely to benefit from an effective treatment (Categories 3 and 4)". The results of AREDS are often interpreted as evidence that the supplements do not work to stop progression in early AMD. For example, the US National Eye Institute website makes the following statement: "AREDS 2 supplements can’t prevent early AMD from developing into intermediate AMD" (<a href="./references#CD000254-bbs2-0136" title="National Eye Institute. AREDS 2 supplements for age-related macular degeneration (AMD). www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration/nutritional-supplements-age-related-macular-degeneration (accessed prior to 2 May 2023).">National Eye Institute 2023</a>). We think this is wrong, as the evidence is uncertain. However, our review demonstrates that, even if the effects of supplements are similar at every stage of AMD, few people with early AMD will benefit from antioxidant supplementation because of the low risk of progression in that group. In <a href="./full#CD000254-tbl-0001">summary of findings Table 1</a> for the comparison of multivitamin and mineral supplement versus placebo or no treatment, we show that many people with early AMD would have to take vitamin supplements for few people to benefit. We estimate that there would be approximately four fewer cases of progression to late AMD for every 1000 people taking vitamins (one fewer to six fewer cases). In contrast, people at high risk of progression (i.e. people with intermediate AMD) are more likely to benefit, with approximately 78 fewer cases of progression for every 1000 people taking vitamins (26 fewer to 126 fewer). </p> <p><a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> compared lutein/zeaxanthin supplements with placebo; almost all participants also took the AREDS formula. Secondary analyses from this study suggested that there may be some benefit in replacing beta‐carotene with lutein, but these analyses were only exploratory (<a href="./references#CD000254-bbs2-0092" title="The Age-Related Eye Disease Study 2 (AREDS2) Research Group. Secondary analyses of the effects of lutein/zeaxanthinon age-related macular degeneration progression AREDS2 Report No. 3. JAMA Ophthalmology2014;132(2):142-9.">AREDS2 2014</a>). Other studies of lutein with or without zeaxanthin were small, of short duration, and did not report relevant outcomes. Limited data on mean visual acuity and quality of life did not suggest any important effects of these supplements on outcomes important to patients. </p> <p>The results of the <a href="./references#CD000254-bbs2-0025" title="GarrettSK , McNeilJJ , SilagyC , SinclairM , ThomasAP , RobmanLD , et al. Methodology of the VECAT study: vitamin E intervention in cataract and age-related maculopathy. Ophthalmic Epidemiology1999;6(3):195-208. GarrettSK , ThomasAP , CicuttiniF , SilagyC , TaylorHR , McNeilJJ . Community-based recruitment strategies for a longitudinal interventional study: the VECAT experience. Journal of Clinical Epidemiology2000;53(5):541-8. RobmanLD , TikellisG , GarrettSK , HarperCA , McNeilJJ , TaylorHR , et al. Baseline ophthalmic findings in the vitamin E, cataract and age-related maculopathy (VECAT) study. Australian and New Zealand Journal of Ophthalmology1999;27(6):410-6. TaylorHR , TikellisG , RobmanLD , McCartyCA , McNeilJJ . Vitamin E supplementation and age-related maculopathy. Investigative Ophthalmology and Visual Science2001;42:S311. TikellisG , RobmanLD , HarperCA , GarrettSK , McNeilJJ , TaylorHR , et al. The VECAT study: methodology and statistical power for measurement of age-related macular features. Vitamin E, cataract, and age-related maculopathy study. Ophthalmic Epidemiology1999;6(3):181-94. ">VECAT 2002</a> study did not support vitamin E supplementation to prevent the incidence or progression of AMD. However, the study was underpowered to answer whether people with signs of AMD, such as those participating in the <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> study, should take vitamin E. Currently, <a href="./references#CD000254-bbs2-0025" title="GarrettSK , McNeilJJ , SilagyC , SinclairM , ThomasAP , RobmanLD , et al. Methodology of the VECAT study: vitamin E intervention in cataract and age-related maculopathy. Ophthalmic Epidemiology1999;6(3):195-208. GarrettSK , ThomasAP , CicuttiniF , SilagyC , TaylorHR , McNeilJJ . Community-based recruitment strategies for a longitudinal interventional study: the VECAT experience. Journal of Clinical Epidemiology2000;53(5):541-8. RobmanLD , TikellisG , GarrettSK , HarperCA , McNeilJJ , TaylorHR , et al. Baseline ophthalmic findings in the vitamin E, cataract and age-related maculopathy (VECAT) study. Australian and New Zealand Journal of Ophthalmology1999;27(6):410-6. TaylorHR , TikellisG , RobmanLD , McCartyCA , McNeilJJ . Vitamin E supplementation and age-related maculopathy. Investigative Ophthalmology and Visual Science2001;42:S311. TikellisG , RobmanLD , HarperCA , GarrettSK , McNeilJJ , TaylorHR , et al. The VECAT study: methodology and statistical power for measurement of age-related macular features. Vitamin E, cataract, and age-related maculopathy study. Ophthalmic Epidemiology1999;6(3):181-94. ">VECAT 2002</a> is the only published study on vitamin E supplementation and AMD progression. </p> <p>The other studies of multivitamin preparations were either too small to provide evidence either way, or the data were not available in a format suitable to include in this review. Pooling results, where possible, did not provide evidence of any benefit of supplementation. However, these studies were of relatively short duration. </p> <p>A total of four published studies investigated zinc supplementation (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>; <a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a>; <a href="./references#CD000254-bbs2-0020" title="NewsomeDA , SwartzM , LeoneNC , ElstonRC , MillerE . Oral zinc in macular degeneration. Archives of Ophthalmology1988;106(2):192-8. ">Newsome 1988</a>; <a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a>), and one study examined a novel zinc‐monocysteine formulation (<a href="./references#CD000254-bbs2-0021" title="NewsomeDA . A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Current Eye Research2008;33(7):591-8. ">Newsome 2008</a>). The <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> study indicated that the beneficial effect of zinc supplementation was of a similar order to that of vitamin supplementation. The other studies provided conflicting evidence. <a href="./references#CD000254-bbs2-0020" title="NewsomeDA , SwartzM , LeoneNC , ElstonRC , MillerE . Oral zinc in macular degeneration. Archives of Ophthalmology1988;106(2):192-8. ">Newsome 1988</a> found a reduction in the risk of visual acuity loss with supplementation over 12 to 24 months. However, <a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a> found no effect of treatment. <a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a>, which intended to recruit 500 participants, was terminated early because the results of the first 40 participants at 24 months indicated no benefit of treatment. The other two studies of zinc supplementation are as yet unpublished, although limited results from <a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a> were published in abstract form and were included here. <a href="./references#CD000254-bbs2-0021" title="NewsomeDA . A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Current Eye Research2008;33(7):591-8. ">Newsome 2008</a> found that zinc‐monocysteine had beneficial effects on visual acuity and contrast sensitivity. </p> </section> <section id="CD000254-sec-0060"> <h3 class="title" id="CD000254-sec-0060">Overall completeness and applicability of evidence</h3> <p>The main evidence that antioxidant vitamin and mineral supplementation is probably of benefit comes from the <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> study. As <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> was a large, well‐conducted, randomised study, potential biases would have been minimised. The only area where bias may have been introduced was if there were different systemic effects of the antioxidant and zinc supplementation (for example, yellowing of skin or difficulty swallowing tablets), which led the participants to guess which group they were in. Alternatively, the retinal fundus photographs might have been different in some way, such that the graders' response was affected by treatment group. However, these scenarios are unlikely, and there was little evidence that unblinding was a problem in the study. The extent to which the results from this one study – conducted in a well‐nourished American population where supplementation is common – can be extrapolated to other settings and populations is unclear. </p> <p>It is worth noting that pooling data from studies other than <a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> revealed little evidence for the effectiveness of antioxidant vitamin and mineral supplements on preventing visual loss or progression of the disease. However, the other studies encompassed many different formulations and, in general, were rather small and of short duration, which may explain the lack of effect. </p> <p><a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> was the only study to examine in detail the question of safety. Investigators found little evidence of harm, but there was an increased risk of hospital admission due to genitourinary complications in people taking zinc supplements (80 mg per day). Other studies have questioned the safety of some of the components of the AREDS formulation. Two large randomised controlled studies have indicated that smokers who take beta‐carotene may be at increased risk of developing lung cancer (<a href="./references#CD000254-bbs2-0094" title="The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. New England Journal of Medicine1994;330(15):1029-35.">ATBC 1994</a>; <a href="./references#CD000254-bbs2-0138" title="OmennGS , GoodmanGE , ThornquistMD , BalmesJ , CullenMR , GlassA , et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. New England Journal of Medicine1996;334(18):1189-90.">Omenn 1996</a>). Subsequent analyses of AREDS studies confirmed this. The Heart Outcomes Prevention Evaluation (HOPE) study found that amongst people with vascular disease or diabetes, vitamin E supplementation was associated with a higher risk of heart failure (<a href="./references#CD000254-bbs2-0134" title="LonnE , BoschJ , YusufS , SheridanP , PogueJ , ArnoldJM . Effects of long term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA2005;293(11):1338-47.">Lonn 2005</a>). </p> <p>We identified two, somewhat dated, systematic reviews addressing the harms of vitamin supplements. Huang and colleagues did not identify any consistent adverse effects of mineral and vitamin supplements, but only included nine RCTs in their review (<a href="./references#CD000254-bbs2-0125" title="HuangHY , CaballeroB , ChangS , AlbergAJ , SembaRD , SchneyerCR , et al. The efficacy and safety of multivitamin and mineral supplement use to prevent cancer and chronic disease in adults: a systematic review for a National Institutes of Health state-of-the-science conference. Annals of Internal Medicine2006;145(5):372-85.">Huang 2006</a>). A subsequent Cochrane Review that investigated antioxidant supplements for preventing all‐cause mortality included 78 studies with 296,707 participants (<a href="./references#CD000254-bbs2-0098" title="BjelakovicG , NikolovaD , GluudLL , SimonettiRG , GluudC . Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database of Systematic Reviews2012, Issue 3. Art. No: CD007176. [DOI: 10.1002/14651858.CD007176.pub2]">Bjelakovic 2012</a>). Bjelakovic and colleagues "found no evidence to support antioxidant supplements for primary or secondary prevention. Beta‐carotene and vitamin E seem to increase mortality, and so may higher doses of vitamin A" (<a href="./references#CD000254-bbs2-0098" title="BjelakovicG , NikolovaD , GluudLL , SimonettiRG , GluudC . Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database of Systematic Reviews2012, Issue 3. Art. No: CD007176. [DOI: 10.1002/14651858.CD007176.pub2]">Bjelakovic 2012</a>). A systematic search of the literature for systematic reviews addressing the harms of vitamin supplements did not identify any further relevant evidence. </p> <p>Whether specific genetic subgroups of people with AMD experience a different risk of benefit or harm from antioxidant supplements remains controversial. Currently, we have not included genetic factors as a planned subgroup analysis in this review. Several different analyses of AREDS data have yielded conflicting results (<a href="./references#CD000254-bbs2-0093" title="AsselMJ , LiF , WangY , AllenAS , BaggerlyKA , VickersAJ . Genetic polymorphisms of CFH and ARMS2 do not predict response to antioxidants and zinc in patients with age-related macular degeneration: independent statistical evaluations of data from the Age-Related Eye Disease Study. Ophthalmology2018;125(3):391-7.">Assell 2018</a>; <a href="./references#CD000254-bbs2-0095" title="AwhCC , LaneAM , HawkenS , ZankeB , KimIK . CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology2013;120(11):2317-23.">Awh 2013</a>; <a href="./references#CD000254-bbs2-0096" title="AwhCC , HawkenS , ZankeBW . Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the Age-Related Eye Disease Study. Ophthalmology2015;122(1):162-9.">Awh 2015</a>; <a href="./references#CD000254-bbs2-0105" title="ChewEY , KleinML , ClemonsTE , AgrónE , RatnapriyaR , EdwardsAO , et al, Age-Related Eye Disease Study Research Group. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. [DOI: 10.1016/j.ophtha.2014.05.008]">Chew 2014b</a>; <a href="./references#CD000254-bbs2-0106" title="ChewEY , KleinML , ClemonsTE , AgrónE , AbecasisGR . Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test?Ophthalmology2015;122(1):212-5.">Chew 2015</a>; <a href="./references#CD000254-bbs2-0129" title="KleinML , FrancisPJ , RosnerB , ReynoldsR , HamonSC , SchultzDW , et al. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology2008;115(6):1019-25. [DOI: 10.1016/j.ophtha.2008.01.036.]">Klein 2008</a>; <a href="./references#CD000254-bbs2-0147" title="SeddonJM , SilverRE , RosnerB . Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis. British Journal of Ophthalmology2016;100(12):1731-7.">Seddon 2016</a>; <a href="./references#CD000254-bbs2-0148" title="VavvasDG , SmallKW , AwhCC , ZankeBW , TibshiraniRJ , KustraR . CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation. Proceedings of the National Academy of Sciences2018;115(4):E696-704.">Vavvas 2018</a>). The most comprehensive and recent analysis concludes that genetic polymorphisms of the complement factor H (CFH) and the age‐related maculopathy susceptibility 2 (ARMS2) genes do not predict response to antioxidant and zinc supplementation in people with AMD (<a href="./references#CD000254-bbs2-0093" title="AsselMJ , LiF , WangY , AllenAS , BaggerlyKA , VickersAJ . Genetic polymorphisms of CFH and ARMS2 do not predict response to antioxidants and zinc in patients with age-related macular degeneration: independent statistical evaluations of data from the Age-Related Eye Disease Study. Ophthalmology2018;125(3):391-7.">Assell 2018</a>). </p> </section> <section id="CD000254-sec-0061"> <h3 class="title" id="CD000254-sec-0061">Certainty of the evidence</h3> <p>As the majority of the studies were placebo‐controlled, we mostly assessed them as being at overall low risk of bias. In particular, we judged the two studies that contributed most of the data to this review as at low risk of bias (<a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>; <a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>). Three studies compared supplements to no treatment (<a href="./references#CD000254-bbs2-0006" title="BerrowEJ , BartlettHE , EperjesiF , GibsonJM . The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy - a randomised controlled trial. British Journal of Nutrition2013;109(11):2008-14. ">Berrow 2013</a>; <a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a>; <a href="./references#CD000254-bbs2-0016" title="LiS , LiuN , LinL , SunED , LiJD , LiPK . Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration. International Journal of Ophthalmology2018;11(6):970-5. ">Li 2018</a>); we judged these to be at high risk of performance bias. However, these studies were small and did not contribute significant amounts of data to the analysis. There was some variable reporting of the smaller studies; the extent to which attrition bias may have played a role was not always clear. There was some evidence of selective outcome reporting with respect to data on visual acuity. We identified several studies that did not report non‐significant data on visual acuity, which might be expected as a key outcome in such studies. Another problem is the variety of ways in which visual acuity can be analysed and reported; for example, as a dichotomous outcome with a variety of potential cut‐points, or as a continuous variable reporting change or final value. It was possible that investigators had analysed visual acuity in a variety of ways and reported the most significant finding. However, in these studies, we did not find evidence of improved visual acuity associated with treatment. </p> <p>The main reasons for downgrading the certainty of the evidence were imprecision (due to small study size) and indirectness. In particular, since all participants in <a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> took multivitamin supplements, the results may not have been a true reflection of the effect of lutein/zeaxanthin supplementation alone. </p> </section> <section id="CD000254-sec-0062"> <h3 class="title" id="CD000254-sec-0062">Potential biases in the review process</h3> <p>This review follows the guidance for the preparation of Cochrane Reviews. We have made various changes to the protocol over the years (see <a href="#CD000254-sec-0085">Differences between protocol and review</a>). Improvements in Cochrane methods, the structure of the data, and collaboration with relevant partners (such as the National Institute for Health and Care Excellence (NICE)) have guided these changes, and we have aimed to avoid data‐driven changes. </p> <p>Our choice of outcome measures for the current update remains the same as for the last update (<a href="./references#CD000254-bbs2-0155" title="EvansJR , LawrensonJG . Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD000254. [DOI: 10.1002/14651858.CD000254.pub4]">Evans 2017</a>), when we revised the outcome measures in order to collect outcomes relevant to the development of the NICE guideline on macular degeneration (<a href="./references#CD000254-bbs2-0137" title="National Institute for Health and Care Excellence (NICE). Age-related macular degeneration. NICE guideline NG82; January 2018. www.nice.org.uk/guidance/ng82 (accessed 23 March 2021).">NICE 2018</a>). Since then, two core outcome sets relevant to macular degeneration have been published (<a href="./references#CD000254-bbs2-0130" title="KrezelAK , HoggR , LohfeldL , ChakravarthyU , Azuara-BlancoA . Core outcomes for geographic atrophy trials. BritishJournal of Ophthalmology2020;104(9):1196-1202.">Krezel 2019</a>; <a href="./references#CD000254-bbs2-0142" title="RodriguesIA , SprinkhuizenSM , BarthelmesD , BlumenkranzM , CheungG , HallerJ , et al. Defining a minimum set of standardized patient-centered outcome measures for macular degeneration. American Journal of Ophthalmology2016;168:1-12.">Rodrigues 2016</a>). These outcome sets suggest additional potential outcomes, such as reading speed and near visual acuity, which are not currently included in our review. However, these outcomes are not commonly reported, if at all, in the studies included in this review, and we have not amended our review outcomes. We may consider these outcomes in future updates if studies amend their outcomes in the light of consensus core outcome sets (as we believe they should do). Contrast sensitivity is reported in some studies of age‐related macular degeneration but is not currently included in our review. Neither of the core outcome sets mentioned above lists contrast sensitivity as an important outcome. In <a href="./references#CD000254-bbs2-0142" title="RodriguesIA , SprinkhuizenSM , BarthelmesD , BlumenkranzM , CheungG , HallerJ , et al. Defining a minimum set of standardized patient-centered outcome measures for macular degeneration. American Journal of Ophthalmology2016;168:1-12.">Rodrigues 2016</a>, for example, clinical measures such as contrast sensitivity were specifically dismissed in favour of patient‐reported outcome measures (PROMs), which are included in the current review in the form of quality of life measures. In <a href="./references#CD000254-bbs2-0130" title="KrezelAK , HoggR , LohfeldL , ChakravarthyU , Azuara-BlancoA . Core outcomes for geographic atrophy trials. BritishJournal of Ophthalmology2020;104(9):1196-1202.">Krezel 2019</a>, which included a substantial number of participants with age‐related macular degeneration, contrast sensitivity was not reflected in the final choice of outcomes. For this reason, we did not amend our review outcomes to include contrast sensitivity. Macular pigment optical density (MPOD) is often reported in studies of lutein/zeaxanthin. However, MPOD level in itself is not a direct measure of AMD and is not currently listed on core outcome sets. </p> <p>For the current update, we consulted with the GRADE group as to how best to grade the evidence on lutein/zeaxanthin in AREDS2. One suggestion was that we should consider indirect comparisons between AREDS and AREDS2 to obtain an estimate of the effect of lutein/zeaxanthin. Unfortunately, as almost all participants in AREDS2 also took AREDS formula, such an analysis would not provide any additional information on the comparison between lutein/zeaxanthin and placebo. This means that we have no high‐quality, large‐scale, placebo‐controlled comparisons for lutein/zeaxanthin, as specified in our protocol. Nevertheless, we have included data from AREDS2 in two ways. Firstly, we have included the prespecified comparisons in that study but downgraded the evidence to reflect the lack of a true placebo control. Secondly, we have reported the post hoc analyses conducted by the AREDS2 investigators, suggesting that lutein/zeaxanthin may replace beta‐carotene in the AREDS supplement. We consider the evidence for lutein/zeaxanthin is rather indirect and, moreover, is not currently supported by other admittedly small, poorer quality, and shorter duration studies. However, other systematic reviews consider this to be high‐quality evidence and suggest that the lack of a placebo control group in AREDS2 may mean that the effects of lutein/zeaxanthin are under‐estimated rather than over‐estimated (<a href="./references#CD000254-bbs2-0150" title="WaughN , LovemanE , ColquittJ , RoyleP , YeongJL , HoadG , et al. Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review. Health Technology Assessment2018;22(27):1-168.">Waugh 2018</a>). We feel this view ignores the fact that people in the lutein/zeaxanthin group also took the AREDS formula. </p> </section> <section id="CD000254-sec-0063"> <h3 class="title" id="CD000254-sec-0063">Agreements and disagreements with other studies or reviews</h3> <p>There have been a number of reviews published on this topic (<a href="./references#CD000254-bbs2-0090" title="AndreattaW , El-SherbinyS . Evidence-based nutritional advice for patients affected by age-related macular degeneration. Ophthalmologica2014;231(4):185-90.">Andreatta 2014</a>; <a href="./references#CD000254-bbs2-0091" title="AngeloG , DrakeVJ , FreiB . Efficacy of multivitamin/mineral supplementation to reduce chronic disease risk: a critical review of the evidence from observational studies and randomized controlled trials. Critical Reviews in Food Science and Nutrition2015;55(14):1968-91.">Angelo 2015</a>; <a href="./references#CD000254-bbs2-0099" title="BroadheadGK , GriggJR , ChangAA , McCluskeyP . Dietary modification and supplementation for the treatment of age-related macular degeneration. Nutrition Reviews2015;73(7):448-62.">Broadhead 2015</a>; <a href="./references#CD000254-bbs2-0101" title="BuschiniE , FeaAM , LaviaCA , NassisiM , PignataG , ZolaM , et al. Recent developments in the management of dry age-related macular degeneration. Clinical Ophthalmology2015;9:563-74.">Buschini 2015</a>; <a href="./references#CD000254-bbs2-0103" title="CarneiroA , AndradeJP . Nutritional and lifestyle interventions for age-related macular degeneration: a review. Oxidative Medicine and Cellular Longevity2017;2017:Article ID 6469138. [DOI: 10.1155/2017/6469138]">Carneiro 2017</a>; <a href="./references#CD000254-bbs2-0104" title="ChewEY . Vitamins and minerals, for eyes only?JAMA Ophthalmology2014;132(6):665-6.">Chew 2014a</a>; <a href="./references#CD000254-bbs2-0110" title="CsaderS , KorhonenS , KaarnirantaK , SchwabU . The effect of dietary supplementations on delaying the progression of age-related macular degeneration: a sytematic review and meta-analysis. Nutrients2022;14(20):13.">Csader 2022</a>; <a href="./references#CD000254-bbs2-0112" title="DownieLE , KellerPR . Nutrition and age-related macular degeneration: research evidence in practice. Optometry and Vision Science2014;91(8):821-31.">Downie 2014</a>; <a href="./references#CD000254-bbs2-0121" title="GroverAK , SamsonSE . Antioxidants and vision health: facts and fiction. Molecular and Cellular Biochemistry2014;388(1-2):173-83.">Grover 2014</a>; <a href="./references#CD000254-bbs2-0122" title="HanusJ , ZhaoF , WangS . Current therapeutic developments in atrophic age-related macular degeneration. British Journal of Ophthalmology2016;100(1):122-7.">Hanus 2016</a>; <a href="./references#CD000254-bbs2-0132" title="LiuR , WangT , ZhangB , QinL , WuC , LiQ , et al. Lutein and zeaxanthin supplementation and association with visual function in age-related macular degeneration. Investigative Ophthalmology and Visual Science2016;56(1):252-8.">Liu 2015</a>; <a href="./references#CD000254-bbs2-0135" title="ManikandanR , ThiagarajanR , GouthamG , ArumugamM , BeulajaM , RastrelliL , et al. Zeaxanthin and ocular health, from bench to bedside. Fitoterapia2016;109:58-66.">Manikandan 2016</a>; <a href="./references#CD000254-bbs2-0139" title="PameijerEM , HeusP , DamenJA , SpijkerR , HooftL , RingensPJ , et al. What did we learn in 35 years of research on nutrition and supplements for age-related macular degeneration: a systematic review. Acta Ophthalmologica2022;100(8):e1541-52.">Pameijer 2022</a>; <a href="./references#CD000254-bbs2-0140" title="PrasadAS . Zinc: an antioxidant and anti-inflammatory agent: role of zinc in degenerative disorders of aging. Journal of Trace Elements in Medicine and Biology2014;28(4):364-71.">Prasad 2014</a>; <a href="./references#CD000254-bbs2-0144" title="SacconiR , CorbelliE , QuerquesL , BandelloF , QuerquesG . A review of current and future management of geographic atrophy. Ophthalmology and Therapy2017;6(1):69-77.">Sacconi 2017</a>; <a href="./references#CD000254-bbs2-0145" title="SchmidlD , GarhoferG , SchmettererL . Nutritional supplements in age-related macular degeneration. Acta Ophthalmologica2015;93(2):105-21.">Schmidl 2015</a>; <a href="./references#CD000254-bbs2-0150" title="WaughN , LovemanE , ColquittJ , RoyleP , YeongJL , HoadG , et al. Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review. Health Technology Assessment2018;22(27):1-168.">Waugh 2018</a>; <a href="./references#CD000254-bbs2-0152" title="ZampattiS , RicciF , CusumanoA , MarsellaLT , NovelliG , GiardinaE . Review of nutrient actions on age-related macular degeneration. Nutrition Research2014;34(2):95-105.">Zampatti 2014</a>). In general, these reviews have provided narrative assessments of observational studies and RCT evidence, focusing mainly on the results of AREDS and AREDS2. On the basis of AREDS, these reviews generally conclude that supplementation may benefit some people with AMD, in harmony with our conclusion. </p> <p>One systematic review of lutein and zeaxanthin supplementation pooled data from eight studies (<a href="./references#CD000254-bbs2-0132" title="LiuR , WangT , ZhangB , QinL , WuC , LiQ , et al. Lutein and zeaxanthin supplementation and association with visual function in age-related macular degeneration. Investigative Ophthalmology and Visual Science2016;56(1):252-8.">Liu 2015</a>). We identified the same eight studies for this review. The overall estimates of effect for visual acuity were similar, with a pooled mean difference of ‐0.04 logMAR (95% CI ‐0.06 to ‐0.03) in <a href="./references#CD000254-bbs2-0132" title="LiuR , WangT , ZhangB , QinL , WuC , LiQ , et al. Lutein and zeaxanthin supplementation and association with visual function in age-related macular degeneration. Investigative Ophthalmology and Visual Science2016;56(1):252-8.">Liu 2015</a> and ‐0.00 logMAR (95% CI ‐0.05 to 0.05) in this review. <a href="./references#CD000254-bbs2-0132" title="LiuR , WangT , ZhangB , QinL , WuC , LiQ , et al. Lutein and zeaxanthin supplementation and association with visual function in age-related macular degeneration. Investigative Ophthalmology and Visual Science2016;56(1):252-8.">Liu 2015</a> used the Jadad scale to assess the quality of the included studies, but did not factor this assessment into the review's conclusions. Similarly, no attempt was made to assess the overall certainty of the evidence. Although <a href="./references#CD000254-bbs2-0132" title="LiuR , WangT , ZhangB , QinL , WuC , LiQ , et al. Lutein and zeaxanthin supplementation and association with visual function in age-related macular degeneration. Investigative Ophthalmology and Visual Science2016;56(1):252-8.">Liu 2015</a> concluded that lutein/zeaxanthin improve visual performance, we would probably have concluded, with the same data, that there was low‐certainty evidence that lutein/zeaxanthin make little important difference to visual acuity, as a mean difference of 2 letters (0.04 logMAR) is probably not clinically significant. <a href="./references#CD000254-bbs2-0132" title="LiuR , WangT , ZhangB , QinL , WuC , LiQ , et al. Lutein and zeaxanthin supplementation and association with visual function in age-related macular degeneration. Investigative Ophthalmology and Visual Science2016;56(1):252-8.">Liu 2015</a> also included contrast sensitivity as an outcome and concluded that lutein/zeaxanthin showed "remarkable benefit". We did not consider contrast sensitivity. </p> <p>There have been two recent reviews of the effect of lutein and zeaxanthin supplementation on macular pigment optical density, which was not an outcome in the current review (<a href="./references#CD000254-bbs2-0116" title="FitzpatrickN , ChachayV , BowtellJ , JackmanS , CapraS , Shore A et al. An appraisal of trials investigating the effects on macular pigment optical density of lutein and zeaxanthin dietary interventions: a narrative review. Nutrition Reviews2022;80(3):513-24.">Fitzpatrick 2022</a>; <a href="./references#CD000254-bbs2-0133" title="LiuY , NiM , WuR , YangZ , ZhuX , ChenJ . The level and efficacy of lutein in patients with age-related macular degeneration: a comprehensive systematic review and meta-analysis. Annals of Translational Medicine2022;10(6):299.">Liu 2022</a>). </p> <p>The authors of <a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> concluded in the main study report that addition "of lutein + zeaxanthin [...] to the AREDS formulation in primary analyses did not further reduce risk of progression to advanced AMD." This is similar to the findings of this review, where we conclude that supplements containing lutein and zeaxanthin may have little or no effect on the progression of AMD. The authors of <a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> go on to suggest that "...because of potential increased incidence of lung cancer in former smokers, lutein + zeaxanthin could be an appropriate carotenoid substitute in the AREDS formulation." Subsequent exploratory analyses of study data from <a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> suggested a benefit of lutein/zeaxanthin versus beta‐carotene in this study population, all of whom were taking supplements. For this reason, the authors of <a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> recommend replacing beta‐carotene with lutein (<a href="https://nei.nih.gov/areds2/PatientFAQ" target="_blank">https://nei.nih.gov/areds2/PatientFAQ)</a>. In the last version of this review, we did not consider these secondary analyses of <a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> due to their exploratory nature. However, we reconsidered this decision for the current review, and we discuss the judgements involved under <a href="#CD000254-sec-0062">Potential biases in the review process</a> above. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000254-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram" data-id="CD000254-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD000254-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD000254-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant multivitamin and mineral supplement versus placebo or no treatment, Outcome 1: Progression to late AMD (neovascular AMD and/or geographic atrophy)" data-id="CD000254-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant multivitamin and mineral supplement versus placebo or no treatment, Outcome 1: Progression to late AMD (neovascular AMD and/or geographic atrophy) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant multivitamin and mineral supplement versus placebo or no treatment, Outcome 2: Progression to neovascular AMD" data-id="CD000254-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant multivitamin and mineral supplement versus placebo or no treatment, Outcome 2: Progression to neovascular AMD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant multivitamin and mineral supplement versus placebo or no treatment, Outcome 3: Progression to geographic atrophy" data-id="CD000254-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant multivitamin and mineral supplement versus placebo or no treatment, Outcome 3: Progression to geographic atrophy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant multivitamin and mineral supplement versus placebo or no treatment, Outcome 4: Progression to visual loss (loss of 3 or more lines on logMAR chart)" data-id="CD000254-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant multivitamin and mineral supplement versus placebo or no treatment, Outcome 4: Progression to visual loss (loss of 3 or more lines on logMAR chart) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant multivitamin and mineral supplement versus placebo or no treatment, Outcome 5: Mean visual acuity" data-id="CD000254-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant multivitamin and mineral supplement versus placebo or no treatment, Outcome 5: Mean visual acuity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant multivitamin and mineral supplement versus placebo or no treatment, Outcome 6: Quality of life" data-id="CD000254-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant multivitamin and mineral supplement versus placebo or no treatment, Outcome 6: Quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lutein with or without zeaxanthin versus placebo, Outcome 1: Progression to late AMD (neovascular AMD and/or geographic atrophy)" data-id="CD000254-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Lutein with or without zeaxanthin versus placebo, Outcome 1: Progression to late AMD (neovascular AMD and/or geographic atrophy) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lutein with or without zeaxanthin versus placebo, Outcome 2: Progression to neovascular AMD" data-id="CD000254-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Lutein with or without zeaxanthin versus placebo, Outcome 2: Progression to neovascular AMD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lutein with or without zeaxanthin versus placebo, Outcome 3: Progression to geographic atrophy" data-id="CD000254-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Lutein with or without zeaxanthin versus placebo, Outcome 3: Progression to geographic atrophy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lutein with or without zeaxanthin versus placebo, Outcome 4: Progression to visual loss (loss of 3 or more lines on logMAR chart)" data-id="CD000254-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Lutein with or without zeaxanthin versus placebo, Outcome 4: Progression to visual loss (loss of 3 or more lines on logMAR chart) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lutein with or without zeaxanthin versus placebo, Outcome 5: Distance visual acuity: mean" data-id="CD000254-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Lutein with or without zeaxanthin versus placebo, Outcome 5: Distance visual acuity: mean </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lutein with or without zeaxanthin versus placebo, Outcome 6: Quality of life" data-id="CD000254-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Lutein with or without zeaxanthin versus placebo, Outcome 6: Quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Vitamin E versus placebo, Outcome 1: Progression to late AMD (neovascular AMD and/or geographic atrophy" data-id="CD000254-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Vitamin E versus placebo, Outcome 1: Progression to late AMD (neovascular AMD and/or geographic atrophy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Vitamin E versus placebo, Outcome 2: Progression to visual loss (loss of 3 or more lines on logMAR chart)" data-id="CD000254-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Vitamin E versus placebo, Outcome 2: Progression to visual loss (loss of 3 or more lines on logMAR chart) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Zinc versus placebo, Outcome 1: Progression to late AMD (neovascular AMD and/or geographic atrophy)" data-id="CD000254-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Zinc versus placebo, Outcome 1: Progression to late AMD (neovascular AMD and/or geographic atrophy) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Zinc versus placebo, Outcome 2: Progression to neovascular AMD" data-id="CD000254-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Zinc versus placebo, Outcome 2: Progression to neovascular AMD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Zinc versus placebo, Outcome 3: Progression to geographic atrophy" data-id="CD000254-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Zinc versus placebo, Outcome 3: Progression to geographic atrophy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Zinc versus placebo, Outcome 4: Progression to visual loss (loss of 3 or more lines on logMAR chart)" data-id="CD000254-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Zinc versus placebo, Outcome 4: Progression to visual loss (loss of 3 or more lines on logMAR chart) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000254-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/urn:x-wiley:14651858:media:CD000254:CD000254-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Zinc versus placebo, Outcome 5: Distance visual acuity: mean" data-id="CD000254-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_t/tCD000254-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Zinc versus placebo, Outcome 5: Distance visual acuity: mean</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/media/CDSR/CD000254/image_n/nCD000254-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000254-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antioxidant multivitamin and mineral supplement versus placebo or no treatment for slowing the progression of age‐related macular degeneration</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Antioxidant multivitamin and mineral supplement versus placebo or no treatment for slowing the progression of age‐related macular degeneration </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with AMD<br/><b>Setting:</b> community<br/><b>Intervention:</b> AREDS formula: vitamin C 500 mg, vitamin E 400 IU, beta‐carotene 15 mg daily, plus zinc 80 mg as zinc oxide, copper 2 mg as cupric oxide (daily)<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with antioxidant multivitamin and mineral supplement</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to late AMD (neovascular AMD, geographic atrophy, or both)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.72<br/>(0.58 to 0.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2445<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Most evidence from AREDS study with average follow‐up of 6 years.</p> <p>AREDS formula (minus beta‐carotene) with lutein/zeaxanthin versus AREDS formula with beta‐carotene: hazard ratio (HR) 0.82 (95% CI 0.69 to 0.96) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/>(9 to 14) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>352 per 1000<br/>(304 to 404) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to neovascular AMD</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.62<br/>(0.47 to 0.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1206<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 6 years. Estimate of effect from study population including AMD categories 3 &amp; 4 only. </p> <p>AREDS formula (minus beta‐carotene) with lutein/zeaxanthin versus AREDS formula with beta‐carotene: HR 0.78 (95% CI 0.64 to 0.94). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/>(5 to 8) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000<br/>(168 to 260) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to geographic atrophy</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.75<br/>(0.51 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1206<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 6 years. Estimate of effect from study population including AMD categories 3 &amp; 4 only. </p> <p>AREDS formula (minus beta‐carotene) with lutein/zeaxanthin versus AREDS formula with beta‐carotene: HR </p> <p>0.94 (95% CI 0.70 to 1.26).</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/>(5 to 11) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>243 per 1000<br/>(179 to 320) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to visual loss (loss of 3 or more lines on logMAR chart)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.77<br/>(0.62 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1791<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Average follow‐up of 6 years</p> <p>AREDS formula (minus beta‐carotene) with lutein/zeaxanthin versus AREDS formula with beta‐carotene: HR 0.88 (95% CI 0.75 to 1.03) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/>(9 to 14) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>367 per 1000<br/>(319 to 420) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life assessed with: change in National Eye Institute Visual Function Questionnaire (NEI‐VFQ) score (higher scores better) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in NEI‐VFQ score in the control group was ‐8.7</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean NEI‐VFQ quality of life score in the intervention group was 12.3 higher (4.24 higher to 20.36 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follow‐up of 24 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Most studies were too small to detect rare adverse effects. Data from AREDS suggested little or no effect on mortality (HR 0.87, 95% CI 0.60 to 1.25). Participants in the antioxidant arms of AREDS more frequently reported yellow skin (8.3% versus 6.0%, P = 0.008). Additional data from AREDS2 found increased risk of lung cancer in the beta‐carotene versus no beta‐carotene group (23 (2.0%) versus 11 (0.9%)), mostly in former smokers. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resource use and costs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is estimated using data from AREDS: low risk = AREDS category 2; high risk = AREDS category 4. </p> <p><b>AMD:</b> age‐related macular degeneration; <b>AREDS:</b> Age‐Related Eye Disease Study; <b>CI:</b> confidence interval; <b>logMAR:</b> logarithm of the minimum angle of resolution; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision because upper confidence interval within range 0.8 to 1.25. <br/><sup>b</sup>Downgraded one level for risk of bias because study was not placebo‐controlled and at high risk of performance and detection bias, and one level for imprecision because confidence intervals included clinically insignificant effect.<br/><sup>c</sup>Downgraded one level for imprecision because included studies were underpowered to look at adverse events, and one level for risk of bias as adverse events were reported inconsistently. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antioxidant multivitamin and mineral supplement versus placebo or no treatment for slowing the progression of age‐related macular degeneration</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000254-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Lutein with or without zeaxanthin versus placebo for slowing the progression of age‐related macular degeneration</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Lutein with or without zeaxanthin versus placebo for slowing the progression of age‐related macular degeneration </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with AMD<br/><b>Setting:</b> community<br/><b>Intervention:</b> lutein 10 mg, zeaxanthin 2 mg<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lutein/zeaxanthin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to late AMD (neovascular AMD, geographic atrophy, or both)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.94 (0.87 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6891 eyes</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 5 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000 (13 to 15)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>404 per 1000 (374 to 434)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to neovascular AMD</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.92 (0.84 to 1.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6891 eyes</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 5 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> <p>(8 to 10)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>276 per 1000</p> <p>(252 to 306)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to geographic atrophy</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.92 (0.80 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6891 eyes</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 5 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> <p>(8 to 11)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>276 per 1000</p> <p>(240 to 315)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to visual loss (loss of 3 or more lines on logMAR chart)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.98 (0.91 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6656 eyes</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝ Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 5 years</p> <p>On average, visual acuity was the same: 0.00 logMAR (95% CI ‐0.05 to 0.05; 3 studies, 231 participants; follow‐up of 12 months) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> <p>(14 to 16)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>421 per 1000</p> <p>(391 to 452)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life assessed with Visual Function Questionnaire (VFQ) (higher scores better)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VFQ quality of life score in the control group ranged from 73.1 to 77.3</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VFQ quality of life score in the intervention group was 1.21 higher (better) (2.59 lower to 5.01 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>308<br/>(2 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝ Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follow‐up of 12 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Most studies were too small to detect rare adverse effects. Data from AREDS2 suggested little or no effect on mortality (HR 1.06, 95% CI 0.87 to 1.31). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resource use and costs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is estimated using data from AREDS: low risk = AREDS category 2; high risk = AREDS category 4. </p> <p><b>AMD:</b> age‐related macular degeneration; <b>AREDS:</b> Age‐Related Eye Disease Study; <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>logMAR:</b> logarithm of the minimum angle of resolution; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision, as confidence interval includes 1 null effect, and one level for indirectness, as study was not placebo‐controlled.<br/><sup>b</sup>Downgraded one level for imprecision, as confidence interval includes 0 null effect, and one level for risk of bias, as studies were poorly reported. <br/><sup>c</sup>Downgraded one level for imprecision as studies were small to detect adverse effects and (for mortality in AREDS2) confidence interval includes 1 null effect; downgraded one level for indirectness as study was not placebo‐controlled; downgraded one level as adverse effects were inconsistently reported. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Lutein with or without zeaxanthin versus placebo for slowing the progression of age‐related macular degeneration</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000254-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Vitamin E versus placebo for slowing the progression of age‐related macular degeneration</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Vitamin E versus placebo for slowing the progression of age‐related macular degeneration</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with AMD<br/><b>Setting:</b> community<br/><b>Intervention:</b> vitamin E (500 IU per day: natural vitamin E in soybean oil medium)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>**</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with vitamin E supplement</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to late AMD (neovascular AMD, geographic atrophy or both)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.36 (0.31 to 6.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>998<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 4 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(5 to 91) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>585 per 1000<br/>(133 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression to neovascular AMD</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression to geographic atrophy</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to visual loss (loss of 3 or more lines on logMAR chart)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.04<br/>(0.74 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1179<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 4 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>16 per 1000<br/>(11 to 22) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>447 per 1000<br/>(318 to 632) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No serious adverse effects were seen. Similar numbers of people in the vitamin E and placebo groups withdrew due to adverse effects (4 versus 7), reported any adverse effect (91 versus 83), or ocular adverse effect (105 versus 90). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resource use and costs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is estimated using data from AREDS: low risk = AREDS category 2; high risk = AREDS category 4. </p> <p><b>AMD:</b> age‐related macular degeneration; <b>AREDS:</b> Age‐Related Eye Disease Study; <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>logMAR:</b> logarithm of the minimum angle of resolution; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for imprecision as only 7 events.<br/><sup>b</sup>Downgraded one level for indirectness as over 80% of the participants in this study had no signs of AMD at baseline.<br/><sup>c</sup>Downgraded three levels for imprecision as the study was underpowered to look at rare adverse effects. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Vitamin E versus placebo for slowing the progression of age‐related macular degeneration</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000254-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Zinc versus placebo for slowing the progression of age‐related macular degeneration</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Zinc versus placebo for slowing the progression of age‐related macular degeneration</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with AMD<br/><b>Setting:</b> community<br/><b>Intervention:</b> zinc*<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>**</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with zinc</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to late AMD (neovascular AMD, geographic atrophy or both)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.83<br/>(0.70 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3790<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Most evidence from AREDS study with average follow‐up of 6 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/>(11 to 15) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>385 per 1000<br/>(346 to 425) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to neovascular AMD</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.76<br/>(0.62 to 0.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2442<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 6 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/>(6 to 9) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>246 per 1000<br/>(210 to 285) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to geographic atrophy</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.84<br/>(0.64 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2442<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up of 6 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/>(6 to 11) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265 per 1000<br/>(215 to 320) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression to visual loss (loss of 3 or more lines on logMAR chart)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>OR 0.87<br/>(0.75 to 1.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3791<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Average follow‐up in study contributing most of the events was 6 years</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000<br/>(11 to 15) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>396 per 1000<br/>(361 to 430) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>In some studies, gastrointestinal symptoms were reported as a reason for withdrawal. Of 286 people randomised into studies of zinc sulfate supplementation compared with placebo (not including AREDS), 5/146 zinc‐treated people withdrew due to gastrointestinal symptoms compared with 2/140 controls. No one developed copper‐deficiency anaemia (high zinc intakes can inhibit copper absorption). In AREDS, participants in the zinc arms reported more anaemia (13.2% versus 10.2%, P = 0.004); however, serum haematocrit levels were the same. In AREDS, zinc was associated with higher risk of genitourinary problems in men, but no difference seen between high‐ and low‐dose zinc groups in AREDS2. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resource use and costs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* Most of the evidence in this table is drawn from the AREDS study, which studied a daily dose of zinc 80 mg as zinc oxide, copper 2 mg as cupric oxide. </p> <p>**<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is estimated using data from AREDS: low risk = AREDS category 2; high risk = AREDS category 4. </p> <p><b>AMD:</b> age‐related macular degeneration; <b>AREDS:</b> Age‐Related Eye Disease Study; <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>logMAR:</b> logarithm of the minimum angle of resolution; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision because upper confidence interval within range 0.8 to 1.25. <br/><sup>b</sup>Downgraded for one level for imprecision (as included studies were underpowered to look at adverse effects), one level for risk of bias (adverse effects were inconsistently reported), and one level for inconsistency (inconsistent results reported). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Zinc versus placebo for slowing the progression of age‐related macular degeneration</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000254-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">AMD clinical classification (Beckman Initiative for Macular Research Classification Committee)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Classification of AMD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition<br/>(lesions assessed within 2 disc<br/>diameters of fovea in either eye)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison with AREDS categories</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terminology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small drusen &lt; 63 μm</p> <p>Medium drusen ≥ 63 μm and &lt; 125 μm</p> <p>Large drusen ≥ 125 μm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small drusen &lt; 63 μm</p> <p>Intermediate drusen ≥ 63 μm and &lt; 125 μm</p> <p>Large drusen ≥ 125 μm</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No apparent aging changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No drusen and</p> <p>no AMD pigmentary abnormalities*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMD Category 1</p> <p>No or small drusen</p> <p>No pigment abnormalities</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal aging changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only small drusen and</p> <p>no AMD pigmentary abnormalities*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMD Category 1</p> <p>No or small drusen</p> <p>No pigment abnormalities</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium drusen</p> <p>No AMD pigmentary abnormalities*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMD category 2</p> <p>Intermediate drusen</p> <p>Pigment abnormalities may be absent or present</p> <p>Also includes small drusen if cover more than 1/150 disc areas</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Large drusen and/or</p> <p>any AMD pigmentary abnormalities*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMD category 3</p> <p>Broader category including intermediate, large drusen, and noncentral geographic atrophy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Late AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neovascular AMD and/or<br/>any geographic atrophy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMD category 4</p> <p>Neovascular AMD or geographic atrophy</p> <p>Also includes visual acuity worse than 6/9 due to AMD</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>From: <a href="./references#CD000254-bbs2-0115" title="Ferris FL 3rd, WilkinsonCP , BirdA , ChakravarthyU , ChewE , CsakyK , et al, Beckman Initiative for Macular Research Classification Committee. Clinical classification of age-related macular degeneration. Ophthalmology2013;120(4):844-51.">Ferris 2013</a> </p> <p>AMD: age‐related macular degeneration; AREDS: Age‐related Eye Disease Study</p> <p>*AMD pigmentary abnormalities: any definite hyper‐ or hypopigmentary abnormalities associated with medium or large drusen but not associated with known disease entities </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">AMD clinical classification (Beckman Initiative for Macular Research Classification Committee)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000254-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Dietary reference values for adults for antioxidant vitamins and minerals from the Food and Nutrition Board of the National Academies of Sciences, Engineering, and Medicine in the USA and the European Food Safety Authority</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Antioxidant vitamin / mineral</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Recommended daily intake</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Tolerable daily upper intake levels***</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Example of 'high dose' in eye supplement</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>USA: RDA*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>European: PRI**</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>USA</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>European</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin C</p> <p>mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 (men)</p> <p>75 (women)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (men)</p> <p>95 (women)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 (AREDS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E</p> <p>mg (international units, IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg (28 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AI****</p> <p>13 (men)</p> <p>11 (women)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 (1465 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 IU (AREDS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carotenoids</p> <p>(none set)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selenium μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (Ocupower)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc</p> <p>mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (men)</p> <p>8 (women)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>*****</p> <p>11 (men)</p> <p>8.9 (women)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (AREDS)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Data sources: <a href="./references#CD000254-bbs2-0126" title="Institute of Medicine. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Available at nap.nationalacademies.org/9810. Washington, DC: The National Academies Press, 2000.">Institute of Medicine 2000</a>; <a href="./references#CD000254-bbs2-0127" title="Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum,Nickel, Silicon, Vanadium, and Zinc. Available at nap.nationalacademies.org/10026. Washington, DC: The National Academies Press, 2001.">Institute of Medicine 2001</a>; <a href="./references#CD000254-bbs2-0114" title="European Food Safety Authority. Dietary reference values. www.efsa.europa.eu/en/topics/topic/dietary-reference-values (accessed 31 January 2023).">European Food Safety Authority 2023</a>. </p> <p>* US standards: the recommended daily allowance (RDA) is the average daily level of intake sufficient to meet the nutrient requirements of nearly all (97–98%) healthy individuals; often used to plan nutritionally adequate diets for individuals.<br/>** European standards: the population reference intake (PRI) is the intake of a nutrient that is likely to meet the needs of almost all healthy people in a population.<br/>*** The tolerable upper intake level is the maximum chronic daily intake of a nutrient (from all sources) judged to be unlikely to pose a risk of adverse health effects to humans.<br/>****Adequate intake: an adequate intake (AI) is used when there isn't enough data to calculate an average requirement. An AI is the average nutrient level, based on observations or experiments, that is assumed to be adequate for the population's needs.<br/>***** Different recommendations according to phytate in diet. This is for 900 mg/day phytate in the diet. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Dietary reference values for adults for antioxidant vitamins and minerals from the Food and Nutrition Board of the National Academies of Sciences, Engineering, and Medicine in the USA and the European Food Safety Authority</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000254-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results of searches for previous versions of this review</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Date review published</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Date searches up to date</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Newly included studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of studies included in the review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of excluded studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Studies awaiting assessment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ongoing studies</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>November 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>August 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0001" title="RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 1: design, subjects and procedures. Journal of the American Optometric Association1996;67(1):12-29. RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 2: antioxidant intervention and conclusions. Journal of the American Optometry Association1996;67(1):30-49. ">AMDSG 1996</a>; <a href="./references#CD000254-bbs2-0020" title="NewsomeDA , SwartzM , LeoneNC , ElstonRC , MillerE . Oral zinc in macular degeneration. Archives of Ophthalmology1988;106(2):192-8. ">Newsome 1988</a>; <a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a> (included February 2002) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>; <a href="./references#CD000254-bbs2-0025" title="GarrettSK , McNeilJJ , SilagyC , SinclairM , ThomasAP , RobmanLD , et al. Methodology of the VECAT study: vitamin E intervention in cataract and age-related maculopathy. Ophthalmic Epidemiology1999;6(3):195-208. GarrettSK , ThomasAP , CicuttiniF , SilagyC , TaylorHR , McNeilJJ . Community-based recruitment strategies for a longitudinal interventional study: the VECAT experience. Journal of Clinical Epidemiology2000;53(5):541-8. RobmanLD , TikellisG , GarrettSK , HarperCA , McNeilJJ , TaylorHR , et al. Baseline ophthalmic findings in the vitamin E, cataract and age-related maculopathy (VECAT) study. Australian and New Zealand Journal of Ophthalmology1999;27(6):410-6. TaylorHR , TikellisG , RobmanLD , McCartyCA , McNeilJJ . Vitamin E supplementation and age-related maculopathy. Investigative Ophthalmology and Visual Science2001;42:S311. TikellisG , RobmanLD , HarperCA , GarrettSK , McNeilJJ , TaylorHR , et al. The VECAT study: methodology and statistical power for measurement of age-related macular features. Vitamin E, cataract, and age-related maculopathy study. Ophthalmic Epidemiology1999;6(3):181-94. ">VECAT 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>November 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>October 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0013" title="KaiserHJ , FlammerJ , StumpfigD , HendricksonP . Visaline in the treatment of age-related macular degeneration: a pilot study. Ophthalmologica1995;209(6):302-5. ">Kaiser 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0010" title="There is no publication for this study. ">France 1998</a> (unpublished but included in 2017 update) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>February 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>November 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a>; <a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a>; <a href="./references#CD000254-bbs2-0025" title="GarrettSK , McNeilJJ , SilagyC , SinclairM , ThomasAP , RobmanLD , et al. Methodology of the VECAT study: vitamin E intervention in cataract and age-related maculopathy. Ophthalmic Epidemiology1999;6(3):195-208. GarrettSK , ThomasAP , CicuttiniF , SilagyC , TaylorHR , McNeilJJ . Community-based recruitment strategies for a longitudinal interventional study: the VECAT experience. Journal of Clinical Epidemiology2000;53(5):541-8. RobmanLD , TikellisG , GarrettSK , HarperCA , McNeilJJ , TaylorHR , et al. Baseline ophthalmic findings in the vitamin E, cataract and age-related maculopathy (VECAT) study. Australian and New Zealand Journal of Ophthalmology1999;27(6):410-6. TaylorHR , TikellisG , RobmanLD , McCartyCA , McNeilJJ . Vitamin E supplementation and age-related maculopathy. Investigative Ophthalmology and Visual Science2001;42:S311. TikellisG , RobmanLD , HarperCA , GarrettSK , McNeilJJ , TaylorHR , et al. The VECAT study: methodology and statistical power for measurement of age-related macular features. Vitamin E, cataract, and age-related maculopathy study. Ophthalmic Epidemiology1999;6(3):181-94. ">VECAT 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>February 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>January 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0026" title="WangH , LiRX , WangMF . Effects of zinc and antioxidant on visual function of patients with age-related macular degeneration. Zhongguo Linchuant Kangfu2004;8:1290-1. ">Wang 2004</a> (included November 2007) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>November 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>August 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0026" title="WangH , LiRX , WangMF . Effects of zinc and antioxidant on visual function of patients with age-related macular degeneration. Zhongguo Linchuant Kangfu2004;8:1290-1. ">Wang 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>October 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>August 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0005" title="BartlettH , EperjesiF . A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology. Nutrition Journal2003;2:12. BartlettHE , EperjesiF . Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. European Journal of Clinical Nutrition2007;61(9):1121-7. ">Bartlett 2007</a>; <a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a>; <a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a>; <a href="./references#CD000254-bbs2-0021" title="NewsomeDA . A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Current Eye Research2008;33(7):591-8. ">Newsome 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a> (included 2017 update) </p> <p><a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a> and <a href="./references#CD000254-bbs2-0041" title="FalsiniB , PiccardiM , MinnellaA , SavastanoC , CapoluongaE , FaddaA , et al. Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration. Investigative Ophthalmology and Visual Science2010;51(12):6118-24. ">Falsini 2010</a> (both excluded 2017 update) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> and NCT91948476 (<a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a>) (both included 2017 update): NCT00879671 (this is the same trial as <a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a> included in October 2012) </p> <p><a href="./references#CD000254-bbs2-0060" title="NCT00893724. Supplemental adjuvants for intracellular nutrition and treatment (SAINTS) [The effect of supplemental adjuvants for intracellular nutrition and treatment on diabetic macular edema and neovascular age-related macular degeneration]. clinicaltrials.gov/ct2/show/NCT00893724 (first received 4 May 2009). ">NCT00893724</a> (excluded 2017 update) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>June 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>March 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a>; <a href="./references#CD000254-bbs2-0006" title="BerrowEJ , BartlettHE , EperjesiF , GibsonJM . The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy - a randomised controlled trial. British Journal of Nutrition2013;109(11):2008-14. ">Berrow 2013</a>; <a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a>; <a href="./references#CD000254-bbs2-0009" title="MurrayIJ , MakridakiM , Van der VeenRL , CardenD , ParryNR , BerendschotTT . Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Investigative Ophthalmology and Visual Science2013;54(3):1781-8. TianY , KijlstraA , Van der VeenRL , MakridakiM , MurrayIJ , BerendschotTT . The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d. PLoS One2013;8:e73387. ">CLEAR 2013</a>; <a href="./references#CD000254-bbs2-0010" title="There is no publication for this study. ">France 1998</a>*; <a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0087" title="NCT01694680. Intervention trial in early age-related macular degeneration (I-TEAM) [Intervention study to assess the effect of daily consumption of a lutein-enriched-egg beverage on maintenance of visual function in subjects with early signs of age-related macular degeneration]. clinicaltrials.gov/ct2/show/NCT01694680 (first received 25 September 2012). ">NCT01694680</a>; <a href="./references#CD000254-bbs2-0088" title="NCT02625376. Resveratrol for exudative age-related macular degeneration (AGED) [Influence of resveratrol and resvega versus placebo on incidence of bilateralisation of exudative AMD: a double masked prospective study]. clinicaltrials.gov/ct2/show/NCT02625376 (first received 6 August 2015). ">NCT02625376</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Current Update (2023)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>November 2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0004" title="AzarG , Quaranta-El MaftouhiM , MasellaJJ , Mauget-FaÿsseM . Macular pigment density variation after supplementation of lutein and zeaxanthin using the Visucam® 200 pigment module: impact of age-related macular degeneration and lens status. Journal Français d'Ophtalmologie2017;40(4):303-13. ">Azar 2017</a>; <a href="./references#CD000254-bbs2-0011" title="AbraldesMJ , NascimentoJ , Hernández-GalileaE , Olmedilla-AlonsoB , Escobar-BarrancoJJ , ZapataMA , et al. A randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration. Nutrients2021;13(4):1253. ">Garcia‐Layana 2021</a>; <a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a>; <a href="./references#CD000254-bbs2-0016" title="LiS , LiuN , LinL , SunED , LiJD , LiPK . Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration. International Journal of Ophthalmology2018;11(6):970-5. ">Li 2018</a>; <a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a>***; <a href="./references#CD000254-bbs2-0022" title="ParravanoM , TedeschiM , MancaD , CostanzoE , Di RenzoA , GiornoP , et al. Effects of Macuprev® supplementation in age-related macular degeneration: a double-blind randomized morpho-functional study along 6 months of follow-up. Advances in Therapy2019;36(9):2493-505. ">Parravano 2019</a>; <a href="./references#CD000254-bbs2-0023" title="PiattiA , CroceA , MazzacaneD , TrainaG , AmbrosinoL , BoniL , et al. Effect of 2-year nutritional supplementation on progression of age-related macular degeneration. European Journal of Ophthalmology2020;30(2):376-81. ">Piatti 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0086" title="ChiosiF , MinutilloE , RinaldiM , GalloO , ManziG . The anti-oxidant effect of vitamin D and homotaurine on progression of early-intermediate age-related macular degeneration. Investigative Ophthalmology and Visual Science2020;61(7):ARVO E-abstract 1789. ">Chiosi 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0087" title="NCT01694680. Intervention trial in early age-related macular degeneration (I-TEAM) [Intervention study to assess the effect of daily consumption of a lutein-enriched-egg beverage on maintenance of visual function in subjects with early signs of age-related macular degeneration]. clinicaltrials.gov/ct2/show/NCT01694680 (first received 25 September 2012). ">NCT01694680</a>; <a href="./references#CD000254-bbs2-0088" title="NCT02625376. Resveratrol for exudative age-related macular degeneration (AGED) [Influence of resveratrol and resvega versus placebo on incidence of bilateralisation of exudative AMD: a double masked prospective study]. clinicaltrials.gov/ct2/show/NCT02625376 (first received 6 August 2015). ">NCT02625376</a>; <a href="./references#CD000254-bbs2-0089" title="NCT03845582. Phase 3 study of ALK-001 in geographic atrophy (SAGA). clinicaltrials.gov/ct2/show/NCT03845582 (first received 19 February 2019). ">NCT03845582</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>* This is an unpublished trial for which we are unlikely to be able to obtain the data. We originally excluded this, but following more recent guidelines (see MECIR standard C12; <a href="http://methods.cochrane.org/mecir" target="_blank">methods.cochrane.org/mecir</a>), we included this study in the June 2017 update. </p> <p>** In the 2017 review, the following studies were listed separately as excluded studies, but we note they are the same study and have combined them in one record for the current update. </p> <p> <ul id="CD000254-list-0004"> <li> <p><a href="./references#CD000254-bbs2-0035" title="CangemiFE . TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD. BMC Ophthalmology2007;7:3. ">Cangemi 2007</a> and ISRCTN57556290 </p> </li> <li> <p><a href="./references#CD000254-bbs2-0070" title="KhachikF , deMouraFF , ChewEY , DouglassLW , Ferris FL 3rd, KimJ , et al. The effect of lutein and zeaxanthin supplementation on metabolites of these carotenoids in the serum of persons aged 60 or older. Investigative Ophthalmology and Visual Science2006;47(12):5234-42. RosenthalJM , KimJ , deMonasterioF , deMonastarioF , ThompsonDJ , BoneRA , et al. Dose-ranging study of lutein supplementation in persons aged 60 years or older. Investigative Ophthalmology and Visual Science2006;47(12):5227-33. ">Rosenthal 2006</a>, Khachik 2006 and NCT00006202 </p> </li> <li> <p>Scalinci 2002 and <a href="./references#CD000254-bbs2-0074" title="ScorolliL , ScalinciSZ , LimoliPG , MoraraM , VismaraS , ScorolliL , et al. Photodynamic therapy for age related macular degeneration with and without antioxidants. Canadian Journal of Ophthalmology2002;37(7):399-404. ">Scorolli 2002</a> </p> </li> <li> <p><a href="./references#CD000254-bbs2-0082" title="Wolf-SchnurrbuschUE , ZinkernagelMS , MunkMR , EbneterA , WolfS . Oral lutein supplementation enhances macular pigment density and contrast sensitivity but not in combination with polyunsaturated fatty acids. Investigative Ophthalmology and Visual Science2015;56(13):8069-74. ">Wolf‐Schnurrbusch 2015</a> and NCT00563979 </p> </li> </ul> </p> <p>*** <a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a> excluded in 2017 version of this review. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results of searches for previous versions of this review</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000254-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Characteristics of included studies</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Type of AMD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Treatment (dose/day)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Treatment duration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Data on eyes or people</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Visual acuity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Progression AMD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0001" title="RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 1: design, subjects and procedures. Journal of the American Optometric Association1996;67(1):12-29. RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 2: antioxidant intervention and conclusions. Journal of the American Optometry Association1996;67(1):30-49. ">AMDSG 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ocuguard:</p> <p>Beta‐carotene 20,000 IU</p> <p>Vitamin E 200 IU</p> <p>Vitamin C 750 mg</p> <p>Citrus bioflavonoid complex 125 mg</p> <p>Quercitin (bioflavonoid) 50 mg</p> <p>Bilberry extract (bioflavonoid) 5 mg</p> <p>Rutin (bioflavonoid) 50 mg</p> <p>Zinc picolinate 12.5 mg</p> <p>Selenium 50 µg</p> <p>Taurine 100 mg</p> <p>N‐acetyl cysteine 100 mg</p> <p>L‐glutathione 5 mg</p> <p>Vitamin B2 25 mg</p> <p>Chromium 100 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Right and left eyes reported separately</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measured using Snellen chart but reported in logMAR units</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Based on Chesapeake Bay grading but using indirect ophthalmoscopy: expressed as an average grade </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMD and VA 20/32 or better in 1 eye</p> <p>956/3640 had AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antioxidants:</p> <p>Vitamin C 500 mg</p> <p>Vitamin E 400 IU</p> <p>Beta‐carotene 15 mg</p> <p>Zinc (zinc oxide) 80 mg</p> <p>Cupric oxide 2 mg</p> <p>Factorial design</p> <p>Antioxidants x zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average duration 6.3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average follow‐up 6.3 years; 2.4% lost to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Person; outcome 'in at least one eye'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss of 3 or more lines VA (equivalent to doubling visual angle) measured using ETDRS chart </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression to advanced AMD: photocoagulation or other treatment for CNV; GA involving centre of the macula, RPE detachment, haemorrhage under the retina, subretinal fibrosis. </p> <p>Colour fundus photography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bilateral large drusen or non‐foveal geographic atrophy (no advanced AMD) or large drusen or non‐foveal geographic atrophy in one eye and advanced AMD in the fellow eye (AREDS Simple Scale Score of 2, 3 or 4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein 10 mg and zeaxanthin 2 mg (1 tablet/day)</p> <p>Almost all participants in both intervention and comparator groups took AREDS supplement and multivitamin with the study medication. </p> <p>Other study arm: there was another study arm looking at docosahexaenoic acid (DHA) 350 mg and eicosapentaenoic acid (EPA) 650 mg (2 soft‐gel capsules/day); it was not included in this review </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 years (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 years (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eyes adjusted for within‐person correlation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression to moderate vision loss using ETDRS charts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression to advanced AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control group had AREDS formula</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0004" title="AzarG , Quaranta-El MaftouhiM , MasellaJJ , Mauget-FaÿsseM . Macular pigment density variation after supplementation of lutein and zeaxanthin using the Visucam® 200 pigment module: impact of age-related macular degeneration and lens status. Journal Français d'Ophtalmologie2017;40(4):303-13. ">Azar 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with stage 4 exudative AMD in only one eye (AREDS criteria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein (5 mg), zeaxanthin (1 mg), omega‐3 fatty acids (DHA 560 mg and GLA 420 mg), vitamin C (80 mg), vitamin E (10 mg), vitamin B6 (2 mg), vitamin B9 (200 micrograms), vitamin B12 (1 microgram), zinc (10 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial eye ‐ eye with non‐exudative AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear how measured, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported, probably not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0005" title="BartlettH , EperjesiF . A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology. Nutrition Journal2003;2:12. BartlettHE , EperjesiF . Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. European Journal of Clinical Nutrition2007;61(9):1121-7. ">Bartlett 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Soft or<br/>hard drusen, and areas of increased or decreased pigment associated with these drusen </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein esters 6 mg<br/>Retinol 750 mg<br/>Vitamin C 250 mg<br/>Vitamin E 34 mg<br/>Zinc 10 mg<br/>Copper 0.5 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial eye selected (initial visit only); if both eyes were eligible for inclusion, the right eye was used </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in logMAR acuity measured using ETDRS chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundus photographs graded using AREDS classification system (4 categories). Mean (standard deviation) grade was reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0006" title="BerrowEJ , BartlettHE , EperjesiF , GibsonJM . The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy - a randomised controlled trial. British Journal of Nutrition2013;109(11):2008-14. ">Berrow 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ocuvite Duo (Bausch and Lomb) vitamin C 150 mg, cupric oxide 400 µg, vitamin E 15 mg, zinc oxide 20 mg, lutein 12 mg, zeaxanthin 0.6 mg, EPA 240 mg, DHA 840 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 weeks and 60 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye per participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3m ETDRS (logMAR)<br/>750 lux retro‐illuminated chart (Sussex Vision) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severity of early AMD in one eye and late AMD (neovascular AMD or central geographic atrophy) in the fellow eye. The study eye was the eye free of late‐stage AMD. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ocuvite (Bausch and Lomb, Berlin, Germany) lutein 12 mg, zeaxanthin 0.6 mg, vitamin E 15 mg, vitamin C 150 mg, zinc oxide 20 mg, copper 0.4 mg (daily dose). One tablet twice daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Every 6 months for 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixture of one and two eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ETDRS charts (logMAR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grading of colour fundus photographs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMD in at least 1 eye having extensive (as measured by drusen area) intermediate (≥ 63 mm, &lt; 125 mm) drusen; and at least one large (≥ 125 mm) drusen or geographic atrophy not involving the centre of the macula </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin C 180 mg</p> <p>Vitamin E 30 mg</p> <p>Zinc 22.5 mg</p> <p>Copper 1 mg</p> <p>Lutein 10 mg</p> <p>Zeaxanthin 1 mg</p> <p>Astaxanthin 4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The eye with the best VA was selected; when both eyes had the same VA, the right eye was chosen for final analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Letters and lines reported as continuous variable (ETDRS chart)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0009" title="MurrayIJ , MakridakiM , Van der VeenRL , CardenD , ParryNR , BerendschotTT . Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Investigative Ophthalmology and Visual Science2013;54(3):1781-8. TianY , KijlstraA , Van der VeenRL , MakridakiM , MurrayIJ , BerendschotTT . The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d. PLoS One2013;8:e73387. ">CLEAR 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMD grade 0 to 4 in one eye (Rotterdam grading) and visual acuity 0.5 or better</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye per participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early Treatment<br/>Diabetic Retinopathy Study (ETDRS) logMAR chart at 4 m </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0010" title="There is no publication for this study. ">France 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neovascular AMD in one eye and drusen in the other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc 30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye per person</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0011" title="AbraldesMJ , NascimentoJ , Hernández-GalileaE , Olmedilla-AlonsoB , Escobar-BarrancoJJ , ZapataMA , et al. A randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration. Nutrients2021;13(4):1253. ">Garcia‐Layana 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neovascular AMD in one eye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retilut® (Laboratorios Thea, Barcelona, Spain) vitamin C 160 mg; vitamin E 24 mg; zinc 20 mg, copper 2 mg, lutein 10 mg, zeaxanthin 2.6 mg, DHA 400 mg, resveratrol 30 mg, hydroxytryosol 3 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye per person</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EDTRS letters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Development of CNV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator group: Theavit® (Laboratorios Mayoli Spindler, Barcelona, Spain) vitamin C 120 mg, vitamin E 20 mg, zinc 15 mg, beta‐carotene 800 mg, vitamin A 800 mg, manganese 2 mg, selenium 50 microgram </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with drusen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc sulfate 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated but assume same as follow‐up duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear but assumed to be people</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'Incidence of new exudative or dry macula lesions'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0013" title="KaiserHJ , FlammerJ , StumpfigD , HendricksonP . Visaline in the treatment of age-related macular degeneration: a pilot study. Ophthalmologica1995;209(6):302-5. ">Kaiser 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nonserous AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visaline:</p> <p>Buphenine HCL 1.5 mg<br/>Beta‐carotene 10 mg<br/>Tocopherol acetate 10 mg<br/>Vitamin C 50 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study eye identified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decimal acuity measured using a Snellen chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Atrophic AMD and reduced vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein 10 mg</p> <p>Ocupower:</p> <p>Natural beta‐carotene (Betatenem) 15,000 IU</p> <p>Vitamin C 1500 mg (as calcium ascorbate‐Ester</p> <p>CB)</p> <p>Vitamin D3 400 IU</p> <p>Vitamin E 500 IU (d‐alpha tocopherol succinate)</p> <p>Vitamin B1 50 mg</p> <p>Vitamin B2 10 mg</p> <p>Vitamin B3 70 mg</p> <p>Vitamin B5 50 mg</p> <p>Vitamin B6 50 mg</p> <p>Vitamin B12 500 µg</p> <p>Folic acid 800 µg</p> <p>Biotin 300 µg</p> <p>Calcium 500 mg</p> <p>Magnesium 300 mg</p> <p>Iodine 75 µg</p> <p>Zinc 25 mg (as zinc L‐methionine‐L‐OptiZincB)</p> <p>Copper 1 mg</p> <p>Manganese 2 mg</p> <p>Selenium 200 µg</p> <p>Chromium 200 µg</p> <p>Molybdenum 75 µg</p> <p>Lycopene 600 µg</p> <p>Bilberry extract 160 mg (standardised to 25% anthocyanosides)</p> <p>Alpha lipoic acid 150 mg</p> <p>N‐acetyl cysteine 200 mg</p> <p>Quercetin 100 mg</p> <p>Rutin 100 mg</p> <p>Citrus bioflavonoids 250 mg</p> <p>Plant enzymes 50 mg</p> <p>Black pepper extract 5 mg (BioperineB)</p> <p>Malic acid 325 mg</p> <p>Taurine 900 mg</p> <p>L‐glycine 100 mg</p> <p>L‐glutathione 10 mg</p> <p>Boron 2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Right and left eyes reported separately</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in logMAR score. Measured using Snellen chart but reported in logMAR units</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early‐stage AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein 20mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear how eyes reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear how measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported, probably not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0016" title="LiS , LiuN , LinL , SunED , LiJD , LiPK . Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration. International Journal of Ophthalmology2018;11(6):970-5. ">Li 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis of early AMD, which was defined as the presence of soft distinct drusen and/or soft indistinct drusen and/or reticular drusen and/or pigmentary abnormalities. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Goji berries (wolfberry)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear how eyes reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measured on a logMAR scale, not reported which chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported, probably not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AREDS categories 2, 3, or 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein 20 mg a day for 3 months and then lutein 10 mg a day for 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study eye identified; if both eyes were eligible, one eye was selected randomly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in graph form, not possible to extract data. Measured using ETDRS chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐exudative AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein 10 mg, zeaxanthin 1 mg, concentrated fish oil 255 mg, DHA 100 mg, EPA 30 mg, vitamin C 60 mg, vitamin E 20 mg, zinc 10 mg, copper 0.25 mg. </p> <p>1 group 1 capsule per day; 1 group 2 capsules per day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study eye: unclear how selected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measured using an ETDRS chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early AMD (drusen, pigmentary abnormalities)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein 10 mg</p> <p>Lutein 20 mg</p> <p>Lutein 10 mg and zeaxanthin 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear how many eyes included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear how measured but reported in logMAR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0020" title="NewsomeDA , SwartzM , LeoneNC , ElstonRC , MillerE . Oral zinc in macular degeneration. Archives of Ophthalmology1988;106(2):192-8. ">Newsome 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drusen or pigmentary change (or both), VA 20/80 or better</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc sulfate 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported by eye; also data from 2 eyes averaged</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of letters lost on EDTRS chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Difficult to extract data on this. Reported number with increased pigment, drusen and atrophy for 2 observers. In general, found results favouring the zinc‐treated group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0021" title="NewsomeDA . A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Current Eye Research2008;33(7):591-8. ">Newsome 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence of macular drusen with or without pigment<br/>changes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc‐monocysteine 25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Right and left eyes reported separately</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of letters read on EDTRS chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0022" title="ParravanoM , TedeschiM , MancaD , CostanzoE , Di RenzoA , GiornoP , et al. Effects of Macuprev® supplementation in age-related macular degeneration: a double-blind randomized morpho-functional study along 6 months of follow-up. Advances in Therapy2019;36(9):2493-505. ">Parravano 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AREDS category 3 features (intermediate AMD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MacuPrev (Farmaplus Italia s.r.l., Italy) lutein 20 mg, zeaxanthin 4 mg, N‐acetylcysteine 140 mg, bromelain 2500GDU 80 mg, vitamin D3 800 IU, vitamin B12 18 mg, alpha‐lipoic acid 140 mg, rutin 157 mg, vitamin C 160 mg, zinc oxide 16 mg, <i>Vaccinium myrtillus</i> 36% Anthocyanosides 90 mg, <i>Ganoderma lucidum</i> 600 mg, zinc‐monocysteine 50 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One eye per person: Quote: "When both eyes fulfilled the inclusion criteria, the eye with the best VA was selected; when both eyes had the same VA, the right eye was chosen for analysis" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear how measured, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported, probably not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0023" title="PiattiA , CroceA , MazzacaneD , TrainaG , AmbrosinoL , BoniL , et al. Effect of 2-year nutritional supplementation on progression of age-related macular degeneration. European Journal of Ophthalmology2020;30(2):376-81. ">Piatti 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate AMD (AREDS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein 10 mg, astaxanthin 4 mg, zeaxanthin 2 mg, vitamin C 90 mg, vitamin E 30 mg, zinc 22.5 mg plus copper 1 mg, omega‐3 fatty acids (fish oil 500 mg, containing EPA 185 mg and DHA 140 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study eye: eye with the best visual acuity was selected for the study; if both eyes had the same VA, the right eye was chosen. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measured using ETDRS chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "retinography"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neovascular AMD in 1 eye, VA better than 20/40 in other eye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc sulfate 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study eye, which was fellow eye; other eye had neovascular AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean logMAR score measured using Bailey‐Lovie chart</p> <p>Note: participants with neovascular event excluded from this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incidence of neovascular lesion in study eye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Original trial of N = 500 terminated by sponsor (Astra) because statistical evaluation of first 40 participants at 24 months follow‐up "did not show any treatment benefit" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0025" title="GarrettSK , McNeilJJ , SilagyC , SinclairM , ThomasAP , RobmanLD , et al. Methodology of the VECAT study: vitamin E intervention in cataract and age-related maculopathy. Ophthalmic Epidemiology1999;6(3):195-208. GarrettSK , ThomasAP , CicuttiniF , SilagyC , TaylorHR , McNeilJJ . Community-based recruitment strategies for a longitudinal interventional study: the VECAT experience. Journal of Clinical Epidemiology2000;53(5):541-8. RobmanLD , TikellisG , GarrettSK , HarperCA , McNeilJJ , TaylorHR , et al. Baseline ophthalmic findings in the vitamin E, cataract and age-related maculopathy (VECAT) study. Australian and New Zealand Journal of Ophthalmology1999;27(6):410-6. TaylorHR , TikellisG , RobmanLD , McCartyCA , McNeilJJ . Vitamin E supplementation and age-related maculopathy. Investigative Ophthalmology and Visual Science2001;42:S311. TikellisG , RobmanLD , HarperCA , GarrettSK , McNeilJJ , TaylorHR , et al. The VECAT study: methodology and statistical power for measurement of age-related macular features. Vitamin E, cataract, and age-related maculopathy study. Ophthalmic Epidemiology1999;6(3):181-94. ">VECAT 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early AMD (18%)</p> <p>Late AMD (0.5%)</p> <p>Rest presumably had no signs of AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E 500 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse eye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss of more than 9 letters (2 or more lines) on Bailey‐Lovie chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigators defined 6 stages of AMD progression and defined progression as movement from a lower stage to a higher stage in their worst eye </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0026" title="WangH , LiRX , WangMF . Effects of zinc and antioxidant on visual function of patients with age-related macular degeneration. Zhongguo Linchuant Kangfu2004;8:1290-1. ">Wang 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early (38%) or late (62%) AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc oxide 80 mg, vitamin C, vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 to 32 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Every 6 months from 24 to 32 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse eye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear how measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear how measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>AMD: age‐related macular degeneration<br/>CNV: choroidal neovascularisation<br/>DHA: docosahexaenoic acid<br/>EPA: eicosapentaenoic acid<br/>ETDRS: Early Treatment Diabetic Retinopathy Study<br/>GA: geographic atrophy<br/>GLA: gamma‐Linolenic acid<br/>logMAR: logarithm of the minimum angle of resolution<br/>RPE: retinal pigment epithelium<br/>VA: visual acuity </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000254-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Multivitamin supplements</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study (brand name)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vitamin A</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vitamin C</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vitamin E</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Beta‐carotene</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Lutein</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Zeaxanthin</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Zinc</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Selenium</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AMDSG 1996 (OcuGuard, Twin Lab Inc, Ronkonkoma, NY)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>750 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,000 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5 mg as zinc picolinate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrus bioflavonoid complex 125 mg quercitin (bioflavonoid) 50 mg bilberry extract (bioflavonoid) 5 mg rutin (bioflavonoid) 50 mg taurine 100 mg N‐acetyl cysteine 100 mg L‐glutathione 5 mg vitamin B2 25 mg chromium 100 µg </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AREDS 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>80 mg as zinc oxide with cupric oxide 2 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Berrow 2013, (Ocuvite Duo, Bausch and Lomb, Berlin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>25 mg as zinc oxide with cupric oxide 0.4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>omega‐3 fatty acids: EPA 240 mg and DHA 840 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bartlett 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retinol 750 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>10 mg with copper 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CARMA 2013 (Ocuvite, Bausch and Lomb, Berlin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>20 mg as zinc oxide with copper gluconate 0.4 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CARMIS 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg plus astaxanthin 4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>zinc 22.5 mg copper 1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Garcia‐Layana 2021 (Retilut)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>20 mg, copper 2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHA 400 mg, resveratrol 30 mg, hydroxytryosol 3 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kaiser 1995 (Visaline, Novopharma Cham, Switzerland)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 mg buphenine HCl</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LAST 2004 (OcuPower, Nutraceutical Sciences Institute (NSI), Boynton Beach, Florida, FloraGlo (Kemin Foods International, Des Moines, Iowa) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2500 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1500 mg vitamin C (as calcium ascorbate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 IU natural vitamin E (d‐alpha tocopherol succinate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,000 IU natural beta carotene (Betatenem)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg as zinc L‐methionine‐L‐OptiZincB 1 mg copper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 IU vitamin D3 50 mg vitamin B1 10 mg vitamin B2 70 mg vitamin B3 50 mg vitamin B 550 mg vitamin B6 500 µg vitamin B12 800 µg folic acid 300 µg biotin 500 mg calcium 75 µg iodine 300 mg magnesium 2 mg manganese 200 µg chromium 75 µg molybdenum 600 µg lycopene 160 mg bilberry extract (standardised to 25% anthocyanosides) 150 mg alpha lipoic acid 200 mg N‐acetyl cysteine 100 mg quercetin 100 mg rutin 250 mg citrus bioflavonoids 50 mg plant enzymes 5 mg black pepper extract (BioperineB) 325 mg malic acid 900 mg taurine 100 mg L‐glycine 10 mg L‐glutathione 2 mg boron </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LUTEGA 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>zinc 10 mg, copper 0.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>concentrated fish oil 255 mg (DHA 100 mg, EPA 30 mg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parravano 2019 (Macuprev, Farmaplus Italia s.r.l., Italy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>16 mg as zinc oxide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N‐acetylcysteine 140 mg, bromelain 2500GDU 80 mg, vitamin D3 800 IU, vitamin B12 18 mg, alpha‐lipoic acid 140 mg, rutin 157 mg, Vaccinium myrtillus 36% anthocyanosides 90 mg, Ganoderma lucidum 600 mg </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Piatti 2020 (Azyr Mega, SIFI S.p.A, Italy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>astaxanthin 4 mg zeaxanthin 2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.5 mg plus copper 1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>fish oil 500 mg, containing EPA 185 mg and DHA 140 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wang 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Multivitamin supplements</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000254-tbl-0010"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Adverse effects in the included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study number</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effects</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0001" title="RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 1: design, subjects and procedures. Journal of the American Optometric Association1996;67(1):12-29. RicherS . Multicenter ophthalmic and nutritional age-related macular degeneration study - part 2: antioxidant intervention and conclusions. Journal of the American Optometry Association1996;67(1):30-49. ">AMDSG 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin (Ocuguard)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One person developed an "allergic reaction", although it was not clear whether this was related to the treatment. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0002" title="Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1417-36. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report no. 6. American Journal of Ophthalmology2001;132(5):668-81. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , DavisMD , et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmology2014;132(3):272-7. ChewEY , ClemonsTE , AgronE , SperdutoRD , SangiovanniJP , KurinijN , et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology2013;120(8):1604-11. ChewEY , KleinML , ClemonsTE , AgronE , RatnapriyaR , EdwardsAO , et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology2014;121(11):2173-80. ClemonsTE , KurinjiN , SperdutoRD , AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related eye disease study: AREDS report no. 13. Archives of Ophthalmology2004;122(5):716-26. JohnsonAR , MunozA , GottliebJL , JarrardDF . High dose zinc increases hospital admissions due to genitourinary complications. Journal of Urology2007;177(2):639-43. Moriarty-CraigeSE , HaKN , SternbergP , LynnM , BresslerS , GenslerG , et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. American Journal of Ophthalmology2007;143(2):206-11. The Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS): design implications AREDS report no. 1. Controlled Clinical Trials1999;20(6):573-600. VitaleS , AgrónE , ClemonsTE , KeenanTDL , DomalpallyA , Danis RP Jr, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmology2020;138(6):610-17. ">AREDS 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin and zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Over 100 comparisons of zinc versus no zinc and antioxidants versus no antioxidants. Participants in the antioxidant arms more frequently reported yellow skin (8.3% versus 6.0%, P = 0.008). No important effect on mortality associated with multivitamin use (hazard ratio for mortality 0.87, 95% CI 0.60 to 1.25). </p> <p>Participants in the zinc arms reported more anaemia (13.2% versus 10.2%, P = 0.004); however, serum haematocrit levels were the same. They found that participants taking zinc had a lower mortality. Later follow‐up of the cohort of people taking part in the AREDS study found that there was a significant increase in hospital admissions due to genitourinary diseases in people taking zinc supplements (11.1% versus 7.6%, P = 0.0003). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0003" title="Age-Related Eye Disease Study 2 (AREDS2) Research Group, ChewEY , ClemonsTE , SangiovanniJP , DanisRP , Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142-9. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005-15. AwhCC , ZankeB . Treatment response to AREDS components as a function of CFH and ARMS2 risk in patients with AMD. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 2994. ChewEY , ChiuCY , AgronE , ClemonsTE , vanAstenF , FanR . Genetic interaction with response to oral micronutrient supplements in the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2017;58(8):ARVO E-abstract 2985. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , McBeeW , AREDS2 Research Group. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282-9. ChewEY , ClemonsTE , AgrónE , DomalpallyA , KeenanTD , VitaleS , et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology2022;140(7):692–8. ChewEY , ClemonsTE , KeenanTD , AgronE , MalleyCE , DomalpallyA . The results of the 10 year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). Investigative Ophthalmology and Visual Science2021;62(8):ARVO E-abstract 1215. HubbardLD , DanisRP , NeiderMW , ThayerDW , WabersHD , WhiteJK , et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. Investigative Ophthalmology and Visual Science2008;49(8):3269-82. McBeeWL , ClemonsTE , ChewEY , SanGiovanniJP . An examination of site visit data audit results compiled during the initial four years of a long-term clinical trial. In: Clinical Trials Conference: 32nd Meeting of the Society of Clinical Trials. 2011 May 15-18; Vancouver (BC). 2011. PapudesuC , ClemonsTE , AgrónE , ChewEY . Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13. Ophthalmology2018;125(4):512-21. VitaleS , AgronE , ClemonsTE , DomalpallyA , DanisRP , KeenanTD , et al. Association of short-term progression in AMD score with risk of development of late AMD and vision loss in the AREDS2 study. Investigative Ophthalmology and Visual Science2019;60(9):ARVO E-abstract 52. Writing Group for the AREDS2 Research Group, BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , HsiaJ , et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763-71. ">AREDS2 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein and zeaxanthin (plus AREDs formula)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "No clinically or statistically significant differences in reported serious adverse events, including rates of development of neoplasms, were noted across the treatment groups in the primary randomization. However, secondary randomization excluding participants who were smokers showed more lung cancers in the beta carotene group than in the no beta carotene group (23 [2.0%] vs 11 [0.9%]) (nominal P = .04)". Quote: "Rates of reported gastrointestinal disorders and hospitalizations for genitourinary diseases were similar in the 2 randomly assigned groups (high‐dose zinc, low‐dose zinc) in AREDS2". Quote: "The HR for mortality comparing lutein zeaxanthin vs no lutein zeaxanthin was 1.06 (95% CI, 0.87‐1.31; P = .56) for lutein zeaxanthin vs no lutein zeaxanthin". Quote: "More lung cancers were noted in the beta carotene vs no beta carotene group (23 [2.0%] vs 11 [0.9%], nominal P=.04), mostly in former smokers." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0004" title="AzarG , Quaranta-El MaftouhiM , MasellaJJ , Mauget-FaÿsseM . Macular pigment density variation after supplementation of lutein and zeaxanthin using the Visucam® 200 pigment module: impact of age-related macular degeneration and lens status. Journal Français d'Ophtalmologie2017;40(4):303-13. ">Azar 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein and zeaxanthin with multivitamins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "No serious adverse events related to the supplements occurred across treatment"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0005" title="BartlettH , EperjesiF . A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology. Nutrition Journal2003;2:12. BartlettHE , EperjesiF . Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. European Journal of Clinical Nutrition2007;61(9):1121-7. ">Bartlett 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "There were no reported adverse effects from any of the study participants."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0006" title="BerrowEJ , BartlettHE , EperjesiF , GibsonJM . The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy - a randomised controlled trial. British Journal of Nutrition2013;109(11):2008-14. ">Berrow 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin (Ocuvite)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not report adverse effects</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0007" title="BeattyS , ChakravarthyU , NolanJM , MuldrewKA , WoodsideJV , DennyF , et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology2013;120(3):600-6. BeattyS , NolanJM , MuldrewKA , WoodsideJ , StevensonMR , ChakravarthyU . Visual outcome after antioxidant supplementation. Ophthalmology2013;120(3):645. LaiY , GrattanJ , ShiY , YoungG , MuldrewA , ChakravarthyU . Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina2011;31(8):1620-6. NeelamK , HoggRE , StevensonMR , JohnstonE , AndersonR , BeattyS , et al. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology2008;15(6):389-401. ">CARMA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin (Ocuvite)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not report adverse effects</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0008" title="PiermarocchiS , SavianoS , ParisiV , TedeschiM , PanozzoG , ScarpaG , et al. Carotenoids in age-related maculopathy Italian study (CARMIS): two-year results of a randomized study. European Journal of Ophthalmology2011;22(2):216-25. ">CARMIS 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "There were no significant systemic or ocular adverse events related to the nutritional supplementation." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0009" title="MurrayIJ , MakridakiM , Van der VeenRL , CardenD , ParryNR , BerendschotTT . Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Investigative Ophthalmology and Visual Science2013;54(3):1781-8. TianY , KijlstraA , Van der VeenRL , MakridakiM , MurrayIJ , BerendschotTT . The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d. PLoS One2013;8:e73387. ">CLEAR 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/42 in the lutein group and 1/42 in the placebo group "discontinued due to medical reasons", but it was unclear if these were complications, per se. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0010" title="There is no publication for this study. ">France 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unpublished study, no data available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0011" title="AbraldesMJ , NascimentoJ , Hernández-GalileaE , Olmedilla-AlonsoB , Escobar-BarrancoJJ , ZapataMA , et al. A randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration. Nutrients2021;13(4):1253. ">Garcia‐Layana 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin (Retilut and Theavit)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/109 adverse events in people receiving multivitamins, including 6 cases of cataract and 5 cases of exudative AMD. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0012" title="HolzFG , WolfensbergerTJ , PiguetB , Gross-JendroskaM , ArdenGB , BirdAC . Oral zinc-therapy in age-related macular degeneration: a double-blind study. German Journal of Ophthalmology1993;2:391. ">Holz 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "the zinc therapy was well‐tolerated".</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0013" title="KaiserHJ , FlammerJ , StumpfigD , HendricksonP . Visaline in the treatment of age-related macular degeneration: a pilot study. Ophthalmologica1995;209(6):302-5. ">Kaiser 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not report adverse effects</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0014" title="RicherS , DevenportJ , LangJC . LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry2007;78(5):213-9. RicherS , StilesW , StatkuteL , PulidoJ , FrankowskiJ , RudyD , et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (lutein antioxidant supplementation trial). Optometry2004;75(4):216-30. ">LAST 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin (OcuPower) and lutein (FloraGlo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The number of adverse effects were tabulated, but the study was underpowered to detect any differences. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0015" title="LiC , RenW , SuiYJ . Effect of lutein intervention on visual function in patients with early age-related macular degeneration. International Eye Science2017;17(11):2109-11. ">Li 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not report adverse effects</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0016" title="LiS , LiuN , LinL , SunED , LiJD , LiPK . Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration. International Journal of Ophthalmology2018;11(6):970-5. ">Li 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Goji berries (wolfberry)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote in Discussion: "... without causing any detectable adverse effects"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0017" title="SchmettererL , WeigertG , KayaS , WerkmeisterR , GahoferG . Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. European Journal of Ophthalmology2013;23(4):605. SchmidlD , WeigertG , KayaS , PempB , SacuS , LastaM , et al. How lutein supplementation affects macular pigment optical density and visual acuity in patients with age related macular degeneration. In: Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology; 2011 Oct 20-22; Zurich, Switzerland. British Journal of Clinical Pharmacology, 2011. WeigertG , KayaS , PempB , SacuS , LastaM , WerkmeisterRM , et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(11):8174-8. ">LISA 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein (Lutamax)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "In two subjects, the withdrawal was due to serious adverse events. One subject had a myocardial infarction, and the other subject developed CNV in the study eye." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0018" title="ArnoldC , WinterL , FrohlichK , JentschS , DawczynskiJ , JahreisG , et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology2013;131(5):564-72. DawczynskiJ , JentschS , SchweitzerD , HammerM , LangGE , StrobelJ . Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Archive for Clinical and Experimental Ophthalmology2013;251(12):2711-23. DawczynskiJ , JentschS , SchweitzerD , HammerM , StrobelJ . Changes of macular pigment and drusen morphology in patients with lutein supplementation [Anderung von makulapigment und drusenmorphologie unter luteinsupplementation]. Klinische Monatsblatter fur Augenheilkunde2012;229(1):69-71. ">LUTEGA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "No adverse or other unintended effects were noted in any of the observed groups in the present study" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0019" title="HuangYM , DouHL , HuangFF , XuXR , ZouZY , LinXM . Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed Research International2015;2015:564738. HuangYM , DouHL , HuangFF , XuXR , ZouZY , LuXR , et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology2015;99(3):371-5. HuangYM , YanSF , MaL , ZouZY , XuXR , DouHL , et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition2013;29(2):387-92. MaL , DouHL , HuangYM , LuXR , XuXR , QianF , et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. American Journal of Ophthalmology2012;154(4):625-34. MaL , YanSF , HuangYM , LuXR , QianF , PangHL , et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology2012;119(11):2290-7. NCT01048476. Effects of lutein and zeaxanthin supplementation on age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01048476 (first received 12 January 2010). ">Ma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lutein and zeaxanthin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "No adverse events were observed or reported." Quote: "No significant adverse events or changes in biochemical or hematologic profiles were observed or reported in any subject throughout the study. No subject developed or reported occasional skin pigmentation (carotenodermia)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0020" title="NewsomeDA , SwartzM , LeoneNC , ElstonRC , MillerE . Oral zinc in macular degeneration. Archives of Ophthalmology1988;106(2):192-8. ">Newsome 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "In the zinc‐treated group, one subject stopped study participation due to the feeling that the study tablet aggravated preexisting peptic ulcer symptoms. Another subject taking zinc complained of gastrointestinal tract upset, which was relieved by taking the study tablet with food." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0021" title="NewsomeDA . A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Current Eye Research2008;33(7):591-8. ">Newsome 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc mono‐cysteine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "ZMC (zinc mono‐cysteine) appeared to be well tolerated"; 1/40 had gastrointestinal symptoms attributable to treatment. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0022" title="ParravanoM , TedeschiM , MancaD , CostanzoE , Di RenzoA , GiornoP , et al. Effects of Macuprev® supplementation in age-related macular degeneration: a double-blind randomized morpho-functional study along 6 months of follow-up. Advances in Therapy2019;36(9):2493-505. ">Parravano 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin (Macuprev)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not report adverse effects</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0023" title="PiattiA , CroceA , MazzacaneD , TrainaG , AmbrosinoL , BoniL , et al. Effect of 2-year nutritional supplementation on progression of age-related macular degeneration. European Journal of Ophthalmology2020;30(2):376-81. ">Piatti 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin (Azyr Mega)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "During the entire study, no significant adverse events were recorded."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0024" title="SturM , TittlM , ReitnerA , MeisingerV . Oral zinc and the second eye in age-related macular degeneration. Investigative Ophthalmology and Visual Science1996;37(7):1225-35. ">Stur 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/56 in the zinc‐treated group and 2/56 in the placebo group withdrew because of gastrointestinal symptoms. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0025" title="GarrettSK , McNeilJJ , SilagyC , SinclairM , ThomasAP , RobmanLD , et al. Methodology of the VECAT study: vitamin E intervention in cataract and age-related maculopathy. Ophthalmic Epidemiology1999;6(3):195-208. GarrettSK , ThomasAP , CicuttiniF , SilagyC , TaylorHR , McNeilJJ . Community-based recruitment strategies for a longitudinal interventional study: the VECAT experience. Journal of Clinical Epidemiology2000;53(5):541-8. RobmanLD , TikellisG , GarrettSK , HarperCA , McNeilJJ , TaylorHR , et al. Baseline ophthalmic findings in the vitamin E, cataract and age-related maculopathy (VECAT) study. Australian and New Zealand Journal of Ophthalmology1999;27(6):410-6. TaylorHR , TikellisG , RobmanLD , McCartyCA , McNeilJJ . Vitamin E supplementation and age-related maculopathy. Investigative Ophthalmology and Visual Science2001;42:S311. TikellisG , RobmanLD , HarperCA , GarrettSK , McNeilJJ , TaylorHR , et al. The VECAT study: methodology and statistical power for measurement of age-related macular features. Vitamin E, cataract, and age-related maculopathy study. Ophthalmic Epidemiology1999;6(3):181-94. ">VECAT 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 in the vitamin E and 7 in the control group died; 16 in the vitamin E group and 17 in the control group had an adverse reaction. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000254-bbs2-0026" title="WangH , LiRX , WangMF . Effects of zinc and antioxidant on visual function of patients with age-related macular degeneration. Zhongguo Linchuant Kangfu2004;8:1290-1. ">Wang 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multivitamin and zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not report adverse effects.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>AMD: age‐related macular degeneration<br/>AREDS: Age‐Related Eye Disease Study<br/>CNV: choroidal neovascularisation<br/>HR: hazard ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Adverse effects in the included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/full#CD000254-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000254-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antioxidant multivitamin and mineral supplement versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Progression to late AMD (neovascular AMD and/or geographic atrophy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.58, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Progression to neovascular AMD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Progression to geographic atrophy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Progression to visual loss (loss of 3 or more lines on logMAR chart) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Mean visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.04, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Mean visual acuity at end of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.09, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Change in visual acuity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.03, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antioxidant multivitamin and mineral supplement versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000254-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Lutein with or without zeaxanthin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Progression to late AMD (neovascular AMD and/or geographic atrophy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Progression to neovascular AMD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Progression to geographic atrophy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Progression to visual loss (loss of 3 or more lines on logMAR chart) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Distance visual acuity: mean <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.05, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Mean visual acuity at end of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.06, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Change in visual acuity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.09, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [‐2.59, 5.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Lutein with or without zeaxanthin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000254-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Vitamin E versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Progression to late AMD (neovascular AMD and/or geographic atrophy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Progression to visual loss (loss of 3 or more lines on logMAR chart) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Vitamin E versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000254-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Zinc versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Progression to late AMD (neovascular AMD and/or geographic atrophy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3790</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.70, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Progression to neovascular AMD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Progression to geographic atrophy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Progression to visual loss (loss of 3 or more lines on logMAR chart) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.75, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Distance visual acuity: mean <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.05, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Mean visual acuity at end of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.04, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 Change in visual acuity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.14, 0.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Zinc versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000254.pub5/references#CD000254-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000254.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD000254-note-0013">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD000254-note-0022">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000254-note-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD000254-note-0021">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD000254-note-0018">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD000254-note-0017">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD000254-note-0016">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD000254-note-0020">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD000254-note-0015">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD000254-note-0014">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000254\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000254\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000254\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000254\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000254\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000254\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000254\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000254\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000254\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000254\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000254\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000254\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000254\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000254\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000254\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000254\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000254\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000254\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000254.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000254.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000254.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000254.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000254.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715619479"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000254.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715619483"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000254.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8b84ddb89371',t:'MTc0MDcxNTYxOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 